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ABSTRACT
Overwhelming inflammatory responses leading to neutrophil invasion are hypothesised to be the 
main cause of mortality in influenza virus induced acute respiratory distress syndrome (ARDS). 
Previously, pulmonary surfactant has been shown to modulate inflammatory responses to bacterial 
agents. The aim of the present study was to investigate the effect of pulmonary surfactant on innate 
immune responses in an in vitro model of influenza virus infected human airway epithelial cells. 
Human lung type II alveolar epithelial cells A549 and BEAS-2B human bronchial epithelial cells 
were infected with influenza A virus H1N1 strains A/Swine/1976/31, A/WSN/33 and A/PR/8/34. 
Poly I:C, Escherichia coli 0111 :B4 LPS and measles virus strain Edmonston were used as cytokine 
stimulation controls. The effect of pulmonary surfactant was compared to that of dexamethasone. 
This in vitro study showed that physiological concentrations (up to 500 fig/ml) of clinically 
approved SP-A and SP-D depleted surfactant preparations (i) were non-toxic in BEAS-2B cells, (ii) 
had no effect on influenza virus infectivity, and (iii) reduced influenza virus induced cytokine 
production comparable to dexamethasone. Porcine Curosurf* significantly inhibited IL-8 and 
RANTES production in A/WSN/33 infected cells, by 30 and 35% respectively (p<0.05). Bovine 
Survanta* had a less pronounced effect. In luciferase reporter assays pulmonary surfactant, in 
contrast to dexamethasone, non-specifically inhibited both TLR3/RIG-I mediated NF-kB promoter 
activation and IFN-0 promoter activation. Our results indicate that SP-A and SP-D depleted 
surfactant preparations attenuate pro-inflammatory responses in influenza A virus infected human 
airway epithelial cells, but inhibitory effects on IFN-/3 promoter activity were also observed. This 
suggests that pulmonary surfactant may be of clinical benefit in reducing pro-inflammatory 
responses in virus induced ARDS, however, a weakening of IFN-/3 mediated anti-viral responses can 
not be excluded.
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1 Introduction
1.1 General introduction
The respiratory tract, both upper tract and lower bronchial and alveolar surfaces, are highly 
susceptible to viral respiratory infections. A variety o f respiratory syndromes including 
common cold, pharyngitis, tracheobronchitis, laryngotracheobronchitis (croup), 
bronchiolitis and pneumonia are caused by different respiratory viruses (Richman et al. 
2002). Viral agents associated with these respiratory syndromes are summarised below 
(Table 1.1). Influenza A virus is the major cause of acute pneumonia in adults, accounting 
for more than one quarter o f all reported cases (Table 1.1). In the United States alone, 
influenza virus infections result in 20 million respiratory illnesses, 114000 hospitalisations 
and 20000 deaths annually, and the great 1918 pandemic killed as many as 20-50 million 
people worldwide (Richman et al. 2002). More recently, in 1997, the first direct 
transmission of the highly pathogenic H5N1 avian influenza to humans occurred in Asia 
(Hong Kong) (Hsieh et al. 2006), raising the prospect of a deadly new global outbreak. In 
addition to the H5N1 virus, H9N2 and highly virulent H7N7 viruses were also reported to 
be directly transmit from birds to humans causing severe diseases (Doherty et al. 2006). 
Numerous studies suggest a direct correlation between massive inflammation during 
influenza virus infection and injuries o f the lung tissue, non respiratory organ failure and 
disease severity (Van Reeth 2000; Julkunen et al. 2001; Le Goffic et al. 2006; Hsieh et al. 
2006).
In normal as well as diseased lung tissues maintenance of pulmonary homeostasis strongly 
depends on the presence and function of pulmonary surfactant. Pulmonary surfactant is a 
surface reducing material consisting of lipids and proteins, particularly rich in 
phospholipids, produced by bronchial and alveolar cells (Chevalier &  Collet 1972; Balis et 
al. 1985; Walker et al. 1986; Persson et al. 1988; Phelps &  Floros 1988; Voorhout et al.
24
1992; Crouch et al. 1992). In addition to its surface tension lowering activity, pulmonary 
surfactant has been shown to modulate the inflammatory processes within the lung. In the 
past, the majority o f work focused on the role o f hydrophilic pulmonary proteins (SP-A and 
SP-D) during bacterial (Ferguson et al. 2006; Giannoni et al. 2006) and viral infection 
(Levine et al. 2002; Levine et al. 2004). However, SP-A and SP-D are not yet approved for 
clinical use. Therapeutic application of animal derived surfactant preparations, from which 
SP-A and SP-D are depleted by chemical purification processes (also know as exogenous 
replacement therapy) has been proven to be an effective treatment in infant respiratory 
distress syndrome (IRDS). This treatment has dramatically improved survival rates in 
premature infants in vivo (Berggren et al. 1984). In vitro studies on the biological activity of 
SP-A and SP-D depleted pulmonary surfactant preparations and surfactant specific lipids are 
scarce. Recent in vitro work from our group and others has shown high effectiveness and a 
wide spectrum of activity o f the phospholipid fraction in reducing inflammatory responses 
in human cells, including primary peripheral blood mononuclear cells (PBMCs) and Mono 
Mac 6 (M M 6) cell line (Thomassen et al. 1992). In these studies inflammation was induced 
by lipopolysaccharide (LPS) from gram negative bacteria as an inflammatory stimulant and 
surfactant phospholipids were found to attenuate production of inflammatory cytokines 
(Morris et al. 2000), lipid mediators (Tonks et al. 2003) and reactive oxygen intermediate 
(ROI) production (Tonks et al. 2001; Tonks et al. 2005). These reports highlighted the 
potential immunomodulatory function of commercially available pulmonary surfactants as 
adjuvant to current treatment of acute respiratory diseases, to potentially reduce the 
inflammatory damage associated with these conditions.
The most commonly used anti-inflammatory treatment in the clinical study are 
corticosteroid related compounds, which are systemically active, leave the patient more 
susceptible to secondary bacterial infections and are known to induce a large number of
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adverse systemic side effects, including immunosupression and metabolic disturbance 
(Deshmukh 2007). Pulmonary surfactant therapy could offer a safe anti-inflammatory action 
at the local level within the lungs for patients with acute respiratory failure caused by viral 
and/or bacterial pathogens.
In the light o f these studies, this project aimed to investigate the possible therapeutic 
potential o f different preparations of exogenous natural pulmonary surfactant, which are 
currently in clinical use, in an in vitro model of influenza virus airway infection. The project 
will:
(i) assess toxicity of pulmonary surfactant in human airway epithelial cells, the principal site 
for influenza virus invasion and primary replication,
(ii) determine the effect o f pulmonary surfactant on influenza virus entry and completion of the 
lytic cycle,
(iii)investigate the effect of pulmonary surfactant on the biosynthesis of cytokines and 
chemokines associated with influenza virus pathology and inflammatory damage,
(iv)provide more insight regarding the mechanisms involved in any modulatory action of 
pulmonary surfactant.
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Virus Frequency o f syndrome
Colds Pharyngitis Tracheobronchitis Croup Bronchiolitis Pneumonia
Children Adults Immunocompromised
individuals
RNA viruses
Influenza A virus + ++ +++ ++ + ++ ++++ +
Influenza B virus + ++ ++ + + + ++ +
PIV-1 + ++ + ++++ +
PIV-2 + ++ + ++ +
PIV-3 + ++ + +++ ++ +++ + +
RSV ++ + ++ ++++ ++++ + ++
Measles virus + + ++ + +
Rhi novirus ++++ ++ + + + +
Enterovirus ++ ++ + +
Corona virus ++ + + +
HIV +
DNA viruses
Adenovirus ++ + ++ ++ ++ ++ ++
Herpes simplex + + + +
virus
Varicella virus + + +
EBV ++
CMV + ++ +++
+ 1-5% of cases, ++  5-15% of cases, + + +  15-25% of cases, + + + +  >25% of cases
Table 1.1: Frequency with which viral respiratory syndromes are caused by specific viral pathogens (Richman et al. 2002).
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1.2 Pulmonary surfactant
1.2.1 Pulmonary surfactant
Pulmonary surfactant is a multicomponent complex fluid lining the alveolar and small 
airways, composed of lipids, proteins and carbohydrates. The major function of pulmonary 
surfactant is to reduce the surface tension in the lungs at the end of expiration. The surface 
tension acts at the air-water interface and tends to make alveoli smaller. By decreasing the 
surface tension pulmonary surfactant increases elasticity of the alveoli allowing the lung to 
inflate more easily (King &  Clements 1972a, b and c).
1.2.1.1 Life cycle and recycling o f pulmonary surfactant
Pulmonary surfactant is produced by alveolar type II cells (Chevalier &  Collet 1972; 
Persson et al. 1988; Crouch et al. 1992) and bronchial Clara cells (Balis et al. 1985; Walker 
et al. 986; Phelps &  Floros 1988; Crouch et al. 1991; Voorhout et al. 1992). Intracellular 
pulmonary surfactant is stored in multilayered membrane structures called lamellar bodies 
(Askin &  Kuhn 1971). After release from lamellar bodies pulmonary surfactant forms an 
organised structure known as tubular myelin (Weibel et al. 1966; Gil &  Weibel 1969) from 
which, during inspiration, a monolayer at the air-water interface is formed. During 
expiration, this monolayer is compressed therefore lowers surface tension and contributes to 
alveolar stability. After use, the pulmonary surfactant is taken up by alveolar type II cells 
(Geiger et al. 1975) or degraded by alveolar macrophages (AMs) (Nichols 1976; Williams 
&  Benson 1981) (Figure 1.1).
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Figure 1.1: Life cycle and recycling of pulmonary surfactant (Goerke 1998). (SAP -  surface 
associated phase, DPPC - dipalmitoylphosphatidylcholine)
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1.2.1.2 Lipid composition
More than 90% of pulmonary surfactant consists of phospholipids and neutral lipids. 
Cholesterol is the major neutral lipid and the phospholipids fraction consists of 
phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI) and sphingomyelin (SM). About half of 
the phosphatidylcholine present, which comprises 80% of the total phospholipid, is in the 
form of dipalmitoylphosphatidylcholine (DPPC). DPPC is the most important surface 
tension reducing component of pulmonary surfactant (Klaus 1961). An additional role for 
pulmonary surfactant lipids in modulating the inflammatory response within the lungs has 
also been suggested, this will be discussed in section 1.2.2.1.
1.2.1.3 Protein composition
Proteins make up the remaining 10% of pulmonary surfactant. Half of these proteins are 
plasma proteins such as albumins, globulins, fibrinogens and regulatory proteins, the 
remaining are surfactant specific proteins SP-A, SP-B, SP-C and SP-D (Crouch &  Wright
2001). Two hydrophilic proteins SP-A and SP-D are formed with subunits consisting of 
trimers o f polypeptide chains (Weis &  Drickamer 1994). Each peptide has two domains.
The N-terminal portion contains repeating glycine triplets and hydroxyproline residues 
which are present in collagen and are responsible for the triple helical structure o f this 
protein. The C-terminal portion shows resemblance to lectins (Crouch et al. 2000). SP-A is 
necessary for the formation of tubular myelin and regulates pulmonary surfactant uptake 
(Wright et al. 1986; Wright et al. 1987). SP-A together with SP-D participate in innate 
immune responses to various infectious agents, this will be discussed in section 1.2.2.2. Two 
strictly hydrophobic proteins SP-B (79 amino acids) and SP-C (33-35 amino acids) are 
essential for a rapid adsorption of phospholipids at the air-water interface (Curstedt et al.
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1987). Surprisingly only two short hydrophobic sequences (valine-, leucine- and iso leucine 
rich) are found in SP-B at positions 37-42 and 54-58, and only one such sequence is found 
in SP-C between positions 13 and 28 (Johansson et al. 1994).
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1.2.2 Pulmonary surfactant -  evidence for a role in pulmonary defense
1.2.2.1 Lipid fractions
In addition to surface tension reductive effects, pulmonary surfactant has been reported to 
modulate innate immune responses to different bacterial (Speer et al. 1991) and viral agents 
(Benne et al. 1995). Commercial pharmaceutical surfactant preparations which lack specific 
surfactant proteins SP-A and SP-D, and also individual classes of pulmonary surfactant 
lipids affect in vitro the inflammatory activity of various immune cells, including 
monocytes, lymphocytes and natural killer (NK) cells. Among them, the most widely 
studied were human monocytes and macrophages (Speer et al. 1991).
In 1988, whole pulmonary surfactant and surfactant phospholipids were shown to suppress 
the lymphoproliferative response to phytohaemagglutinin (PHA) (Wilsher et al. 1988a).
This immunosuppressive property of pulmonary surfactant was shown to be related to its 
phospholipid composition. Phosphatidylcholine, phosphatidylglycerol and 
phosphatidylinositol were the most potent inhibitors of this response (Wilsher et al. 1988b). 
The same group reported that cytotoxic activity o f NK cells was affected by pulmonary 
surfactant lipids treatment (Wilsher et al. 1988c). In 1991 Speers and co-workers showed 
that phagocytosis o f Stapylococcus aureus in human monocytes exposed to CurosurC was 
impaired (Speer et al. 1991). Curosurf* is modified porcine pulmonary surfactant containing 
99% phospholipids and 1% surfactant proteins SP-B and SP-C. One year later synthetic 
Exosurf Neonatal®3, composed of 85% DPPC, 9% hexadecanol and 6% spreading agent 
tyloxapol, and modified bovine pulmonary surfactant Survanta®3 were reported to suppress 
LPS induced TNF-a, IL-lj3 and IL-6 production in alveolar macrophages and a monocytic 
cell line (Thomassen et al. 1992), by inhibition of NF-kB activation (Antal et al. 1996). 
Interestingly, the inhibitory effect of Exosurf Neonatal®3 was later associated with the 
spreading agent tyloxapol in this surfactant preparation (Thomassen et al. 1995). Walti and
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others showed that release of superoxide anions, arachidonic acid metabolites (prostaglandin 
E2 (PGE2), tromboxane B2 (TXB2) and leukotriene C4 (LTC4)) and TNF-a induced by 
various bacterial components was impaired in peripheral human blood monocytes incubated 
with Curosurf11 (Walti et al. 1997). Previously our group has shown that LPS induced 
reactive oxygen intermediates (ROIs) (Tonks et al. 2001; Tonks et al. 2005), lipid mediators 
(platelet activating factor (PAT) and PGE2) (Tonks et al. 2003) and TNF-a (Morris et al. 
2000) production is attenuated by treatment of monocytes with surfactant preparations or 
surfactant phospholipids. Moreover, DPPC was reported to reduce cell membrane fluidity 
(Tonks et al. 2001). Consequently, since enzymes responsible for PAF and ROIs generation 
affected by phospolipids are membrane associated (Tonks et al. 2003; Tonks et al. 2005), a 
possible mechanism of action of pulmonary surfactant lipids may be the disruption of cell 
membranes.
In contrast, little is known about the function of pulmonary surfactant lipids in viral 
infections, with a previous study indicating that entry of adenovirus was increased in the 
presence of DPPC (Balakireva et al. 2003).
1.2.2.2 Surfactant speci fic proteins
The role of pulmonary surfactant associated proteins SP-A and SP-D in innate immunity 
against various viruses, including influenza virus, is well characterised. In contrast, the role 
of SP-B and SP-C in viral infections is unknown. In vitro SP-A was shown to bind to 
influenza virus via its carbohydrate domain and to reduce influenza virus infectivity in 
alveolar macrophages (Benne et al. 1995). The observed reduction was due to an opsonic 
activity o f SP-A and increased phagocytic clearance of the opsonised virus by these cells 
(Benne et al. 1997). SP-A was also found to bind to cytomegalovirus (CM V) and stimulate 
its binding and uptake by type II pneumocytes and alveolar macrophages, without having
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any effect on CM V replication (Weyer et al. 2000). Unlike SP-A, SP-D binds influenza 
virus via its lectin domain (Hartshorn et al. 2000). Incubation of SP-D with influenza virus 
enhanced neutrophil binding of influenza virus and neutrophil respiratory burst to the virus 
(Hartshorn et al. 1994). Augmentation of respiratory burst was found to depend on the 
multimerisation level of SP-D molecule. Interestingly, when neutrophils were incubated 
with SP-D before influenza virus was added, the oxidative response to the virus was reduced 
(White et al. 2005). Both, SP-A and SP-D have been shown to inhibit haemagglutination of 
influenza virus (Malhotra et al. 1994; Hartshorn et al. 1994). Additionaly, SP-D was found 
to bind to envelope protein (gpl20) o f immunodeficiency virus (H IV ), consequently 
inhibiting H IV  infectivity and replication (Meschi et al. 2005). In vivo studies reported that 
SP-A and SP-D deficient mice had decreased influenza virus clearance, increased 
inflammation, greater epithelial injury and more cellular infiltrates within the lung (Levine 
et al. 2001; Levine et al. 2002; Li et al. 2002), indicating that pulmonary surfactant 
associated proteins SP-A and SP-D play an important role in innate defence responses to 
influenza virus. A similar in vivo outcome was observed in SP-A and SP-D deficient mice 
during respiratory syncytial virus (RSV) (Levine et al. 1999; Levine et al. 2004) and 
adenovirus infection (Harrod et al. 1999).
Details concerning the involvement of SP-A and SP-D in the pulmonary defence against 
bacteria go beyond the subject o f this work. However, it is worth mentioning that these 
proteins are active against wide range of microbial patogens, including Mycobacterium 
tuberculosis (Tino &  Wright 1996; Ferguson et al. 2006), Pseudomonas aeruginosa (Griese 
&  Starosta 2005; Giannoni et al. 2006), Streptococcus pneumoniae (Hartshorn et al. 1998; 
Jounblat et al. 2004), Klebsiella pnumoniae (Kostina et al. 2005), Staphylococcus aureus 
(Hartshorn et al. 1998), Escherichia coli (Hartshorn et al. 1998), Haemophilus influenzae 
(Tino &  Wright 1996) and many other microbial pathogens commonly infecting the
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respiratory tract. SP-A and SP-D significantly contribute to microbial recognition, 
regulation of phagocytosis and modulation of inflammation within respiratory tract.
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1.2.3 Pulmonary surfactant -  role in pulmonary diseases
1.2.3.1 Infant respiratory distress syndrome (IRDS)
Pulmonary surfactant starts to be produced around 24 weeks of pregnancy but does not 
reach adequate level until 32 weeks of pregnancy. Insufficiency o f pulmonary surfactant 
production in premature infants leads to IRDS (previously called hyaline membrane 
disease). Exogenous surfactant replacement therapy was shown to be an effective treatment 
option in this syndrome (Speer et al. 1995). Introduction of this treatment has significantly 
lowered mortality o f premature babies (Speer et al. 1995).
Two types o f pulmonary surfactants are used in exogenous surfactant therapy - natural 
surfactants derived from animals and synthetic surfactants (Table 1.2). Animal surfactants 
are obtained from either lung minces or lung lavages. Bovine (Survanta00, Surfacten*, 
Infasurf00, Alveofact00 and BLES™) and porcine (Curosurf8*) preparations contain small 
amounts o f hydrophobic proteins SP-B and SP-C. Many of the components of natural 
surfactants, including pulmonary surfactant proteins, are not present in artificial preparations 
(Exosurf Neonatal00 and ALEC) (Suresh &  Soil 2002). Comparative studies showed that 
animal surfactant preparations are superior in exogenous surfactant replacement therapy to 
their synthetic analogues which lack surfactant specific proteins (Soli &  Blanco 2001). As a 
result, Exosurf Neonatal00 is no longer in use and novel artificial preparations (Surfaxin00 and 
Venticute00) are enriched with recombinant human-like proteins (Suresh &  Soil 2002).
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Origin Pulmonary surfactant Additional characteristic Specific proteins
Bovine lung mince Survanta® (beractant)
Surfacten® (surfactant TA)
Enriched with DPPC, 
tripalmitoylglycerol and palmitic acid
SP-B, SP-C
Bovine lung lavage Infasurf® (calfactant) 
Alveofact® (SF-RI) 
BLES™
Chloroform/methanol extracted
Porcine lung mince 
Human amniotic fluid
Curosurf® (poractant alfa) No neutral lipids 
Chloroform/methanol extracted 
Liquid gel chromatography purified
Currently not used
Artificial surfactant Exosurf Neonatal® (colfosceril 
palmitate)
ALEC (pumactant)
Composed of 85% DPPC, 9% 
hexadecanol,
6% tyloxapol (spreading agent)
Composed of 7:3 mixture of DPPC 
and phosphatidylglycerol
Surfaxin® (lucinactant) Composed of DPPC, 
palmitoyloleoylphosphatidyl-glycerol 
and palmitic acid
21-residue peptide called KL4 
(sinapultide), a mimic of SP-B
Venticute® Composed of DPPC, 
palmitoyloleoylphosphatidyl-glycerol, 
palmitic acid and calcium chloride
Recombinant human SP-C
Table 1.2: Comparison of two types of pulmonary surfactant preparations (Suresh &  Soil 2002).
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Pulmonary surfactant preparations are derived from different sources and undergo different 
purification processes (Table 1.2). As a consequence some of them show higher 
performance in vivo than the others, porcine preparations seem to be more advantageous 
than bovine. As an example, a comparative study between bovine Survanta® and porcine 
Curosurf® shows that premature children treated with Curosurf* have more rapid 
improvement in oxygenation, reduced ventilatory requirements, fewer side effects and 
higher survival rate (Speer et al. 1995). Other comparative studies between these two 
pulmonary surfactant preparations show that Curosurf* treatment needs fewer additional 
doses of pulmonary surfactant (Ramanathan et al. 2004). A similar study reports that not 
only porcine Curosurf® but also bovine Alveofact® treatment is associated with shorter 
ventilation, oxygen administration and hospitalisation when compared to Survanta® 
(Baroutis et al. 2003). In addition, another bovine pulmonary surfactant Infasurf® has been 
shown to produce a longer duration of beneficial effects than Survanta® in IRDS (Bloom et 
al. 1997). Similar therapeutic effects are observed when comparing BLES™ and Survanta®. 
No differences in ventilator requirements, survival rate and occurrence of chronic lung 
disease are observed, however BLES™ treated infants achieve better oxygenation rate that 
Survanta® treated infants (Lam et al. 2005).
Pulmonary surfactant deficiency and alterations in pulmonary surfactant composition with 
regard to surfactant proteins and lipids can also develop secondarily in patients with acute 
respiratory distress syndrome (ARDS) (Nakos et al. 1998), pneumonia (Griese 1999), 
sudden infant death syndrome (SIDS) (Griese 1999), asthma (Heeley et al. 2000), chronic 
pulmonary diseases (Greene et al. 1999) and idiopathic pulmonary fibrosis (Gunther et al.
1999). These changes are affecting the quantity and/or the composition of human pulmonary 
surfactant.
38
1.3 Pulmonary surfactant and ARDS
Currently there is insufficient data whether surfactant replacement therapy in ARDS reduces 
morbidity and mortality, however, it has been shown to improve oxygenation, improve lung 
compliance and decrease need for ventilator support in patients with ARDS. In 1994 Spragg 
and co-workers performed studies on six patients with ARDS which were treated with a 
single dose of hydrophobic components of porcine surfactant. This treatment was well 
tolerated, had no pro-inflammatory activity and resulted in modest improvement in gas 
exchange. No significant changes in lung compliance were detected in this study (Spragg et 
al. 1994). One year later artificial surfactant replacement therapy was shown to bring 
stabilisation in gas exchange, reduced ventilatory support and improved pulmonary 
compliance in children (Perez-Benavides et al. 1995). In 1996 Anzueto and others analysed 
the administration of Exosurf Neonatal* in a patient group consisting of 725 adults with 
sepsis induced ARDS. They reported that synthetic surfactant therapy had no effect on 
survival rate, duration of stay in the intensive care unit and ventilatory requirements 
(Anzueto et al. 1996). In contrast, reduced mortality was observed in bovine Survanta 
treated ARDS patients, as evaluated in study group of fifty nine patients (Gregory et al.
1997). Some promising data were also obtained in severe bum patients. In this study bovine 
Alveofact* treatment significantly improved gas exchange and lung compliance. O f note is 
that all these patients survived in spite o f extensive lung injuries (Pallua et al. 1998). 
Improvement in oxygenation was also achieved by administration of a new generation 
pulmonary surfactant preparation Venticute*, although no differences in survival rate were 
observed in this study involving 448 patients with ARDS from various causes (Spragg et al. 
2004).
Surfactant replacement in the treatment o f endotoxin induced ARDS was also studied in a 
pig model. Moderate improvement in lung function was preliminary observed in the
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presence of bovine pulmonary surfactant by Nieman and co-workers (Nieman et al. 1996). 
In this study aerosolised Infasurf40 failed to completely improve ventilation abnormalities 
and histological changes caused by ARDS. Nebuliser administration system improved 
oxygenation in this porcine model of endotoxin induced lung injury (Lutz et al. 1998).
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1A Corticosteroids and ARDS
The administration of exogenous corticosteroids is the current anti-inflammatory treatment 
approach in ARDS and in other respiratory conditions associated with increased pro- 
inflammatory cytokine production, including sepsis and severe community acquired 
pneumonia (SCAP) (Thomas &  Fraser 2007; Annane 2007). Although corticosteroids are 
potent inhibitors for various inflammatory cytokines in vitro (Mukaida et al. 1994), 
corticosteroid therapy in ARDS show variable results. Some studies show that 
corticosteroids treatment results in increased mortality (Steinberg et al. 2006) whereas 
others show that corticosteroid administration results in reduced mortality (Annane et al. 
2006). Although patients treated with corticosteroids also have a shorter ventilation period, 
improved oxygenation, improved lung injury and reduced stay in the intensive care units 
(Steinberg et al. 2006; Annane et al. 2006; Meduri et al. 2007), oral or intramuscular 
administration of corticosteroids for more than a few days results in severe side effects, 
including immunosuppression, metabolic disturbance, fat redistribution, osteoporosis, 
growth suppression, myopathy, ophthalmic side effects and hypothalamic-pituitary-adrenal 
(HPA) axis suppression (Deshmukh 2007).
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1.5 Influenza virus
1.5.1 Classification
The influenza virus is a negative stranded (-) RNA virus of the family Orthomyxoviridae 
with 5 genera (Influenza virus A, B and C, Thogotovirus, and Isavirus). Influenza types A 
and B cause seasonal epidemics whereas influenza virus type C infection causes mild 
respiratory illness. Influenza viruses A and C infect multiple species, whereas influenza 
virus type B only infects humans. Influenza type A viruses are divided into subtypes based 
on two surface glycoproteins called haemagglutinin (HA or H) and neuraminidase (NA or 
N), also known as sialidase. There are 16 known HA types and 9 NA types. Three types of 
HA (HA1, HA2 and HA3) and two types o fN A  (NA1 and NA2) are found in influenza 
viruses commonly circulating in humans, whereas all o f types are present in avian influenza 
viruses (Richman et al. 2002). The first isolated human influenza virus H1N1 caused the 
greatest influenza pandemic in 1918, also known as “Spanish flu” killing 20-50 million 
people woldwide (Taubenberger 2006). Genetic rearrengement, known as antigenic shift, 
resulted in the emergence of two other human viruses: H2N2 and H3N2. These subtypes 
caused the “Asian” pandemic in 1957 and the “Hong Kong” pandemic in 1968, respectively 
(Kilboume 2006). In 1997 the first direct transmission of highly pathogenic H5N1 avian 
influenza to humans occurred in Hong Kong, later in Vietnam, Thailand, Indonesia and 
Cambodia, however, human to human transmission of this subtype has not yet been reported 
(Hsieh et al. 2006). In addition to H 5N 1 virus, H9N2 and H7N7 avian influenza viruses 
were also shown to directly transmit from birds to human causing severe diseases and 
raising the possibility o f new pandemic (Doherty et al. 2006). Only A type influenza viruses 
undergo antigenic shift, and consequently cause epidemic outbreaks in unprotected 
populations. Historically, influenza virus pandemics appeared at irregular intervals and
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caused significant increases in mortality rates in all age groups (Richman et al. 2002) (Table 
1.3).
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Year of appearance Time of circulation 
(year)
Virus subtype Common designation Estimated mortality in 
the United States
Comments
1889 ?28 H3N? High Estimated mortality of 
270000 -  360000 in 
Europe
1918 39 H1N1 Spanish, swine 548000 Avian ancestor
1957 11 H2N2 Asian 86000 Avian reassortant
1968 Present H3N2 Hong Kong 34000 Avian reassortant
1976 <1 H1N1 Swine 1 death Outbreak limited to one 
U.S. military base
1977 Present H1N1 Russian Negligible Reappearance of earlier 
circulating virus
1997 <1 H5N1 Chicken or bird Not applicable (6 deaths 
in Hong Kong)
Firs proven avian- 
human transmission
Table 1.3: Influenza virus pandemics and other important influenza events during the past century (Richman et al. 2002).
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1.5.2 Structure
The influenza A virion is 80 -  120 nm in diameter and usually roughly spherical, although 
filamentous forms can occur (Sieczkarski &  Whittaker 2005). The genome contains eight 
pieces of segmented negative-sense single stranded RNA, which encode 10 proteins. Three 
viral proteins are inserted into the lipid envelope: haemagglutinin, neuraminidase and the 
ion channel protein (M2). Between membrane and core is the location of the matrix protein 
(M l) . The core is made up of ribonucleoproteins (RNPs) which are composed of the 
genomic RNA segments, a trimeric RNA polymerase (PB1, PB2 and PA subunits) and 
stoichiometric quantities of nucleoprotein (NP). Small quantities of two non-structural 
proteins (NS1 and NS2) are also found in the virion (Whittaker 2001) (Figure 1.2).
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Figure 1.2: Structure (panel A) and life cycle (panel B) of influenza virus (Whittaker 2001).
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1.5.3 Binding
Influenza A and B HAs bind to cell surface 5-A-acetyl neuraminic acids (sialic acids) that 
are present on either glycoproteins or glycolipids. Avian influenza viruses preferentially 
attach to a - ( 2 ,3 ) - H n k e d  sialic acids, while human influenza viruses preferentially attach to 
a-(2,6)-linked sialic acids (Rogers et al. 1983). Swine trachea contains sialic acids with both 
a-(2,3) and a-(2,6) linkages therefore pigs can be infected with avian and human influenza 
viruses in addition to swine influenza viruses. Single amino acid substitutions at the position 
226 in influenza haemagglutinin change receptor binding specificity (Rogers et al. 1983) 
which can alter or extend the host range of the virus by enabling it to recognise different 
sialic acid linkages. Sialic acid, although acting as an efficient attachment factor, is not 
sufficient as an influenza virus receptor. N-linked glycoproteins are required for successful 
virus internalisation (Chu &  Whittaker 2004).
1.5.4 Uncoating and nuclear import
Influenza virus undergoes uptake by endocytosis, reaching early endosomes at about 5-15 
minutes after binding and late endosomes at about 35-45 minutes post infection (figure 1.2). 
The low pH in late endosomes is essential for both influenza virus uncoating and HA  
maturation. The interior o f influenza virus becomes acidified through the M2 ion channel 
(Sugrue &  Hay 1991; Pinto et al. 1992). This acidification primes disruption of Ml-vRNPs 
complexes (Bui et al. 1996). The further pH drop triggers conformational changes in the HA  
to expose a fusion peptide (Sieczkarski &  Whittaker 2003). Subsequent fusion of the viral 
envelope with the endosomal membrane is crucial for vRNPs release into cytoplasm.
Nuclear import of vRNPs is mediated by a nuclear localization sequence (NLS) present on 
viral nucleoprotein (O'Neill et al. 1995) (Figure 1.2).
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1.5.5 Replication, transcription and nuclear export
The influenza virus type A genome is transcribed and replicated by the viral RNA- 
dependent RNA polymerase within the cells nucleus. This polymerase consists of three 
subunits: PB1, PB2 and PA. During the initial phase of replication PB2 binds to the N 7- 
methyl guanine cap of host mRNAs (Fechter et al. 2003). This structure is cleaved from 
mRNA by PB1, remaining attached to PB2 (Shi et al. 1995). The cap serves as a primer for 
RNA synthesis and 11-15 nucleotides (complementary to the conserved sequence at 3’ end 
of the vRNA) are added by PB1, after which PB2 dissociates from the growing strand. PB1 
and PA then complete the synthesis (Braam et al. 1983).
In infected cells the negative-sense vRNA templates are:
transcribed into gene lenght 3’polyadenylated messenger RNA (mRNA), 
replicated through full lenght non-polyadenylated complementary RNA  
(cRNA) intermediates to produce negative-sense viral RNA (vRNA) molecules.
The nuclear export of viral mRNA is controlled by the viral non-structural protein NS1 
(Chen &  Krug 2000). The vRNPs assembly takes place in the nucleus and influenza virus 
NS2 protein mediates the nuclear export of vRNPs (O'Neill et al. 1998; Neumann et al.
2000) (Figure 1.2).
1.5.6 Glycoprotein processing and the role of HA
Haemagglutinin mediates binding to cell surface and fusion of the viral envelope with the 
endosomal membrane. Before the fusion o f viral and host membranes can occur, the 
precursor HA molecule (HA0) must be cleaved into two disulfide-linked subunits (HA1 and 
HA2). The cleavability of the HA molecule is associated with the pathogenicity of influenza 
virus (Bosch et al. 1979). The HAs of some highly virulent avian strains have a polybasic 
cleavage site and are activated by proteases present in almost all cells. The most important
enzyme among these proteases is furin (Stieneke-Grober et al. 1992; Walker et al. 1994). 
Furin is located in the trans Golgi network (TGN) therefore HAs of these strains are mainly 
cleaved in the TGN while transported to the site of virus maturation. The HAs of 
apathogenic avian strains and the human influenza viruses have a single arginine at their 
cleavage site and are activated at the cell surface on budding virus or on released particles 
by secretory proteases, such as a factor X-like enzyme present in allantoic fluid of 
embryonated eggs (Gotoh et al. 1990) or tryptase Clara found in rat bronchiolar epithelial 
Clara cells (Kido et al. 1992).
1.5.7 Assembly and budding
For successful assembly all influenza constituents are trafficked to the apical surface of 
epithelial cells. Matrix protein plays a critical role in this process. M l interacts with HA,
NA (Ali et al. 2000), M2 (McCown &  Pekosz 2006), vRNA (Ye et al. 1987) and host cell 
membrane (Ruigrok et al. 2000). Budding of the virus take place in specific regions of the 
plasma membrane which are known as detergent insoluble glycolipid enriched domains 
(DIGs) or lipid raffs (Scheiffele et al. 1999; Zhang et al. 2000) therefore influenza virions 
seem to have a lipid composition different from the host membrane. At the stage of virus 
release viral morphology is determined. HA, NA (Jin et al. 1997), M l, M2 (Roberts et al.
1998) but also actin microfilament networks and a polarised cell phenotype (Roberts &  
Compans 1998) are important determinants of viral spherical versus filamentous nature. The 
mature viruses are able to detach because neuraminidase cleaves sialic acid residues from 
the host cell. After the release of new influenza virus the host cell dies.
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1.5.8 Clinical picture and pathology
The influenza disease is characterised by chills, fever, aches throughout the body, fatigue, 
sore throat and nasal congestion. Gastrointestinal symptoms may also occur, including 
vomiting, abdominal pain and diarrhoea. The influenza virus causes a sudden onset of 
illness, about 24 -  48 hours after infection. The infection starts when influenza virus reaches 
lung epithelial cells. After primary replication and innate immune responses in these cells, 
influenza virus infects alveolar macrophages. Subsequent activation of neutrophils, T cells 
and macrophages from the peripheral blood at the site of infection results in massive 
cytokine response, leading to severe local inflammation (Table 1.4). Highly virulent strains 
of influenza virus can also replicate in non-respiratory organs, leading to severe systemic 
inflammation (de Jong et al. 2006; Hsieh et al. 2006).
Influenza virus infected monocytes and macrophages produce mainly mononuclear cell 
attracting CC chemokines, including monocyte chemoattractant protein-1 (MCP-1) (CCL2), 
macrophage inflammatory protein-1 (MIP-1) (CCL4) and regulated on activation normal T 
cell expressed and secreted (RANTES) (CCL5) (Matikainen et al. 2000) whereas expression 
of polymorphonuclear lukocyte (PMNs) chemoattractants CXC, including growth related 
gene product (GRO) (CXCL2) and interleukin-8 (IL-8) (CXCL8) is limited in these cells 
(Sprenger et al. 1996). Human airway epithelial cells produce RANTES, MCP-1 and IL-8 in 
response to influenza virus infection (Matsukura et al. 1996; Adachi et al. 1997). Type I 
interferons (IFNs) are the key anti-viral cytokines produced by influenza virus infected 
monocytes, macrophages and lung epithelial cells (Ronni et al. 1995; Ronni et al. 1997). 
Human airway epithelial cells show rather poor production of interferon alpha/beta (IFNc^jS) 
and pro-inflammatory cytokines, such as interleukin-1 beta (IL-1/3), interleukin-6 (IL-6) and 
tumor necrosis factor-alpha (TNF-a) (Ronni et al. 1997) whereas influenza infected
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monocytes and macrophages produce large amounts of IFNa//3, IL -1/3, IL-6 and TNF-a  
(Ronni et al. 1995).
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Cytokine/
chemokine
Function During influenza virus 
infection produced by
References
IFN-a/3 
and IFN-y
TNF-q
IL-lp
IL-6
MIP-1
(CCL4)
MIG
(CXCL9)
IP-10
(CXCL10)
RANTES
(CCL5)
IL-8
(CXCL8)
Inhibit of viral replication 
Stimulate of CLT mediated killing 
Increase MHCI expression 
Activate macrophages and neutrophils 
Promote T-cell proliferation 
Direct antiviral effect 
Neutrophil chemoattractant 
Stimulates macrophage phagocytosis 
and production of IL-1 
Increases vascular preambility 
Increases expression of adhesion 
factors on endothelium 
Increases vascular preambility 
Stimulates IL-6 production 
Pro-inflammmatory cytokine 
Activates T-cells
Monocyte and T-cell chemoattractant 
Activates neutrophils
Monocyte and T-cell chemoattractant 
Monocyte and T-cell chemoattractant
Monocyte, T-cell and DC 
chemoattractant 
Activates T cells 
Neutrophils and T-cell 
chemoattractant 
Activates neutrophils
Respiratory epithelium 
T cells 
NK cells
T cells
Monocytes/Macrophages
Neutrophils
DC
Monocytes/Macrophages
DC
Respiratory epithelium 
T cells
Monocytes/Macrophages
DC
T cells
Monocytes/Macrophages
Neutrophils
DC
Respiratory epithelium 
Monocytes/Macrophages 
Respiratory epithelium 
T cells
Monocytes/Macrophages 
Respiratory epithelium 
T cells
Monocytes/Macrophages 
Respiratory epithelium 
Monocytes/Macrophages 
Neutrophils____________
(Zhang et al. 1996; Moskophidis & Kioussis 1998; To et al. 2001; 
Tumpey et al. 2005; Lipatov et al. 2005; de Jong et al. 2006)
(Shaw et al. 1992; Peper & Van Campen 1995; Zhang et al. 1996; Liu et 
al. 1999; Zhao et al. 2001; Hussell et al. 2001; Cheung et al. 2002; 
Humphreys et al. 2003; Xu et al. 2004; Guan et al. 2004; Beigel et al. 
2005; Tumpey et al. 2005)
(Kozak et al. 1995; Kobasa et al. 2004; Schmitz et al. 2005; Lipatov et 
al. 2005)
(Kozak et al. 1997; Adachi et al. 1997; Hayden et al. 1998; Kaiser et al. 
2001; Kobasa et al. 2004; Chan et al. 2005; Lipatov et al. 2005; de Jong 
etal. 2006)
(Dawson et al. 2000; Cheung et al. 2002; Kobasa et al. 2004)
(Peiris et al. 2004b;de Jong et al. 2006c)
(Peiris et al. 2004; Guan et al. 2004; Chan et al. 2005; Zhou et al. 2006; 
de Jong et al. 2006)
(Dawson et al. 2000; Cheung et al. 2002; Chan et al. 2005; Zhou et al.
2006)
(de Jong et al. 2006)
Table 1.4: Links between influenza virus infections and cytokine/chemokine mediated pathology (La Gruta et al. 2007).
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1.5.9 Influenza virus specific anti-viral treatment and vaccine 
Some of the steps in the influenza virus life cycle can be inhibited by anti-viral drugs. 
Amantadine (Symmetrel*) and rimantadine (Flumadine* ) target the pH-dependent 
uncoating of virus. The target of amantadine is the ion channel M2 (Hay et al. 1985; Pinto et 
al. 1992). Nuclear export of NP in influenza-infected cells is inhibited by the antibiotic 
leptomycin B (LM B) (Elton et al. 2001). Zanamivir (Relenza*) and oseltamivir (Tamiflu*), 
two analogues of sialic acid, bind and block sialic acid-binding sites of NA. Although these 
antiviral agents have prophylactic and therapeutic activity, amantadine, rimantadine and 
oseltamivir resistance has appeared recently (He et al. 2007; Aoki et al. 2007; Deyde et al.
2007).
Currently, the use of inactivated influenza vaccine is the most important tool to reduce 
influenza virus associated morbidity and mortality. However, vaccine immunity decreases 
gradually and annual re-immunisation is necessary even if  the vaccine antigens remain 
unchanged. Specific groups such as elderly and those with respiratory diseases such as 
asthma and chronic obstructive pulmonary disease (COPD) are encouraged to take up such 
vaccinations.
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1.6 Measles virus
1.6.1 Classification
The measles virus is a negative stranded (-) RNA virus of the Morbillivirus genus within the 
Paramyxoviridae family. Although some antigenic drift was detected in the surface 
glycoproteins o f measles virus, these variations did not reduce the effectiveness of the 
immunity induced by natural infection and measles vaccines. On the basis of the nucleotide 
sequences of haemagglutinin and nucleoprotein genes, wild type measles viruses were 
divided into at least 15 different genotypes (Richman et al. 2002).
1.6.2 Structure
The measles virus virion is enveloped and measures 100 -  300 nm in diameter. The viral 
genome is nonsegmented negative sense single stranded RNA, which encodes 8 proteins. 
Two viral polypeptides are inserted into lipid envelope: the haemagglutinin (H) and fusion 
protein (F). Under the lipid membrane are a matrix protein (M ) and the nucleocapsid which 
encompasses the genomic RNA molecule in association with nucleoprotein (N), 
phosphoprotein (P) and large polymerase protein (L). The measles virus P and L proteins are 
components o f the RNA-dependent RNA polymerase complex. Small quantities of two non- 
structural proteins (C and V ) are also found in the infected cells but not in the measles virus 
virion. These proteins regulate replication of the genome (Richman et al. 2002) (Figure 1.3).
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Figure 1.3: Structure (panel A) and life cycle (panel B) of measles virus (Moss & Griffin 2006).
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1.6.3 Binding
The measles virus H protein is necessary for receptor binding. F protein is essential for 
subsequent membrane fusion. Wild-type measles virus strains use signalling lymphocyte 
activation molecule (SLAM), also known as cluster differentiation 150 (CD150), as a 
receptor (Ono et al. 2001). SLAM is expressed on cells of the immune system (Sidorenko &  
Clark 1993; Cocks et al. 1995) which is consistent with tropism of measles virus. In addition 
to the SLAM molecule, laboratory-adapted strains, including the Edmonston strain, are also 
able to use CD46 as a receptor (Dorig et al. 1993; Manchester et al. 2000). CD46 is widely 
distributed on all human cells except red blood cells (Liszewski et al. 1991). A single amino 
acid substitution at position 481 or 546 in the measles virus H may convert a measles virus 
strain which can use SLAM as a receptor into a strain which can also use CD46 as a 
receptor (Hsu et al. 1998; Li &  Qi 2002).
1.6.4 Uncoating
When measles virus H attaches to SLAM or CD46 the fusion peptide of F protein initiates 
fusion of the viral envelope with the cell membrane, resulting in the entry of the viral 
nucleocapsid into the cell cytoplasm. This occurs at neutral pH (Richman et al. 2002).
1.6.5 Replication and transcription
The measles virus genome is transcribed by the viral RNA-dependent RNA polymerase in 
the cytoplasm. The polymerase recognises a consensus sequence at the beginning of each 
gene, terminates synthesis at the end of each gene and then reinitiates at the consensus 
sequence of the next gene. The viral mRNAs are capped at the 5’ end and polyadenylated at 
the 3’ end. The viral mRNAs are translated to produce viral proteins. Viral RNA replication 
involves full length positive-sense cRNA synthesis. This is used as a template for full length
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negative-sense vRNA. The measles virus N  protein shifts transcription to replication. The 
nucleocapsid, and not free genomic RNA, is the template for all measles RNA synthesis 
(Richman et al. 2002) (Figure 1.3).
1.6.6 Assembly and budding
Measles virus virions are produced by budding. M  is the key protein during virus assembly. 
This protein interacts with the cytoplasmic domains of the integral membrane proteins (H 
and F protein) and the nucleocapsid and brings them into association with cell membrane. 
Cellular actin micro filaments are also required for measles virus maturation (Bohn et al. 
1986).
1.6.7 Pathology
Measles is a disease characterised by fever, cough, coryza (runny nose), conjunctivitis and 
maculopapular rash (Richman et al. 2002). The infection starts when measles virus reaches 
epithelial cells o f the respiratory tract. During the 8 to 12 days incubation period between 
exposure to the virus and the onset of clinical symptoms, the measles virus proliferates in 
epithelial cells and spreads to local lymph nodes (Richman et al. 2002). Replication in 
lymph tissues is followed by viraemia and dissemination of measles virus to many organs, 
including lungs, lymph nodes, skin, gastrointestinal tract, liver and kidney (Richman et al.
2002). Infection of epithelial cells, endothelial cells, lymphocytes, monocytes and 
macrophages as well as production of cytokines and chemokines in these target organs plays 
a central role in measles pathogenesis (Table 1.5). In developing countries, measles virus 
alone accounts for 6-21% of the morbidity and 8-93% of mortality due to acute lower 
respiratory infections (Markowitz &  Nieburg 1991).
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Cytokine/ Function During measles virus References
chemokine infection produced by
IFN-a/p See table 1.2 Respiratory epithelium (Schneider-Schaulies et al. 1993; Finke et al. 1995; Helin et al. 2001)
and IFN-y T cells 
Glial cells
TNF-o T cells
Monocytes/Macrophages 
Glial cells
(Schneider-Schaulies et al. 1993; Finke et al. 1995; Zilliox et al. 2007)
IL-ip Monocytes/Macrophages 
Glial cells
(Schneider-Schaulies etal. 1993; Zilliox et al. 2007)
IL-6 Respiratory epithelium 
Glial cells
(Ghali & Schneider-Schaulies 1998; Helin et al. 2001)
MIP-1 Glial cells (Xiao et al. 1998)
(CCL4)
MIG
(CXCL9)
IP-10 Neurons (Patterson et al. 2003)
(CXCL10)
RANTES Neurons (Xiao et al. 1998; Noe et al. 1999; Patterson et al. 2003)
(CCL5) Glial cells
IL-8 Respiratory epithelium (Sato et al. 2005; Zilliox et al. 2007)
(CXCL8) Monocytes/Macrophages
Table 1.5: Links between measles virus infections and cytokine/chemokine mediated pathology (La Gruta et al. 2007).
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1.6.8 Measles virus specific anti-viral treatment and vaccine 
At the moment, live attenuated measles vaccine is the safest and the most effective tool to 
tackle virus transmission. Measles vaccine is available in a monovalent form, and with live 
attenuated rubella vaccine (MR), and with live attenuated rubella mumps vaccine (M M R) 
(Beck et al. 1986). In 1998 Wakefield and co-workers suggested an association between 
M M R vaccine and neurodevelopmental disorders leading to autism in children (Wakefield 
et al. 1998). However, further studies of the M M R and autism hypothesis did not support 
this causal association (Fombonne &  Chakrabarti 2001; D'Souza et al. 2006; Richler et al.
2006). Moreover, Wakefield was charged with serious professional misconduct by the 
General Medical Council in 2006. In the United States and other developed countries M M R  
is the vaccine of choice for use in routine vaccination programme. Although a compulsory 
vaccination programme is imposed, measles virus is still resisting eradication, mainly due to 
some limitations of available measles vaccines, including low vaccine uptake (Fleck 2003) 
and light and heat inactivation (Hilleman 1989).
For the therapeutic treatment, a number of compounds have been investigated which could 
be used as inhibitors of measles virus. These include ribavirin, antisense molecules (Koschel 
et al. 1995), adenosine and guanosine nucleosides (Barnard et al. 2001), brassinosteroids 
(Wachsman et al. 2002), coumarines, pyranocoumarines (Barnard et al. 2002) and peptide 
inhibitors (Barnard 2004). None of them however was accepted for human clinical trials 
mainly because of high toxicity and low effectiveness.
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1.7 Virus recognition and the host response
The human host is able to recognise and respond to the presence of a wide range of 
infectious agents. The innate immune response to viruses is regulated by different pattern 
recognition receptors (PRRs) and associated signalling pathways. Viral genomes are 
recognised by Toll-like receptors (TLRs) and RIG-like receptors (RLRs). Their signalling 
pathways lead to upregulation of pro-inflammatory and anti-viral responses. Amongst these 
receptors, Toll-like receptor 3 (TLR3) (Alexopoulou et al. 2001), Toll-like receptor 7 
(TLR7) (human)/Toll-like receptor 8 (TLR8) (mice) (Lund et al. 2004) and retinoic acid 
inducible protein-I (R IG -l)/melanoma differentiation associated protein 5 (MDA5) 
(Pichlmair et al. 2006) are involved in the innate immune response to RNA viruses, their 
signalling pathways will be discussed in sections 1.7.1.1, 1.7.1.2 and 1.7.1.3. Whilst beyond 
scope of this study, it should be noted that the presence of virus is also detected by antibody 
dependent (Rothbarth et al. 1999) and independent mechanisms (McMichael 1994) 
associated with the adaptive immune response.
1.7.1 TLR-dependent recognition
TLRs are group of receptors first identified in Drosophila (Rosetto et al. 1995). These 
receptors have structural similarities to interleukine-1 receptor (IL-1R) and to date 10 TLRs 
have been described in man. All have been found to participate in recognition of pathogen 
associated molecular patterns (PAMPs). TLRs are transmembrane proteins with an 
intracellular Toll/interleukin-1 receptor (TIR) domain and extracellular leucine rich repeat 
(LRR) motifs (Sandor &  Buc 2005). TLRs play a critical role in immunity against bacterial 
and viral pathogens. Different TLRs interact with specific ligands and lead to different 
cytokine responses. Toll-like receptor 1 (TLR1) and Toll-like receptor 2 (TLR2) 
heterodimers sense bacterial triacylated lipopeptides (Jin et al. 2007) whereas TLR2 and
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Toll-like receptor 6 (TLR6) heterodimers recognise bacterial diacylated lipopeptides 
(Okusawa et al. 2004). Toll-like receptor 4 (TLR4) detects LPS from gram negative bacteria 
(Chow et al. 1999). Toll-like receptor 5 (TLR5) is a receptor for flagellin from bacteria 
(Hayashi et al. 2001). TLR3 senses synthetic and viral dsRNA (Alexopoulou et al. 2001) 
whereas TLR7 and TLR8 recognise viral ssRNA and synthetic imidazoquinolene based 
compounds (Diebold et al. 2004). Toll-like receptor 9 (TLR9) is a receptor for unmethylated 
CpG-containing DNA motifs, which occur in bacterial and viral DNA (Hemmi et al. 2000). 
Signalling by TLRs involves five adaptor proteins, including myeloid differentiation factor 
88 (MyD88), MyD88 adaptor like protein (MAL), TIR domain containing adapter 
inducing IF N -fi (TRIF), T R IF  related adaptor molecule (TRAM) and sterile a  and 
armadillo m otif containing protein (SARM). MyD88 is used by all TLRs with the 
exception of TLR3 which uses only TRIF (Yamamoto et al. 2003). MAL is used by TLR2 
and TLR4 and its function is recruitment of MyD88 (Yamamoto et al. 2002). TRAM is 
required to recruit TRIF to TLR4 (Fitzgerald et al. 2003). SARM negatively regulates TRIF  
(Carty et al. 2006), therefore modulates TLR3 and TLR4 signalling.
1.7.1.1 TLR3
TLR3 is a sensor for single and double stranded RNA (Alexopoulou et al. 2001; Marshall- 
Clarke et al. 2007). The localisation of TLR3 is cell type dependent. Human fibroblasts 
express TLR3 on the cell surface (Matsumoto et al. 2002) whereas dendritic cells 
(Matsumoto et al. 2003), macrophages (Nishiya et al. 2005), epithelial cells (Guillot et al. 
2005) and TLR3 transfected HEK293 cells (Funami et al. 2004) express TLR3 in endosomal 
compartments. As shown in figure 1.4, TLR3 signalling leads to the activation of two 
transcription factors: nuclear factor-kappa B  (NF-kB) and interferon regulatory factor 3 
(IRF3). This activation is mediated by the TLR3 associated molecule TRIF also known as
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TIR containing adaptor molecule-1 (TICAM -1). Binding of TN F receptor associated 
factor 6 (TRAF6) to the N-terminal region of TRIF activates N F -kB  whereas association of 
TANK binding kinase 1 (TBK1) with C-terminal domain of TRIF is essential for IRF3 
activation (Yamamoto et al. 2002; Oshiumi et al. 2003; Sato et al. 2003; Jiang et al. 2004). 
Upon stimulation, TRAF6 forms a complex with TGF-fiactivating kinase (TAK1) and 
TAK1 binding protein 2 (TAB2) which first co-localises with TLR3 and then translocates to 
the cytosol where TAK1 is activated (Jiang et al. 2004). Activation of TAK1 (Wang et al. 
2001) and auto-ubiquitination of TRAF6 (Lamothe et al. 2007) are two steps required for 
subsequent IkB  kinase (IKK) activation. TAK1 phosphorylates IK K  and activated IKK  
complex (composed of IkB  kinase alpha (IKKa), IkB  kinase beta (IKK/3), and N F-kB  
essential modulator (NEMO) subunits) phosphorylates inhibitory kB proteins (IkB s) which 
are then degraded through the ubiquit in-dependent proteasome pathway. The role of IkB s is 
to sequester N F -kB  in the cytoplasm o f unstimulated cells. After proteasomal degradation of 
IkBs, N F -kB  translocates to the nucleus and triggers the transcription of pro inflammatory 
genes. Phosphorylation of IKK  by TAK1 is regulated by TRAF6 and Ubcl3-Uevl A  
complex also known as TRAF6 regulated IK K  activator 1 (TRIKA1) (Wang et al. 2001). 
TRAF6 together with Ubcl3-UevlA catalyse the synthesis of polyubiquitin chains linked 
through lysine 63 (K63) o f ubiquitin (Deng et al. 2000) and this K63-linked 
polyubiquitination is necessary for TAK1 activation (Wang et al. 2001). Interestingly, whilst 
K63-linked ubiquitin chains are important for activation and interaction of proteins, K48- 
linked ubiquitin chains are important for proteasomal degradation of proteins. The same 
TRIKA1 complex is necessary for TRAF6 K63-linked autoubiquitination (Figure 1.4).
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Figure 1.4: TLR3 signalling pathway (Hiscott et al. 2006; Hiscott 2007). (arrow -  activation by 
phosphorylation)
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1.7.1.2 TLR7
TLR7 is involved in the recognition of single stranded RNA viruses, including influenza and 
vesicular stomatitis virus (Lund et al. 2004). Like all o f the TLRs (except TLR3) TLR7 
interacts with the TIR  domain-containing adaptor molecule MyD88 (Lund et al. 2004), as 
shown in figure 1.5. MyD88 associates with two serine-threonine kinases IL-1R associated 
kinase 1 (IR A K I) (Li et al. 1999) and IL -1R  associated kinase 4 (IRAK4) (Suzuki et al. 
2002; Li et al. 2002; Picard et al. 2003). IRAK4 phosphorylates IRAKI acting upstream of 
this molecule. Once activated, IRAKI forms a complex with TRAF6 (Cao et al. 1996) 
which is able to activate the NF-kB transcription factor. IRAKI (Uematsu &  Akira 2007) 
and IRAK4 (Kim et al. 2007) are also important regulators of TLR7 mediated production of 
type I interferon. Interferon regulatory factor 7 (IRF7) transcription factor is directly bound 
and phosphorylated by IR A K I protein. Induction of type I interferon might involve a direct 
interaction of MyD88 adaptor molecule with TRAF6 and IRF7 with the omission of serine- 
threonine kinases (Kawai et al. 2004). In this scenario ubiquitin ligase activity of TRAF6 is 
essential for IRF7 activation (Figure 1.5).
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1.7.2 TLR-independent recognition
Although Toll-like receptors are important sensors of viral pathogens, viral infections are 
also detected through TLR-independent mechanisms. RIG-I and MDA5 are two cytoplasmic 
receptors involved in antiviral innate immunity. These proteins are members o f the 
DExD/Hbox helicase family of proteins. RIG-I has been shown to be critical for 
paramyxoviruses, influenza virus and Japanese encephalitis virus detection, whereas MDA5  
is essential for picomavirus sensing (Kato et al. 2006). The N-terminal region of RIG-I, 
containing two caspase recruitment domains (CARD) and C-terminal region harbouring 
RNA helicase domain, binds double stranded RNA and 5’-phosphorylated single stranded 
RNA (Yoneyama et al. 2004; Pichlmair et al. 2007; Takahasi et al. 2008). In influenza virus 
infected cells RIG-I-mediated antiviral responses to single stranded RNA bearing 5’- 
phosphates are abrogated by influenza non-structural protein NS1 (Opitz et al. 2007; 
Pichlmair et al. 2007). As shown in figure 1.6, the N-terminal CARD domain of RIG-I 
interacts with another CARD domain protein CARD adaptor inducing IFN -fi (CARDIF), 
also known as IFN-ftpromoter stimulator-1 (IPS-1), mitochondrial antiviral signalling 
protein (MAVS) and virus induced signalling protein (VISA). Importantly, CARDIF  
associates with the mitochondrial membrane and this localization is crucial for its function. 
The major protease expressed by the hepatitis C virus (HCV) -  NS3/4A releases CARDIF  
from the mitochondrial membrane by proteolytic cleavage. This cleavage results in 
cytoplasmic distribution of CARDIF, loss of interaction with RIG-I and inhibition of 
downstream signalling (Li et al. 2005; Lin et al. 2006; Loo et al. 2006). Stimulation of RIG- 
I/CARDIF leads to activation of transcription factors NF-kB, IRF3 and IRF7. TN F receptor 
associated factor 3 (TRAF3), TRAF fam ily member associated NF-kB activator (TANK), 
TANK binding kinase-1 (TBK1) and inducible IkB  kinase epsilon (IKKe) are responsible 
for type I IF N  induction. TRAF3 binds CARDIF (Saha et al. 2006). TANK bridges
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upstream mediators CARDIF and TRAF3 with downstream mediators TBK1, IKKe and 
IRF3 (Guo &  Cheng 2007). In addition TANK links TBK1 and IKKe to NEMO. Upon RIG- 
I stimulation NEMO acts upstream of kinases TBK1 and IKKe and is essential for IRF3 
phosphorylation, formation of IRF3 dimers, DNA binding and IRF3-dependent gene 
expression (Zhao et al. 2007). RIG-I is positively regulated by tripartite m otif protein 25 
(TRIM25) (Gack et al. 2007) and negatively regulated by ring finger protein 125 (RNF125) 
(Arimoto et al. 2007). The TRIM25 ubiquitin ligase induces lysine 63 (K63)-linked 
ubiquitination of the N-terminal CARD domains of RIG-I (Gack et al. 2007) which is 
crucial for antiviral activity. The RNF125 is also a ubiquitin ligase which is responsible for 
ubiquitin-dependent proteasomal degradation of RIG-I (Arimoto et al. 2007) (Figure 1.6).
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Figure 1.6: RIG-I signalling pathway (Hiscott et al. 2006; Hiscott 2007). (arrow -  activation by 
phosphorylation)
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1.7.3 IFN-a//3 signalling pathway
During viral infection, activation of TLRs and RLRs and subsequent activation of two 
transcription factors of IRF family (IRF3 and IRF7) induces type I interferons (interferon 
alpha/beta (IFN-a//3)). IFN-c^/3 are the key cytokines which elicit anti-viral responses 
through activation of IF N  stimulated genes (ISGs). As shown in figure 1.7, the mechanism 
of this activation is initiated when secreted IFN-a//3 bind to IFN-a/($ receptor (IFNR) 
composed of two subunits IFNR-1 and IFNR-2 (Stark et al. 1998). Ligand -  receptor 
interaction activates receptor associated tyrosine kinases; tyrosine kinase 2 (Tyk2) and 
Janus associated kinase 1 (Jakl) which then transphosphorylate each other. Once activated, 
Tyk2 and Jakl phosphorylate their downstream substrates which are signal transducers and 
activators o f  transcription 1 and 2 (Statl and Stat2) (Darnell, Jr. et al. 1994; Ihle &  Ken- 
1995; Schindler &  Darnell, Jr. 1995; Stark et al. 1998). Phosporylated Statl factors form 
two different transcriptional activator complexes; homodimers known as IF N -a  activated 
factor (AAF)IIFN-y activated factor (GAF) (Decker et al. 1991) and heterotrimers, together 
with phosphorylated Stat2 and another transcription factor interferon regulatory factor 9 
(IRF9), known as IF N  stimulated gene factor 3 (ISGF3) (Darnell, Jr. et al. 1994; Haque &  
Williams 1994; Bluyssen et al. 1996). Type I interferons are mainly responsible for the 
formation of ISGF3. These complexes translocate into the nucleus where AAF binds to the 
IFN -y  activated sequence (GAS) (Decker et al. 1991; Lew et al. 1991) and ISGF3 binds the 
IF N  stimulated regulatory element (ISRE) (Kessler et al. 1990; Williams 1991) leading to 
transcriptional induction of large number of ISGs. Amongst the best known IFN induced 
proteins are the 2 ’5 '-oligoadenylate synthetase (OAS) and protein kinase R  (PKR). OAS 
catalyses the formation of 2’5’-adenylic acid which in turn activates ribonuclease L (RNase 
L). RNase L is involved in degradation of RNA within the infected cell therefore creating 
the signal for apoptosis. Interestingly, activation of RNase L by 2’5’-adenylic acid, which
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results in production of small RNA products from self RNA may also initiate IFN 
production. This signalling involves RIG-I, MDA-5 and CARDIF activation (Malathi et al.
2007). PKR phosphorylates eukaryotic translation initiation factor 2 (eIF2). After 
phosphorylation, eIF2 has a reduced ability to initiate translation therefore PKR inhibits 
viral and cellular protein synthesis (Figure 1.7).
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Figure 1.7: IFN signalling pathway (Taniguchi &  Takaoka 2002).
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1.8 Experimental model
Invasion of and primary replication of influenza virus in target cells are initially sensed by 
the host innate immune system. Bronchial and alveolar epithelial cells play an essential role 
in this innate immune response and are considered as a key regulators of influenza virus 
infection by releasing of a variety of pro-inflammatory and anti-viral products, including IL- 
8, RANTES, IL-6 and IFN-/3 (Bemasconi et al. 2005; Guillot et al. 2005). This early 
cytokine production by non-immune cells was previously suggested to be responsible for 
local as well as systemic inflammatory damage in the most severe cases of influenza (Van 
Reeth 2000; Hsieh et al. 2006). As proposed by Le Goffic and co-workers, at least two 
pathways are involved in influenza virus recognition and subsequent production of 
inflammatory agents in bronchial epithelial cells (Le Goffic et al. 2007). In their model, 
activation of TLR3 was shown to regulate pro-inflammatory response whereas activation of 
RIG-I receptor was demonstrated to mediate pro-inflammatory and anti-viral responses. 
Previous studies have indicated the ability o f pulmonary surfactant to modulate cellular 
responses including inflammatory responses in different types of specialised human immune 
cells in vitro, including lymphocytes (Wilsher et al. 1988a; Wilsher et al. 1990), natural 
killer cells (Wilsher et al. 1988c) and monocytes upon bacterial challenge (Morris et al. 
2000; Tonks et al. 2001; Tonks et al. 2003; Tonks et al. 2005). In light of these studies it 
was hypothesised that pulmonary surfactant may also play a role in the modulation of 
cytokine and chemokine produced by structural pulmonary epithelial cells in response to 
viral challenge.
The purpose of this study was therefore to investigate the effect of pulmonary surfactant on 
inflammatory responses induced by influenza virus infection in human airway epithelial 
cells, in an experimental in vitro model. Specifically the effect on IL-8, RANTES and IL-6 
production, which promotes rapid inflammatory leukocytes extravasation, and IFN-/3
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production were examined (Guillot et al. 2005). Two types of cells were studied 
simultaneously, human bronchial epithelial cells (BEAS-2B) and alveolar epithelial cells 
(A549). These cell lines were infected with three different strains of influenza virus type A  
(two human strains A/WSN/33 and A/PR/8/34, and one swine A/Swine/1976/31). Influenza 
A virus is the most pathogenic in man and the importance of parallel investigation of strains 
from different species is supported by evidence of interspecies transmissions of this virus 
(Myers et al. 2007). LPS stimulation was used in this study as a positive control for cells 
ability to upregulate NF-kB mediated innate responses (Rittig et al. 2003). The effect of 
natural pulmonary surfactant preparations, derived either from porcine (CurosurfK) or 
bovine (Survanta®) sources, was compared to that achieved by dexamethasone, one of the 
most potent synthetic anti-inflammatory corticosteroid hormones and a direct inhibitor of 
NF-kB.
We further investigated the role of pulmonary surfactant and dexamethasone on TLR3 and 
RIG-I dependent signalling in influenza infected BEAS-2B and HEK293 cells transfected 
with expression vectors encoding these proteins. The introduction of HEK293 cells to our 
study facilitated the clear dissection of pathways involved in the observed effect by the 
receptor of interest. We were interested specifically in NF-kB dependent pro-inflammatory 
responses and IFN-/3 dependent anti-viral responses. In order to demonstrate the validity of 
our test system, controls, consisting of the cells infected with measles virus or transfected 
with synthetic dsRNA, were also included in these experiments.
73
1.9 Aims
The aim of this study was to investigate the biological effect of commercially available SP- 
A and SP-D depleted preparations of pulmonary surfactant on influenza virus infected 
human airway epithelial cells.
The main aims of the study were:
1. to assess toxicity of commercially available pulmonary surfactant preparations
in human bronchial and alveolar epithelial cells,
2. to determine the effect of pulmonary surfactant on influenza virus entry in lung 
epithelial cells,
3. to investigate the effect of pulmonary surfactant on the production of
inflammatory mediators during in vitro influenza virus infection,
4. to determine the effect o f pulmonary surfactant on innate signalling pathways
which regulate pro-inflammatory and anti-viral responses during in vitro influenza virus 
infection.
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2 Materials and Methods
2.1 General methods
2.1.1 Cell culture techniques
2.1.1.1 Cell lines
2.1.1.1.1 BEAS-2B
The human bronchial epithelial cell line (BEAS-2B) was obtained from the European 
Collection of Cell Cultures (ECACC, U K -  ECACC No. 95102433). BEAS-2B cells were 
derived from an autopsy of a non-cancerous individual. These cells were infected with a 
replication-defective SV40/adenovirus 12 hybrid and cloned (Reddel et al. 1989). Bronchial 
and alveolar epithelial cells were previously shown to be the primary entry sites for 
respiratory viruses within the lung and to play a major role in virus induced inflammation. 
Influenza virus infected BEAS-2B cells have been reported to produce significant amounts 
of IL-8, RANTES, IL-6 and IFN-/3. In addition, using dual luciferase reporter assays, 
influenza virus treated BEAS-2B cells have been found to be easily transfected and a 
suitable model for studying revevant signalling pathways (Guillot et al. 2005).
2.1.1.1.2 A549
The human alveolar epithelial cell line (A549) was obtained from ECACC (ECACC No. 
86012804). A549 cells were initiated in 1972 by Giard through explant culture of lung 
carcinomatous tissue from a 58-year-old Caucasian male (Giard et al. 1973). Similar to 
BEAS-2B cells, influenza virus infected A549 cells were observed to express many different 
cytokines and chemokines, including IL-8, RANTES, IL-6 and IFN-/3 and therefore this cell 
type may play an important role in influenza pathology. Previous data also indicated that 
NF-kB activation was essential for IL-8 production in influenza virus treated A549 cells 
(Bemasconi et al. 2005).
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2.1.1.1.3 MDCK
The dog kidney epithelial cell line (M DCK) was obtained from ECACC (ECACC No.
85011435). MDCK cells were isolated from the kidney of a normal female adult Cocker 
Spaniel in 1958 by Madin and Darby (Madin Darby Canine Kidney). These cells were 
demonstrated to be permissive for a range of viruses including influenza virus (Meguro et al. 
1979). Although embryonated chicken eggs are used for influenza vaccine production, 
MDCK cells are an alternative host for influenza virus propagation for laboratory purposes. 
In addition, these cells proved to be highly sensitive for plaque assay of influenza virus 
(Gaush &  Smith 1968) and this method enabled the accurate and sensitive quantitation of 
infectious virus.
2.1.1.1.4 HEK293
The human kidney epithelial cell line (HEK293) was a kind gift from Dr Mario Labeta, 
Infection and Immunity, Department of Medical Biochemistry and Immunology, School of 
Medicine, Cardiff University, Cardiff, UK. HEK293 cells were previously shown to be 
easily transferable are therefore routinely used in reporter assay experiments (Bowie et al. 
2000). These cells do not express TLRs therefore the TLR of interest can be introduced and 
the observed effect can be associated with the receptor transfected in a clean system.
2.1.1.1.5 HEK293-TLR3
The human kidney epithelial cell line (HEK293) stably transfected with human TLR3 
(HEK293-TLR3) was a kind gift from Dr Andrew Bowie, School o f Biochemistry and 
Immunology, Trinity College, Dublin, Ireland. These cells were recently used to identify 
ligands for TLR3 (Marshall-Clarke et al. 2007). Since influenza virus infected BEAS-2B 
cells were found to activate NF-kB and IFN-/3 promoters in a TLR3 dependent manner
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(Guillot et al. 2005), HEK293-TLR3 cells were chosen as a model to investigate the 
mechanisms of action of pulmonary surfactant in our experimental model.
2.1.1.1.6 HEK293-RIG-I
HEK293-RIG-I cells were generated as part of this thesis. This is described in section 
2.1.1.7. Cytoplasmic receptor RIG-I has previously been demonstrated to mediate antiviral 
responses in influenza virus (Le Goffic et al. 2007) and measles virus (Berghall et al. 2006; 
Shingai et al. 2007; Phimet et al. 2007) infected cells. Consequently, HEK293-RIG-I cells 
were used as a model to investigate the mechanisms underlying the immunomodulatory 
actions of pulmonary surfactant.
2.1.1.1.7 B95a
The B lymphoblastoid cell line (B95a), transformed with Epstein-Barr virus (EBV), was 
obtained from ECACC (ECACC No. 01092505). The parent line B95-8 was derived from a 
cotton-top marmoset (Saguinus oedipus). These cells express SLAM the receptor for wild- 
type measles virus present in clinical specimens (Tatsuo et al. 2000). Therefore they are 
used as a host cell line for the isolation of measles virus. In addition, these cells are also a 
useful tool for measles virus propagation and quantitation since B95a cells infected with 
measles virus show syncytium formation and giant cell cytopathic effect (CPE) (Figure 2.3).
All cell lines were routinely tested for mycoplasma contamination using the VenorwGeM 
(Minerva, UK) PCR screening method.
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2.1.1.2 Preparation o f supplemented media
F-12K Nutrient Mixture, Kaighn's Modification Medium with L-glutamine (Gibco, UK) was 
supplemented with 10% (v/v) foetal bovine serum (FBS) (Gibco, UK). This medium was 
routinely used for the culture of BEAS-2B cells. Dulbecco's Modified Eagle's Medium 
(DM EM ) with 4500 mg/L glucose and L-glutamine without sodium pyruvate (Gibco, UK) 
was supplemented with 5% (v/v) FBS and used for the culture of A549, MDCK and B95a 
cells. DM EM  with 4500 mg/L glucose and L-glutamine without sodium pyruvate (Gibco, 
UK) supplemented with 10% FBS was used for the culture of HEK293 cells. G-418 was 
added to this medium at the final concentration 500 fJLg/m\ for selection of stably transfected 
HEK293-RIG-I cells. G418 disulfate salt, also known as geneticin, is an aminoglycoside 
antibiotic which is toxic to mammalian cells. This salt blocks polypeptide synthesis by 
inhibiting the elongation step in eukaryotic cells. The toxic effect of G418 can be neutralised 
by the product o f the neomycin resistant gene of bacterial origin which can be expressed in 
eukaryotic cells and which is present in RIG-I expression vector used in this study.
2.1.1.3 Sub-culturing o f cells
All cell lines were sub-cultured before reaching confluency, on average every 2 to 3 days. In 
order to propagate adherent cells culture medium was removed and discarded and the cell 
monolayer was briefly rinsed with trypsin solution TrypLE™ Express (Gibco, UK) (1 ml 
per T75 flask) to remove all traces of serum that contains trypsin inhibitors. Fresh trypsin 
solution was added to flask (1 ml per T75 flask) and the cells were incubated at 37°C until 
the cell monolayer was dispersed (usually within 5 minutes - inverted microscope 
observation). The cells were aspirated by gentle pipetting. Harvested cells were centrifuged 
at room temperature for 5 minutes at 500 x g. Appropriate aliquots of the cell suspension 
were added to culture vessels in supplemented media.
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2.1.1.4 Determination o f cell number
Cell density was determined using a counting chamber (also known as haemocytometer). 
The entire counting grid of this chamber consists of 9 large squares (Figure 2.1). Each 
square has a surface area of 1 mm2, and the depth of the chamber is 0.1 mm. To determine 
the final cell density in cells/ml, 15 p\ of an aliquot of evenly suspended cells was applied to 
chamber and the cells in one large square were counted (using a light microscope). Then the 
total cell count was divided by 0.1 (chamber depth) and divided by 1 mm2 (the total surface 
area counted). The count obtained in cells/mm3 was multiplied by 1000 because there are 
1000 mm3 per ml.
Cell count calculation example
Each large square has surface area of 1 mm2 and a depth of 0.1 mm, giving it a volume of 0.1 
mm3. I f  the total cell count in one large square is 80 (number of cells should be statistically 
significant, about 100 cells), then the cell count is 80 cells per 0.1 mm3, which equals 800 
cells per mm3. This result needs to be multiplied by 1000 to determine cell count per ml. In 
this example, the final count is 800000 cells per ml.
Figure 2.1: Counting grid of haemocytometer.
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2.1.1.5 Freezing o f cells
For long term storage and to maintain laboratory stocks, cells are routinely stored in liquid 
nitrogen. Before placing the cells in liquid nitrogen, the cells are exposed to a gradual 
freezing process, an optimum cooling rate is an important factor during this process. When 
the freezing is slow extracellular ice is produced before intracellular ice crystal start to form 
leading to osmotic imbalance. As a result water migrates out of the cell preventing 
intracellular organelles damage due to ice crystal formation and recrystallization during the 
thawing process. During fast freezing less osmotic imbalance is observed however more 
intracellular ice is produced. Eukaryotic cells are therefore frozen at a slow rate with an 
addition of cryoprotectants like dimethyl sulfoxide (DMSO) or glycerol. DMSO acts at two 
levels; it interferes with the lattice structure of the ice reducing the formation of ice crystals 
and partially solubilises the membrane so that it is more resistant to damage. Freezing 
medium contains also high percentage of FBS to dilute DMSO and to reduce its toxic effect 
(Mazur 1970).
The cells (at 50 -  80% confluency) were suspended in freezing solution containing: 10% 
dimethyl sulfoxide (DMSO) (v/v) (Sigma-Aldrich, UK), 40% FBS (v/v) and 50% 
supplemented medium (v/v). The cells were transferred to a cryogenic vial (Nunc, UK). 
Cells were initially frozen at -70°C for 24 hours in isopropanol containing vessel (for a 
gradual freezing) before transfer to the vapour phase of liquid nitrogen at -196°C for long­
term storage.
2.1.1.6 Thawing o f cells
Cryogenic vials containing cells were removed from liquid nitrogen storage and thawed 
rapidly at 37°C. Thawed cells were transferred to pre-warmed supplemented medium with
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FBS and incubated for 1 hour at 37°C till cells have settled. After incubation medium was 
changed to avoid the toxic effect of DMSO on cells.
2.1.1.7 Generation o f stably transfected H E K 293-R IG -I cells 
Stable transfection is achieved by integration of the plasmid DNA into the chromosomal 
DNA of target cells. While transient transfection is beneficial for fast analysis, stable 
transfection enables long-term gene expression. The mechanism of integration of the 
plasmid DNA, delivered by non-viral methods, is not clear and depends probably on DNA  
repair and recombination enzymes present in cells (Haber 1999).
HEK293 cells were transfected with 0.3 fig of RIG-I expression vector in a 96 well plate as 
described in section 2.2.8.6. Following transfection, cells were incubated for 48 hours at 
37°C prior to re-seeding into 12 wells plate in D M EM  with 10% FBS and 500 fig/ml of G- 
418 (selection medium). The cells were re-seeded (since they were not reaching confluence) 
three more times into new 12 wells plates every second day, using selection medium. This 
time was required for the G-418 to act on the nontransfected cells, which detached and were 
washed away during the medium exchange. During this process all cells died in the negative 
control well (nontransfected HEK293 cells). After one week from the last transfer, when 
cells formed eleven relatively large and separated colonies, cells were sub-cultured at the 
ratio of 1:10 into T25 flask in selection medium. Again after one week, the cells were sub­
cultured at the ratio of 1:10 into new T25 flask in DMEM with 10% FBS and frozen when 
they reached confluence as described in section 2.1.1.5. A mixed population of resistant 
cells was used in this study since single cell culture of resistant cells could contain resistant 
mutant cells.
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2.1.2 Virus cultivation
2.1.2.1 Strains o f viruses
2.1.2.1.1 Influenza virus strain A/WSN/33
Influenza A (H1N1) A/WSN/33 was obtained from the ECACC - the National Collection of 
Pathogenic Viruses (ECACC-NCPV -  NCPV No. 402). The strain was isolated from throat 
washings of a patient with influenza in London in 1933 (Bumet 1951).
2.1.2.1.2 Influenza virus strain A/PR/8/34
Influenza A (H1N1) A/PR/8/34 was also obtained from the ECACC-NCPV (NCPV No. 
235). The strain was isolated from a patient in Puerto Rico in 1934 (Francis, Jr. &  Magill 
1935).
2.1.2.1.3 Influenza virus strain A/Swine/1976/31
Influenza A (H1N1) A/Swine/1976/31 was obtained from the American Type Culture 
Collection (ATCC -  ATCC No. VR-99). The strain was isolated from a hog in Iowa in 1976 
(Jensen &  Peterson, Jr. 1957).
2.1.2.1.4 Measles virus strain Edmonston
Measles virus Edmonston was obtained from the ATCC (ATCC No. VR-24). The strain was 
isolated from the blood of patient in acute phase of typical measles in 1954 in Massachusetts 
(Enders &  Peebles 1954).
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2.1.2.2 Propagation o f viruses
2.1.2.2.1 Propagation of influenza virus in cell culture
MDCK cells support influenza virus replication therefore these cells were initially selected 
for virus propagation and testing of virus entry and cytopathogenicity. Since replication of 
influenza virus requires proteolytic activation (Klenk et al. 1975) MDCK cells were infected 
with influenza virus strain A/PR/8/34 and A/WSN/33 in the presence of a high purity 
TrypLE or in the presence of L-l-tosylamido-2-phenylethyl chloromethyl ketone-treated 
(TPCK) trypsin (Sigma, UK). TPCK treatment inhibits contaminating chymotrypsin activity 
without affecting trypsin activity (Schoellmann &  Shaw 1963). For virus propagation M DCK  
cells (harvested from confluent T75 flasks) were incubated with influenza virus (original 
stock) (MOI 0.5) in 1900 jul of DM EM  with 2 pg/ml TrypLE or with 2 jig/ml trypsin TPCK 
treated at 37°C for 30 minutes. After the adsorption period, 10 ml o f DM EM  were added to 
each cell suspension. The cells were seeded into T75 flasks and incubated for 3 days at 
37°C. Harvested supermatants were centrifuged for 5 minutes at 500 x g to remove cell 
debris and FBS was added as a stabilizer at a final concentration of 0.5%. The influenza 
virus was quantified by haemagglutination test as described in section 2.1.2.4.1. Influenza 
stocks were stored at -70°C. Cytopathogenicity tests and entry assays were conducted 
similarly in a reduced scale, in 96 and 12 well plates, without or with cover slips, 
respectively, as described in sections 2.1.2.4.2 and 2.1.2.4.3.
2.1.2.2.2 Inoculation of embryonated chicken eggs with influenza virus 
Embryonated chicken eggs (ECEs) may be used for the isolation of a number of different 
viruses. Influenza virus was propagated for the first time using this laboratory technique in 
1940 by Frank Macfarlane Burnet (Pearson 1944). Embryonated chicken eggs are 
bacteriologically sterile. All the three germinal layers (mesoderm, ectoderm and endoderm)
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are present in the embryo so that its tissues and covering membranes provide useful sites for 
the propagation of viruses. Although tissue culture methods have to some extent replaced 
the use of eggs for culture of most viruses, the chicken embryo still offers the most sensitive 
host system for influenza and poxviruses (Norpoth et al. 1975; Clavijo et al. 2002). Eggs are 
used at various stages of the embryo’s development according to the tissue preference of the 
virus to be cultivated. The inoculation is made in such a way that the virus is introduced as 
close as possible to the most susceptible tissue. The amniotic cavity, allantoic cavity, yolk 
sac and chorioallantoic membrane are used for isolation of different viruses (Figure 2.2). 
Intra-amniotic inoculation
Inoculation of the amniotic sac allows for the propagation of influenza A, B and C, 
parainfluenza 1, 2, 3, 4 and mumps viruses. The embryo is located in this compartment, 
therefore viruses can efficiently replicate within the respiratory track of the chicken. This 
method uses 10 to 15 day old embryos. The disadvantages are small amount of yield (about 
1 ml per egg) and high possibility of damage to the embryo during inoculation (Sommerville 
1983).
Intra-allantoic inoculation
Inoculation of the allantoic cavity is used for influenza A, B and parainfluenza 1, 2, 3, 4 
viruses. This compartment is used for propagation of the viruses which are already adapted 
to the chicken eggs by being primary isolated in the amniotic sac. This method, widely used 
by the vaccine manufacturers, uses 9 to 12 day old embryos. In comparison to the intra- 
amniotic route of inoculation, the yield is large (5 to 10 ml per egg) however allantoic fluids 
usually contain urate and phosphate and the virus may be adsorbed to these and can be 
removed by centrifugation (Sommerville 1983).
Yolk sac inoculation
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Inoculation of the yolk sac is used for various Chlamydia strains which multiply in the 
primitive haemopoietic cells lining the membrane of the yolk sac. This method uses 5 to 8 
day old embryos (Sommerville 1983).
Chorioallantoic membrane inoculation
Inoculation of the chorioallantoic membrane is used for the propagation of poxvirus or 
herpes simplex viruses, using embryos 10 to 12 days old (Sommerville 1983).
Chorioallantoic membrane
ShellEmbryo
Shell membrane
Amniotic cavity
Amnion
Albumin
Air sac
Yolk sac
Extra-embryonic cavity
Allantoic cavity
Figure 2.2: Diagram of the embryonated chicken egg indicating the regions used for propagation of 
viruses (Jeffries 1987).
Freshly layed, fertilised specific pathogen free (SPF) eggs were obtained from the Institute 
for Animal Health (Compton, Newbury, UK). SPF eggs are produced in filtered-air- 
positive-pressure (FAPP) poultry housing and are proven to be free from specific pathogens.
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The list of these specific pathogens includes fourteen viruses, two bacteria, two 
mycoplasma, two protozoa, one coccidian and helminth (Table 2.1).
No. Disease Test
1 Infectious bronchitis AGPT
2 Infectious bursal disease AGPT
3 Avian encephalomyelitis AGPT
4 Chicken embryo lethal orphan AGPT
5 Avian influenza AGPT
6 Reovirus infection AGPT
7 Reticuloendotheliosis AGPT
8 Fowl pox AGPT
9 iryngotracheitis AGPT
10 Marek's disease AGPT
11 Newcastle disease HI
12 Egg drop syndrome HI
13 Avian leucosis EUSA
14 Swollen head syndrome EUSA
15 Chicken anaemia FAT
16 Mycoplasma gallisepticum RPAT
17 Mycoplasma synoviae RPAT
18 Salmonella pullorum RPAT
19 Infectious coryza HI
20 Lecocytozoonosis AGPT
21 Blood protozoa Giemsa stain
22 Coccidiosis Salt floatation
23 Helminths Salt floatation
Table 2.1: Pathogen monitoring for SPF poultry (adapted from Veterinary Research Institute). 
(AGPT -  agar gel precipitin test, HI -  haemagglutination inhibition, ELISA - enzyme-linked 
immunosorbent assay, FAT -  fluorescent antibody technique, RPAT -  rapid plate agglutination test)
After 2-3 hours in transit at room temperature, the eggs were kept in the incubator at 37°C at 
relative humidity of 30-40%. They were turned twice daily by hand for 7 days. The eggs 
were examined daily in a darkened room over a bright trans-illuminating lamp to make sure 
embryo was present alive and mobile, by looking for “eye” complex. A pencil mark was 
made on the shell to indicate the air sac position. Before inoculation the egg shell was 
cleaned with 80% ethanol and small hole was made with sterile drill over the air sac.
Holding the egg up to the candler, the embryo was located. The needle was inserted into the 
hole of the egg and the chorioallantoic membrane was pierced. Using a short stabbing
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motion, the needle was pushed down further and when the embryo was moved with the tip 
of the needle 100 pi of influenza virus stock solution was injected into the amniotic cavity. 
The needle was removed and the hole was sealed with a drop of candle wax. Avian 
influenza grows well at 35°C and at 37°C. The recommended optimal temperature for 
mammalian influenza is 35°C. The inoculated eggs were incubated at this temperature for 3 
days. Before harvesting virus, the eggs were chilled at 4°C for 18 hours to constrict blood 
vessels and to make harvesting easier. The shell over the air sac, wiped with 80% ethanol, 
was broken with sterile forceps and the chorioallantoic membrane was pushed aside. Both 
amniotic and allantoic fluids were collected using a syringe and needle. Chicken embryos 
were killed by decapitation. Harvested fluids were centrifuged at 4°C for 5 minutes at 500 x 
g to remove excess blood and tissues. The isolates were titrated by haemagglutination test, 
tissue culture infecting dose 50 and immunofluorescence. Influenza stocks were stored at - 
70°C. Non-infected ECE fluids were shown to be non-toxic for A549 and BEAS-2B cells. 
The embryo was inoculated with influenza virus at day 7 of incubation and collection was 
performed at day 10. The gestation period of chicken (Gallus domesticus) varies between 20
and 22 days. According to The Animals (Scientific Procedures) Act 1986 these embryos are
not in the group of protected animals.
“Protection extends to certain immature forms from the following stages of development:
•  mammals, birds and reptiles - from halfway through the gestation or incubation 
period;
•  fish, amphibia and Octopi vulgaris - from the time at which they become 
capable of independent feeding. “ (Paragraph 2.7)
Since the influenza virus inoculation and collection were completed before the halfway 
point of gestation, these experiments were outside the act and therefore did not require a 
Home Office Personal or Project licence.
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2.1.2.2.3 Propagation of measles virus in cell culture
Wild-type measles virus strain require different numbers of passages in various cells, 
including primary monkey kidney cells, continuous monkey kidney cell lines (VERO and 
CV-1) and B95a cells, before appearance of cytopathic effects (CPE) characteristic for 
measles virus (Kobune et al. 1990). For that reason it is recommended to passage the virus 
form one cell culture to another over extended period of time and to check each passage for 
CPE. Here, as early as 1 day after infection, fused cells (syncytia) were visible (Figure 2.3). 
These multinucleated giant cells are a typical CPE of measles virus infection.
Measles virus strain Edmonston was grown in B95a cells. B95a cells (confluent T75 flask) 
were infected with 2 ml o f measles virus stock (M OI 0.5). After a 15 minutes adsorption 
period, during which the flask was moved from side to side to allow the virus to adsorb, 8 
ml of DMEM were added to the cells. The cells were incubated for 2 days at 37°C. Using a 
cell scraper the cells were collected together with the supernatant, frozen at -70°C and then 
thawed at 37°C. The sample was centrifuged for 5 minutes at 500 x g and the collected 
supernatant (10 ml) was used for the next infection. B95a cells (confluent T150 flask) were 
infected with prepared supernatant. After 15 minutes of adsorption period 10 ml of DM EM  
were added to the cells. The cells were incubated for 2 days at 37°C. Again using cell 
scraper the cells were collected together with the supernatant (20 ml), frozen at -70°C and 
the thawed at 37°C. The process was repeated with additional four T150 flasks of B95a 
cells. 40 ml o f supernatant were frozen in 1 ml aliquots after FBS was added to the 
harvested fluids as a stabilizer at a final concentration of 20%. Measles stocks were stored at 
-70°C.
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Figure 2.3: Uninfected B95a cells (X20) (A) and B95a cells infected with measles virus strain 
Edmonston (X20) (B).
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2.1.2.3 Purification and concentration o f influenza virus
Density gradient centrifugation is a widely used method for purification of many different 
biological particles. The purpose of influenza virus gradient centrifugation was to purify and 
concentrate the virus without affecting viral infectivity. The conventional influenza virus 
purification protocol uses sucrose gradient centrifugation. Recently, a new iodixanol 
centrifugation medium was described which was claimed to be superior to sucrose and other 
conventional gradient media (Ford et al. 1994). Sucrose solutions are both highly viscous 
and hyperosmotic therefore the rate of sedimentation for small particles is slow and water 
migrates out of the centrifuged specimens (dehydratation). Iodixanol is highly soluble in 
water and a 60% (w/v) solution has low density (about 1.32 g/ml). In addition iodixanol 
solutions are iso-osmotic up to 60% (w/v) (Ford et al. 1994). Above all in vitro (Ford et al. 
1994) and in vivo (Nossen et al. 1990; Svaland et al. 1992) data show that this novel density 
gradient medium has very low toxicity for cells in culture.
A/Swine/1976/31 was purified in Optiprep™ (iodixanol) (Nycomed Pharma AS, Norway) 
gradient. 10 ml of influenza-containing fluid from embryonated chicken eggs was 
transferred to a 33 ml quick-seal polyallomer tube (Beckman Coulter, UK). The virus 
solution was underlaid with 10 ml o f 15% (w/v) iodixanol containing 1 M NaCl in PBS-MK  
(PBS containing 1 mM MgCh-bFhO and 2.5 mM KC1), 8 ml of 25% (w/v) iodixanol in 
PBS-MK and 7 ml of 40% (w/v) iodixanol in PBS-MK. To locate the 25% (w/v) density area 
after centrifugation phenol red solution (Sigma-Aldrich, UK) was included in the upper 15% 
(w/v) and lower 40% (w/v) density volumes at a concentration of 0.1 pg/ml. The tube was 
sealed, placed into SW 28 - swinging-bucket rotor (Beckman Coulter, UK) and centrifuged 
at 4°C for 1 hour at 96500 x g (Hermens et al. 1999; Zolotukhin et al. 1999; Locker et al. 
2000). Fractions of 1ml were collected from the bottom of the tube and the influenza virus 
titer was determined by haemagglutination test. Influenza stocks were stored at -70°C.
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2.1.2.4 Titration o f viruses
2.1.2.4.1 Haemagglutination test -  titration of influenza virus
Many viruses contain proteins that can agglutinate the red blood cells of different species. 
This property is called haemagglutination. The viruses most commonly showing 
haemagglutination are the ortho- and paramyxoviruses. These viruses agglutinate 
erythrocytes of human (group 0), chicken, monkey and guinea-pig origin. Animal species of 
red blood cells (RBCs), temperature, diluent and pH are critical parameters of the 
haemagglutination assay (Table 2.2).
Influenza virus contains an envelope glycoprotein called haemagglutinin, which binds to N- 
acetyl-neuraminic acid-containing glycoprotein on erythrocytes.
Virus Animal Species Erythrocytes 
Showing Haemagglutination (0.5% )
Optimal Condition for 
Erythrocyte Suspension
GP HO Chick Mon pH Diluent Temp.(°C)
Influenza A, 
B, C
+ + + + 7.0 PBS 4-22
Parainfluenza 
1-3, mumps, 
NDV
+ + + + 7.0 PBS 4-22
Measles - - + 7.0 PBS 37
Respiratory
syncytial
virus
7.0 PBS
Table 2.2: Haemagglutination characteristics of Orthomyxoviridae and Paramyxoviridae 
(Sommerville 1983). (+  virus-induced agglutination of RBCs, - no agglutination of RBCs, GP -  guinea 
pig, HO -  human type 0 , Chick -  day old chicken, Mon -  monkey, preferably African green)
The haemagglutination test is a non-specialised method to determine the amount of virus
present in a sample. This is achieved by making serial dilutions of the virus and adding the
same volume of dilute RBCs suspension to each dilution. In wells where the concentration
of influenza virus is high, RBCs are agglutinated and linked together in a 3-dimensional
matrix. In wells where the concentration of influenza virus is below a critical point (1
HAU), the RBCs settle out at the bottom of the well to form “button” (Figure 2.4).
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ENDPOINT OF TITRATION 1:16 = >  TITER 16 HAU/volume (50 ni) =
320 HAU/ml
1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 Virus dilution
Haemagglutination Lack of haemagglutination
Figure 2.4: Haemagglutination assay of influenza virus strain A/WSN/33 grown in SPF-16 egg.
Virus stock was two fold diluted from 1:2 to 1:256. A suspension of chicken red blood cells was 
added and the result was recorded.
The end point of the titration is the highest dilution of the virus, which causes complete 
agglutination. The titre of the virus is expressed as the reciprocal of the endpoint dilution in 
haemagglutination units (HAUs).
Before use the chicken red blood cells (RBCs) (Fiebig Nahrstofftechnik, Germany) were 
washed twice in 0.85% saline by centrifugation and a 5% chicken RBC suspension was 
prepared in 0.85% saline. This solution was kept at 4°C for no longer than 7 days. Longer 
storage results in lysis of RBCs (haemolysis). 50 /d of 0.85% saline were added to each well 
of round bottom 96 well plate (Nunc, Denmark). The last row H I-H I 2 was used as a 
negative controls. 50 fi 1 of undiluted influenza-containing fluid was added to the following 
wells of the first column A l-G l and 50 fi\ of 0.85% saline were added to the last well of this 
column H I. 50 fx\ of well mixed fluid was transferred from well A l to well A2. This 
procedure was repeated for the whole row and 50 //I was discarded from the last well in the 
series A1-A12. The other rows were set up in the same manner. Finally, 50 fx\ of 0.5%
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chicken RBCs in 0.85% saline suspension was added to each well. Influenza virus also 
contains a neuraminidase in the virus particle. The presence of this enzyme, which cleaves 
N-acetyl-neuraminic acid from glycoprotein receptors, elutes bound virus from red blood 
cells. As a result, the lattice formed by haemagglutination is reversed. To minimize elution, 
after mixing, the plate was incubated at 4°C for no longer than 1 hour. The results were 
recorded.
In contrast to plaque assay or TCID50, the haemagglutination test does not give any 
measurement of viral infectivity because virus replication is not required in this assay.
2.1.2.4.2 Tissue culture infecting dose 50 -  titration of influenza virus 
Influenza virus was titrated by tissue culture infecting dose 50 (TCID50). TCID50 is the 
quantity of virus in a specified volume that will infect 50% of a number (n) of cell culture 
microplate wells. TCID50 and plaque assays are used to determine viral CPE whereas 
counts of fluorescent foci are used to quantify virus infectivity.
MDCK and A549 cells (104 cells/well) were plated into a 96 well plates (Nunc, Denmark) in 
DM EM  with 5% FBS one day before infection. BEAS-2B cells (104 cells/well) were plated 
into 96 well plate in F-12K with 10% FBS one day before infection. Virus stocks were 
serially diluted in DMEM/F-12K, and dilutions from 10'1 to 10'" were plated across 8 wells 
(100 fi\ per well). At 6 days post infection, the wells were stained with crystal violet, and 
scored for the presence of cytopathic effect (CPE). Titers were calculated according to 
Karber’s formula (Karber, G. 1931) (Figure 2.5).
I = (% of wells infected at dilution above 50% - 50%) / (% of wells infected at dilution 
above 50% - % of wells infected at dilution below 50%)
50% endpoint titer = 10 above 50%. <uk,8h>
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I = interpolated value of the 50% endpoint (also known as the proportional distance) 
h = dilution factor
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BDilutions Positives Wells inoculated % Infected
10’1 8 8 100
10'2 8 8 100
10'3 8 8 100
Iff4 6 8 75
10'5 4 8 50
10'6 4 8 50
10'7 0 8 0
10'8 0 8 0
10'9 0 8 0
1010 0 8 0
10'u 0 8 0
NC 0 8 0
C
I = (75 -  50) /  (75 -  0) = 0.5
50% endpoint titer = 10 "*-(a33xl> = io ^ 33 = 21 379.620 =
21.4 x 103 TCID50 /  100 pi = 21.4 x 104 TCID50 /  ml = 2.14 x 105 TCID50 /  ml
Figure 2.5: TCID50 calculation example - virus stock was serially diluted from 10'1 to 1 0 11, and 
each dilution was plated across 8 wells. At 6 days post infection, the wells were stained with crystal 
violet, and scored for the presence of CPE (filled circles) -  graphical presentation (panel A), tabular 
presentation (panel B) and calculation (panel C). (NC-negative control, I = (%  of wells infected at 
dilution above 50% - 50%) /  (%  of wells infected at dilution above 50% - % of wells infected at 
dilution below 50%), 50% endpoint titer = 10 109 diludon above 50%' (I x 109 h), I = interpolated value of the 
50% endpoint (also known as the proportional distance), h = dilution factor)
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2.1.2.4.3 Immunofluorescence -  titration of influenza virus 
Infectivity/entry into target cells of influenza virus was determined by direct 
immunofluorescence using purified murine monoclonal antibodies. These antibodies were 
targeted against the matrix protein and nucleoprotein and were conjugated to fluorescein 
isothiocyanate (FITC). FITC has an absorption maximum at 490 nm and emission maximum 
at 520 nm (Figure 2.6A). Characteristic bright apple green fluorescence was observed within 
cytoplasm and nucleus of infected cells (Figure 2.7). Background staining was performed 
with Evans Blue. This unspecific fluorochrom has an absorption maximum at 550 nm and 
emission maximum at 610 nm therefore fluorescence was red-shifted (Figure 2.6B).
MDCK and A549 cells (lx lO 5 cells/well) were plated into 12 well plates (Nunc, Denmark) 
with 16 mm glass cover slips in DM EM  with 5% FBS one day before infection. BEAS-2B 
cells (lx lO 5 cells/well) were plated into 12 well plates with 16 mm glass cover slips in F- 
12K with 10% FBS one day before infection. Virus stocks were serially diluted in 
DMEM/F-12K, and each dilution plated across 4 wells (500 /xl per well). After the 
adsorption period at 37°C for 30 minutes, 1500 /d of DMEM/F-12K were added per each 
well. 24 hours later the cells were fixed with 3% paraformaldehyde for 5 minutes, 
permeabilized with 0.5% Triton X-100 for 30 seconds and washed with PBS prior to 
incubation with blocking buffer (PBS containing 50 mM Tris, 100 mM NaCl, 5mM EDTA, 
0.05% Tween 20 pH 7 with 2% BSA and 0.25% gelatine) at 37°C for 30 minutes. 
Monoclonal antibodies (DakoCytomation, UK) against the matrix protein and nucleoprotein 
of influenza virus A at 1:10 dilution in blocking buffer were added, followed by incubation 
at 37°C for 30 minutes. Samples were then washed three times with PBS, and cover slips 
were mounted onto glass slides using mounting fluid (DakoCytomation, UK). Infection was 
examined by using a fluorescence microscope Olympus BX5I and AxioVision 4.4 software. 
Influenza-infected cells were counted.
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AFigure 2.6: MDCK cells infected with influenza virus strain A/Swine/1976/31 -  FITC staining (X20) 
(A) and Evans Blue staining (X20) (B).
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AFigure 2.7: A549 cells infected with influenza virus strain A/Swine/1976/31 (X100) (A and B).
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2.1.2.4.4 Plaque assay -  titration of influenza virus
The plaque assay remains the gold standard for virus quantification. The plaque itself can be 
described as an area of dead cells or as area of infected cells in a cell monolayer. The 
production of plaques representing original titer under liquid medium is impossible. In case 
of influenza virus, new influenza virions detach from the host cells when neuraminidase 
cleaves sialic acid residues from the cell membrane. After this release, new influenza virus 
spreads over the cell monolayer with the liquid medium forming uneven secondary infected 
cells which do not represent the original titer. To overcome this problem different solid and 
semisolid overlay media are used. Amongst these, two the most favourable are agar and 
methylcellulose overlays. Recently, new Avicel-containing media were introduced, superior 
to both agar and methylcellulose (Matrosovich et al. 2006). Avicel is a off-white powder 
composed of insoluble microcrystalline cellulose to which water dispersible sodium 
carboxymethylcellulose is added. Different influenza virus subtypes (H1N1, H3N2, H5N1 
and H7N7) have been shown to be able to form plaques under Avicel overlay. Plaque 
numbers were shown to be higher in the presence of Avicel than in the presence of agar.
This might be due to inhibition of virus infectivity by heated agar. In addition plaques were 
found to be larger under Avicel when compared to agar and methylcellulose. The low 
viscosity of the Avicel also allowed reduction of the format of this assay to a 96 well plate 
(Matrosovich et al. 2006).
Avicel RC 581 was the kind gift from the manufacturer (Honeywill &  Stein Ltd., UK). A  
stock suspension was prepared by dissolving 2.4 g of Avicel powder in 100 ml of distilled 
water on a standard magnetic stirrer for 1 hour. The Avicel stock solution was sterilized by 
autoclaving for 20 minutes at 121°C and stored at room temperature. The overlays were 
prepared by mixing stock solutions of Avicel with equal volumes of medium.
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BEAS-2B cells (4 x 104 cells/well) were plated into 96 well plates in F-12K with 10% FBS. 
After 24 hours, cells were infected with 50 /d/well of serial dilutions of influenza virus 
strain A/WSN/33 and A/PR/8/34 in F-12K. After 1 hour incubation, without removal o f the 
inoculum, 100 ^1/well o f 1.2% Avicel RC 581 overlay media was added. After 24 hours of 
incubation the overlays were removed and the cells were fixed with 3% paraformaldehyde 
solution for 30 minutes at 4°C and permeabilized with 0.5% Triton X-100 for 10 minutes at 
room temperature. Influenza virus infected BEAS-2B cells were immunostained by 
incubating for 1 hour at 37°C with mouse monoclonal antibodies specific for the influenza A 
virus nucleoprotein (Chemicon, UK) (1:500 dilution in blocking buffer) followed by 1 hour 
incubation at 37°C with peroxidase labelled anti-mouse antibodies (Chemicon, UK) (1:1000 
dilution in blocking buffer). True Blue™ (Kirkegaard &  Perry Laboratories, UK), a 
peroxide substrate, was then added for 1 hour at 37°C. Stained plates were washed with 
water to stop the reaction and dried. Plates were scanned on a flat bed scanner and the 
number of plaques was examined by using Corel PHOTO-PAINT X3 software (Figure 2.8).
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Figure 2.8: Plaque assay under Avicel overlay. BEAS-2B cells were infected with influenza virus 
strain A/PR/8/34; negative control (left column), 10-3 (middle column) and 10-4 dilution (right 
column). (NC -  negative control)
2.1.2.4.5 Syncytia counting method -  titration o f measles virus
B95a cells ( lx lO 5 cells/well) were plated into 24 well plates (Nunc, Denmark) in DM EM  
with 5% FBS one day before infection. Measles virus stock was serially diluted from 10'1 to 
10'5 in DM EM , and each dilution was plated across 4 wells (300 /zl/well). A fter the 
adsorption period at 37°C for 30 minutes, 700 fA o f  DM EM  were added per each well. 72 
hours later the cells were examined for the presence o f multinucleated giant cells and 
syncytia were counted.
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2.2 Specific methods
2.2.1 Preparation of pulmonary surfactant and dexamethasone
2.2.1.1 Preparation o f pulmonary surfactant
In these studies Curosurf00 (Chiesi, UK) and Survanta00 (Abbott Laboratories Ltd., UK) were 
diluted in medium to obtain a specific concentration of phospholipid (from 31.25 to 500 
pg/ml) (Table 2.3).
Curosurf® (poractant at fa) Survanta® (beractant)
Company Chiesi, UK Abbott Laboratories Ltd., UK
Batch numbers 061350 40-705-27
066120 41-957-27
069097
Origin Porcine lung minces Bovine lung minces
Composition Polar lipids, mainly Phospholipids, neutral lipids,
phospholipids, and fatty adds, and hydrophobic
hydrophobic proteins SP-B proteins SP-B and SP-C
and SP-C supplemented with 
dipalmitoyl phosphatidylcholine 
(DPPC), palmitic acid and 
tripalmitoylglycerol
Phospholipids 80 mg/ml 25 mg/ml
concentration
Suspension 0.9% sodium chloride 0.9% sodium chloride
solution
Colour White to creamy white White to light brown
Table 2.3: Comparison of Curosurf® and Survanta®.
2.2.1.2 Preparation o f dexamethasone
The effects of pulmonary surfactant preparations were compared to those of dexamethasone. 
Dexamethasone is a potent synthetic type of steroid hormone which acts as an anti­
inflammatory agent as well as immunosuppressant. Currently, dexamethasone is used to 
treat many inflammatory and autoimmune conditions associated with increased 
inflammatory activity (Nguyen et al. 2007; Scarborough et al. 2007).
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Dexamethasone (Sigma, UK) was dissolved in 70% ethanol at stock concentration of 2 
mg/ml and stored frozen at -20°C, and diluted in medium when added to cell culture.
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2.2.2 Preparation of stimulants
2.2.2.1 Preparation o f polyinosinic-polycytidylic acid (poly(I-C))
Poly(I-C) is a synthetic analogue of viral dsRNA which is synthesised during replication of 
ssRNA viruses. Poly(I-C) was previously demonstrated to elicit innate immune response 
through the induction of high levels of proinflammatory cytokines and antiviral factors 
(Guillot et al. 2005h). Poly(I-C) (Sigma-Aldrich, UK) was dissolved in endotoxin-free water 
at stock concentrations of 1 mg/ml and 100 /-ig/ml and stored frozen at -20°C.
2 .2 2 .2  Preparation o f lipopolysaccharide (LPS)
LPS is a major component of the outer membrane of gram negative bacteria (Ziegler- 
Heitbrock 1995). This glycolipid contributes greatly to the structural integrity of bacteria 
and protects the membrane from damage. In addition, LPS acts as an endotoxin and induces 
strong innate immune responses in vitro and in vivo. LPS stimulates the cells to produce and 
release an array of inflammatory mediators, therefore it was used in this study as a positive 
control for the ability of cells to produce cytokines and chemokines.
LPS from Escherichia coli (serotype 0111:134) (Sigma-Aldrich, UK) was dissolved in 
endotoxin-free water at stock concentrations of 1 mg/ml, 100 /zg/ml and 10 /zg/ml and stored 
at -20°C.
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2.2.3 Limulus amoebocyte lysate (LAL) assay for endotoxin
2.2.3.1 Limulus amoebocyte lysate assay
In order to exclude the possible effects of trace amounts of LPS on cytokine and chemokine 
secretion as well as on NF-kB and IFN-p promoter activation all virus samples as well as 
poly(I-C) preparations and plasmids were tested for the presence of endotoxin by LAL assay 
(BioWhittaker, UK).
The major component of the LAL assay is a protein derived from the blood of the horseshoe 
crab Limulus polyphemus. This proenzyme, part of the innate immune system, is activated 
upon endotoxin stimulation. As a result of this activation, the functional enzyme acts as the 
blood clotting agent (Bang 1956; Levin &  Bang 1964a and b; Young et al. 1972). In the 
LAL assay L-nitroanilide is cleaved to produce the yellow compound p-nitroaniline. The p- 
nitroaniline release is measured photometrically at 405 nm (Figure 2.9).
Endotoxin
Proenzyme __________________  Enzyme
Enzyme
L-nitroanilide ------------------------------- ► p-nitroaniline
Figure 2.9: Schematic diagram of LAL assay principle (adapted from Bio Whittaker).
2.2.3.2 Preparation o f limulus amoebocyte lysate assay
The assay was performed according to the manufacturer’s instructions. Endotoxin standard 
was reconstituted in pyrogen-free water to a final concentration 50 endotoxin units (EU)/ml 
(1 EU corresponds to 100 pg of endotoxin). This solution was vortexed for 5 minutes and 
then serially diluted to give standard values of 0.005, 0.05 and 0.5 EU/ml. Each standard 
and tested sample (50 p\) was pipetted in duplicate into wells of a microtiter plate. The plate
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was placed in the KQCL reader and set to warm up to 37°C. The LAL reagent was 
reconstituted by adding 2.6 ml o f pyrogen-free water. To each well 50 /d of reconstituted 
LAL reagent was added. Readings were taken for 100 minutes. Endotoxin concentrations in 
the test samples were determined from the standard curve.
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2.2.4 CellTiter96® A Q ueous one solution cell proliferation assay
2.2.4.1 CellTiter96® AQ ueousone solution cell proliferation assay 
The CellTiter 96w Aqueous Assay (Promega, UK) is a colorimetric method for the 
evaluation of cell death or toxicity. The CellTiter 96w Aqueous Assay is composed of the 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H- tetrazolium, inner salt] (MTS) and an electron transfer reagent phenazine 
methosulfate (PMS). MTS (Owen’s reagent) is reduced into a water-soluble formazan by 
enzymes found only in metabolically active cells (Cory et al. 1991). Formation of reducing 
agents such as nicotinamide adenine dinucleotide hydride (NADH) and nicotinamide 
adenine dinucleotide phosphate (NADPH) is required to accomplish the reduction of 
tetrazolium (Berridge &  Tan 1993). Dehydrogenase enzymes which are found in the 
mitochondrial respiratory chain are thought to generate these pyridine nucleotide cofactors 
(Figure 2.10). The quantity of formazan product (measured by the amount of absorbance at 
490 nm) is proportional to the number of viable cells in culture.
Substrate
NAD
Product
NADH
ETR-reduced ETR
MTS Formazan
Figure 2.10: Schematic diagram of cellular metabolism by which MTS is converted to coloured 
formazan (adapted from Promega). (NADH - nicotinamide-adenine-dinucleotide hydride, NADPH - 
nicotinamide-adenine dinudeotide phosphate, ETR -  electron transfer reagent, MTS - [3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt])
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2.2.4.2 Assessment o f BEAS-2B and A549 cell viability following pulmonary 
surfactant treatment
BEAS-2B cells (2.5 x 103 cells/well) were plated into 96 well plates (Nunc, Denmark) in F- 
12K with 10% FBS. A549 cells (2.5 x 103 cells/well) were plated into 96 well plates (Nunc, 
Denmark) in DM EM  with 5% FBS. After 24 hours cells were incubated with different 
concentrations of Curosurf® (batch# 066120 and 069097) or Survanta® (batch # 40-705-27 
and 41-957-27) (500, 250, 125, 62.5 and 31.25 /xg/ml) for 2 hours at 37°C. Following 
incubation, Curosurf® or Survanta® solutions were removed, cells were washed 3 times with 
PBS and 100 fi\ of fresh F-12K/DMEM medium was added to each well. Each experimental 
condition was tested in quadruplicate. At different time points (24, 48 and 72 hours) equal 
volumes of CellTiter 96® AQ reagent were added (20 /d/well) and the plate was incubated 
for 1 hour at 37°C. Absorbance was recorded at 492 nm (Titretec plate reader, Lab Systems, 
UK).
2.2.4.3 Assessment o f BEAS-2B cell viability following Survanta treatment and 
influenza virus infection
BEAS-2B cells (2.5 x 103 cells/well) were plated into 96 well plates (Nunc, Denmark) in F- 
12K with 10% FBS. After 24 hours cells were incubated with different concentrations of 
Survanta® (batch # 40-705-27) (500, 250, 125, 62.5, 31.25,15.63 and 7.81 /zg/ml) for 2 
hours at 37°C. Following incubation, Survanta® solutions were removed, cells were washed 
three times with PBS and were infected with influenza virus strain A/PR/8/34 and 
A/WSN/33 at an MOI 2. Each experimental condition was tested in quadruplicate. At 
different time points (24, 72 and 120 hours) equal volumes of CellTiter 96® AQ reagent 
were added (20 /d per well) and the plate was incubated for 1 hours at 37°C. Absorbance 
was recorded at 492 nm (Titretec plate reader, Lab Systems, UK).
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2.2.5 Enzyme linked immunosorbent assay (ELISA)
2.2.5.1 Enzyme linked immunosorbent assay (sandwich ELISA )
ELISA is a biochemical technique that measures the amount of antigen or antibody in a 
sample. In cytokine sandwich ELISA assays soluble cytokine or chemokine proteins are 
captured between two layers o f antibodies; capture and biotinylated detection antibodies.
The targeted cytokines are then quantified using a colorimetric reaction based on the activity 
of a streptavidin horseradish peroxidise (HRP) complex bound to the biotinylated detection 
antibody. Streptavidin is a tetrameric protein which shows high affinity to biotin. Each 
monomer of streptavidin binds one molecule of biotin therefore acting as signal 
amplification molecule. Horseradish peroxidase is an enzyme which catalyses the reaction 
with the substrate, for example tetramethylbenzidine (TMB). TMB is an analogue of 
benzidine which is oxidised during the enzymatic degradation of H20 2 by horseradish 
peroxidase. The oxidised product of this chromogen has a deep blue colour which is 
detected spectrophotomerically.
2.2.5.2 Determination o f IL-8, R AN TES and IL -6  production by ELISA
The level of cytokines produced by cells under various conditions was measured in a 
standard “sandwich” enzyme-linked immunosorbent assay (ELISA) using human paired 
antibodies (R&D Systems, UK) (Table 2.4). Monoclonal mouse anti-human antibody 
(capture antibody) was diluted in PBS to give an appropriate final concentration (Table 2.4). 
100 /d of this unlabeled antibody was added to each well of maxisorb 96 well plates (Nunc, 
UK) and the plate was incubated overnight at room temperature to allow complete binding 
of antibody. The plate was then washed three times with wash buffer (PBS containing 
0.05% Tween 20) and the remaining sites for protein binding on the plate were blocked by 
adding 300 jd of blocking buffer (PBS containing 1% BSA and 5% sucrose) to each well.
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The plate was incubated for 1 hour at room temperature. During the incubation period, 
recombinant human cytokine standard was 2 fold serially diluted in diluent (de-ionised 
water containing 20 mM Tris, 150 mM NaCl, 0.1% BSA and 0.05% Tween 20, pH 7.3) to 
give an appropriate range of standard values (Table 2.4). The plate was washed three times 
with wash buffer and 100 fi\ of standard and samples were added to the plate in duplicate. In 
order to mix the standards and the samples the plate was gently tapped for 1 minute and then 
incubated for 2 hours at room temperature. The plate was then washed three times and 100 
fil of biotinylated goat anti-human antibody (detection antibody) in diluent added to each 
well (Table 2.4). To allow the binding of this labelled antibody to antigen, completing the 
“sandwich”, the plate was incubated for 2 hours at room temperature. Following three 
washes, 100 fil of 1:200 dilution of streptavidin horseradish peroxidase (HRP) conjugate in 
diluent was added. The plate was incubated for 20 minutes at room temperature and then 
washed again three times. The bound biotin-streptavidin complex was detected by adding 
100 fi\ of 3,3’,5,5’-tetramethylbenzidine (TMB) (Kirkegaard &  Perry Laboratories, UK). 
After incubation in darkness for 25 minutes at room temperature the reaction was stopped 
by adding 50 fi 1 of 0.5 M H2S04. A clear yellow colour was formed after addition of the 
acidic stop solution. This colorimetric endpoint was read spectrophotomerically at 450 nm 
(Titretec plate reader, Lab Systems, UK). The cytokine concentration was determined by 
comparing the signal of unknown samples against those of the standard curve.
110
IL-8 RANTES IL-6
Final
concentration 
Standard Clone
Capture Clone 
antibody
IL-8 DuoSet® MAB678
ELISA kit DY208 
4 pg/ml 1 pg/ml 4 pg/ml
MAB206
Final
concentration 
Detection Clone 
antibody
Final
concentration
IL-8 DuoSet® 278-RN
EUSA kit DY208
From 2000 to From 1000 to
31.25 pg/ml 15.6 pg/ml
IL-8 DuoSet® BAF278
EUSA kit DY208 
20 ng/ml 10 ng/ml
206-1L
25 ng/ml
From 1200 to 
18.75 pg/ml 
BAF206
Table 2.4: Antibodies used to determine IL-8, RANTES and IL-6 concentration by EUSA.
2.2.5.3 Determination o f IFN-beta production
The level of IFN-0 was measured in a one step “sandwich” enzyme-linked immunosorbent 
assay (ELISA) using human IFN-/3 ELISA kit (Biosource, UK). Human IFN-/3 standard, 
after reconstitution in 1 ml of ice-cold endotoxin-free water, was prepared from 200 IU/ml 
to 3.125 IU/ml in doubling dilutions (200, 100, 50, 25, 12.5, 6.25 and 3.125 IU/ml) in ice- 
cold dilution buffer (phosphate buffer containing 0.1% BSA and 0.05% Tween 20) 
provided. The enzyme (HRP) labelled monoclonal mouse anti-human IFN-/3 antibody was 
prepared by dissolving lyophilizate with 6 ml of ice-cold dilution buffer. 96 well plate 
already coated with the affinity-purified polyclonal goat anti-human IFN-/3 antibody was 
primed by washing once with wash buffer (PBS containing 0.05% Tween 20) and 50 pi of 
enzyme-labelled antibody together with 100 pi of either standard or sample were added to 
each well. The plate was incubated for 2 hours at room temperature on a microplate shaker. 
After completion of the antigen-antibody reaction the plate was washed three times and 100 
pi of colour developer solution added to each well. Colour developer was prepared by 
mixing 10 ml o f sodium acetate-citrate buffer containing H2O2 with 0.5 ml of TMB solution. 
Covered plate was incubated for 30 minutes at room temperature on a microplate shaker. 
After incubation 100 pi o f 0.5 mol/L H2SO4 were added and the absorbance was read
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spectrophotomerically at 450 nm using Titretec plate reader (Lab Systems, UK). The IFN-/3 
concentration was determined by comparing the signal of unknown samples against those of 
the standard curve.
2.2.5.4 Effect o f influenza virus on IL -8 , RANTES and IL -6  production in BEAS- 
2B cells
BEAS-2B cells (1 x 105 cells/well) were plated into 12 wells plates in F-12K medium with 
10% FBS. After 24 hours monolayers were infected with decreasing multiplicity of infection 
(M OI) of influenza virus strains A/WSN/33 and A/PR/8/34 (1, 0.1, 0.01, 0.001 and 0.0001) 
for 12, 24 and 48 hours. Supernatants were assessed for IL-8, RANTES and IL-6 by ELISA  
as described in section 2.2.5.2.
2.2.5.5 Effect o f pulmonary surfactant on IL-8, RANTES and IL -6  production 
induced by influenza virus in BEAS-2B cells
BEAS-2B cells were grown to confluence as described in section 2.2.5.4. After 24 hours 
cells were incubated with different concentrations of Curosurf40 (batch # 066120) or 
Survanta40 (batch # 41-957-27) (500, 250 and 125 /tg/ml) for 2 hours at 37°C. Following 
incubation, Curosurf40 or Survanta40 solutions were removed, cells were washed 3 times with 
PBS before infection with influenza virus, as described in section 2.2.5.4. Collected 
supernatants were assessed for cytokines as described in section 2.2.5.2.
2.2.5.6 Effect o f dexamethasone on IL-8, RANTES and IFN-/3 production induced 
by poly(I-C), LPS, influenza virus and measles virus in BEAS-2B cells 
BEAS-2B cells were grown to confluence as described in section 2.2.5.4. After 24 hours 
cells were incubated with 1 /tg/ml of dexamethasone for 2 hours at 37°C. Following
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incubation, dexamethasone solution was removed, cells were washed 3 times with PBS 
before stimulation with poly(I-C) (50 fxg/ml) and LPS (1 /*g/ml) or infection with influenza 
virus strain A/WSN/33 (M OI 1), influenza virus strain A/PR/8/34 (MOI 1) and measles 
virus (M OI 0.01) for 24 hours. Supernatants were tested for IL-8, RANTES and IFN-p by 
ELISA as described in sections 2.2.5.2 and 2.2.5.3.
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2.2.6 Plaque assay
2.2.6.1 Effect o f pulmonary surfactant on viral infectivity in BEAS-2B cells 
BEAS-2B cells (0.4 x 105 cells/well) were plated into 96 well plates in F-12K medium with 
10% FBS. After 24 hours, cells were incubated with different concentrations of Curosurf0 
(batch # 066120) or Survanta00 (batch # 41-957-27) (500, 250 and 125 //g/ml) for 2 hours at 
37°C. Following incubation, Curosurf® or Survanta® solutions were removed, cells were 
washed 3 times with PBS and were infected with 50 /d/well of serial dilutions of influenza 
virus strain A/WSN/33 and A/PR/8/34 in F-12K. Plaque assay was completed as described 
in section 2.1.2.4.4.
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2.2.7 Liquid chromatography and mass spectrometry of phospholipids
2.2.7.1 Liquid chromatography and mass spectrometry
Chromatography is one of the most powerful methods for separating and analysing the 
composition of lipids, especially in combination with mass spectrometry which provides 
information about the chemical structure of lipid molecules (Maskrey et al. 2007). A 
chromatographic analysis involves passing a sample of lipids through a column that contains 
a matrix capable of retarding the flow of lipids. Lipids in the sample are separated because 
their affinities to the matrix differ. The stronger the affinity between the specific lipid and 
the matrix, the slower it passes through the column. After separation and identification, the 
concentration of each of the lipids is determined by a suitable detector.
After chromatography, mass spectrometry is applied to analyse lipid composition. Each lipid 
is exposed to ionization and then separated into a number of ions (peaks) based on 
differences in masses and charges, which are quantified using suitable detectors. This 
procedure is used to determine the total fatty acid profile and to calculate the type and 
concentration of fatty acids present in the original lipid sample.
Liquid chromatography and mass spectrometry can be used not only to determine the 
complete profile of the molecule present in a lipid but also to calculate the degree o f lipid 
oxidation and the extent of heat or radiation damage or to determine the presence of 
antioxidants (Guardiola et al. 2007).
2.2.7.2 Liquid chromatography and mass spectrometry of phospholipids
Liquid chromatography and mass spectrometric analysis of Curosurf40 (batch # 061350 and 
069097) and Survanta00 (batch # 41-957-27) was performed with the assistance of Dr Val 
O ’Donnell, Department of Medical Biochemistry and Immunology, Cardiff University, 
Cardiff.
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Briefly, pulmonary surfactant solutions were diluted 1:1000 in methanol and separated on a 
Spherisorb S5W 4.6 x 150-mm column (Waters Ltd., UK). Mass spectra were obtained on a 
Q-Trap instrument (Applied Biosystems 4000 Q-Trap, UK).
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2.2.8 Dual luciferase reporter assay
2.2.8.1 Dual luciferase reporter assay
The Dual-Luciferase* Reporter Assay System (Promega, UK) allows for simultaneous 
measurement of two reporter enzyme activities (luciferases) within a single sample. One 
enzyme is derived from the light-emitting organ of the firefly (Photinus pyralis) another 
from sea pansy (Renilla reniformis). The reporter gene is under the control of the target 
promoter. The luciferase activity correlates with the target promoter activation. The Renilla 
reporter gene is under the control of the herpes simplex virus (HSV) thymidine kinase (TK) 
promoter. The Renilla luciferase activity provides an internal control to normalise against 
transfection efficiency. Firefly protein is a 62 kDa molecular weight oxidase. This enzyme 
requires ATP, molecular oxygen, Mg2+ and firefly luciferin as a substrate to generate light. 
Renilla luciferase is 36 kDa protein which catalyses coelenterazine oxidation by oxygen to 
produce light (Figure 2.11).
Firefly luciferase
Firefly ludferin + ATP + 0 2--------------------------------------> Oxyluaferin + ATP + PPi + C02 + light
Mg2+
Renilla luciferase
Coelenterazine + 0 2 -------------------------------------------------------------> Coelenteramide + C02 + light
Figure 2.11: Bioluminescent reactions catalysed by firefly and Renilla luciferases (adapted from 
Promega).
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2.2.8.2 Plasmids
NF-kB firefly reporter plasmid (ILR #217)
The pNF-icB-Luc plasmid contains four tandem copies of the NF-kB consensus sequence 
located upstream of the TATA like promoter ( P t a l )  region from the herpes simplex virus 
thymidine kinase (HSV-TK) promoter. The firefly reporter gene is located downstream from 
P t a l -  After endogenous NF-kB proteins bind to k  enhancer element (kB4), transcription is 
induced and the reporter gene is activated. The luciferase coding sequence is followed by 
the by the simian virus 40 (SV40) late polyadenylation signal to ensure proper processing of 
the luciferase transcript in eukaryotic cells. Located upstream of NF-kB is a synthetic 
transcription blocker (TB), which is composed of adjacent polyadenylation and transcription 
pause sites for reducing background transcription. Vector also contains fl origin for ssDNA 
production, a pUC origin of replication and ampicillin resistance gene (amp1)  for 
propagation and selection in E. coli. This plasmid was referred to by us as NF-kB firefly 
reporter plasmid (internal laboratory reference number (ILR #) 217) (Baeuerle &  Baltimore 
1996; Peltz 1997; Baeuerle 1998) (Figure 2.12).
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B glll
Kpnl, SacI, M lul, Nhel H in d lll
ori
luciferase
5000 bpamp
SV40 
Poly ApUC
ori Xbal
Figure 2.12: Schematic diagram of pNF-KB-Luc plasmid (adapted from Clontech).
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IFN-ff firefly reporter plasmid (ILR # 231)
The pGL3-IFN-/3-Luc plasmid was generated by L in  and co-workers (Lin et al. 2000) by 
cloning the EcoRJ-TaqI fragment (-280 to +20; filled in w ith  the Klenow enzyme) from 
pUC/326 into the Nhel site (filled in w ith  the Klenow enzyme) o f  the pGL3 basic vector 
(Promega) (Figure 2.13). This plasmid was referred to by us as IFN-/3 fire fly  reporter 
plasmid (ILR  #231).
synthetic 
Poly A
Kpnl
SacI
M lul
Nhel
Smal
Xhol
BgHI
H in d lll
f l  ori
on
4818 bp
S a il
BamHI luciferase Ncol
N arl
SV40 Poly A
Xbal
Figure 2.13: Schematic diagram of pGL3 vector (adapted from Promega).
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TLR3 expression plasmid (ILR # 220)
The pFLAG -C M Vl-TLR 3 plasmid was generated by Schoenemeyer and co-workers 
(Schoenemeyer et al. 2005) by cloning PCR-amplified fu ll length TLR3 cDNA into the 
pFLAG -C M V l vector (Sigma) (Figure 2.14). This plasmid was referred to by us as TLR3 
expression plasmid (ILR  # 220).
Spel
ori
f l  ori
CMV promoter
4732 bp
SV40 promoter
T7 promoter Jyr
StuI 
Xhol
H in d lll
EcoRV
Age! Bam H I
Smal
Figure 2.14: Schematic diagram of pFLAG-CMVl vector (adapted from Sigma).
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RIG-I expression plasmid (ILR # 227)
The pcDNA3-Neo-FLAG-RIG-I plasmid was generated by Venkataraman and co-workers 
(Venkataraman et al. 2007) by cloning PCR-amplified RIG-I cDNA into pcDNA3-Neo 
vector (Invitrogen Life Technologies) (Figure 2.15). This plasmid was referred to by us as 
RIG-I expression plasmid (ILR  # 227).
H in d lll, Kpnl, BamHi, BstXI, EcoRI, 
EcoRV, BstXI, Notl, Xhol, Hbal, A pa l
Ndel
N rul
CMV promoter f l  ori
B g lll
SV40 promoter
5400 bp
neomycin
Pvul
SV40 PolyA
BsmI
Smal
T th llll
Figure 2.15: Schematic diagram of pcDNA3-Neo vector (adapted from Invitrogen Life 
Technologies).
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Renilla reporter plasmid (ILR # 238)
The phRL-TK plasmid (Promega) contains the herpes simplex virus thymidine kinase 
(HSV-TK) promoter which provides low to moderate levels o f  Renilla luciferase expression. 
The Renilla reporter gene is located downstream HSV-TK promoter. The luciferase coding 
sequence is followed by the by the simian virus 40 (SV40) late polyadenylation signal. T7 
promoter preceding the Renilla reporter gene can be used to synthesise RNA transcripts in 
vitro using T7 RNA polymerase. This plasmid was referred to by us as Renilla reporter 
plasmid (ILR  # 238) (Lorenz et al. 1991) (Figure 2.16).
Xbal
BamHi
luciferase
T7 promot<
EcoRI
H in d lll
HSV-TK promoter
B g lll
Csp45I Nhel
Figure 2.16: Schematic diagram of phRL-TK plasmid (adapted from Promega).
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2.2.8.3 Preparation of agar plates and liquid bacterial growth medium
The 7.8 g of Columbia Agar Base (Oxoid, UK) was dissolved in 200 ml o f distilled water. 
Agar solution was sterilized by autoclaving for 20 minutes at 121°C. In order to prepare 
plates the agar solution was transferred from autoclave to water bath at 45°C for at least 20 
minutes and then 20 ml poured into each 8.25 cm diameter plastic disposable plate (Sterilin 
Ltd., UK) (20 ml creates a layer of agar 3.5 mm thick) and plates were allowed to cool down 
following overnight incubation at 37°C. When selective ampicillin plates were prepared 1 pi 
of 100 mg/ml antibiotic stock solution was added for each 1 ml of media. Ampicillin was 
added at 42°C in water bath.
Liquid bacterial growth broth -  LB broth (Luria Bertani broth) was prepared by adding 10 g 
of Tryptone Soy Broth (Oxoid, UK), 5 g of yeast extract (Bio Gene, UK) and 10 g of NaCl 
to 800 ml o f distilled water. pH was then adjusted with NaOH to 7.5 and the volume was 
adjusted to 1000 ml with distilled water. LB broth was sterilized by autoclaving for 20 
minutes at 121°C and stored at room temperature. When selective ampicillin liquid bacterial 
growth broth was prepared 1 pi of 100 mg/ml antibiotic stock solution was added for each 1 
ml of media.
2.2.8.4 Transformation of bacteria
One bead of frozen competent cells Top 10 bacteria was placed onto agar plates and 
incubated overnight at 37°C. The next day a single colony was selected for starter culture. 
The starter culture was grown in 10 ml of LB medium overnight in 37°C shaker. The 
following day 1 ml o f Top 10 bacteria was washed 3 times with endotoxin-free water by 
centrifugation for 1 minute at 500 x g and the pellet was resuspended with 40 pi of 
endotoxin-free water. 10 pi of plasmid DNA in TE buffer were added to bacteria. DNA  
suspended in bacteria was transferred gently to an electroporation cuvette and electroporated
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with a Gene Pulser apparatus (Bio-Rad, UK) that was set at 2.5 kV, 25 pF, and 400 U. 400 
pi of LB broth was added immediately to the cuvette and cells were incubated in an 
eppendorf tube for 30 minutes at 37°C to recover. The electric pulse causes the formation of 
temporary aqueous pores in cell membrane by disruption of phospholipid bilayers. This 
damage results in increased electric potential across the membrane so that charged 
molecules like DNA move through the pores. As this movement takes place the cell 
membrane discharges and the pores quickly close. Transformed bacteria were then plated 
onto ampicillin selective agar plates (ampicillin corresponds with the resistance offered by 
plasmids used in these studies) and the plates were incubated overnight at 37°C.
After incubation a single colony was selected and grown in 10 ml o f selective ampicillin 
liquid bacterial broth overnight in 37°C shaker. 100 pi of this culture were transferred in 100 
ml of selective LB medium and grown again overnight in 37°C shaker before plasmid 
purification.
2.2.8.5 Purification of plasmids
All plasmids were purified using the Pure Link™ HiPure Plasmid DNA Purification Kit 
(Invitrogen, UK). The bacteria were harvested by centrifugation for 30 minutes at 3500 g 
and resuspended with 4 ml of resuspension buffer containing RNase prior to lysis with 4 ml 
of lysis buffer. The lysates were incubated for 5 minutes at room temperature. 4 ml o f 
precipitation buffer were added and lysates were clarified at 18°C for 10 minutes at 3500 x 
g. The cleared lysates were applied to pre-equilibrated anion exchange midi columns. DNA  
interacts with the positive charges on the surface of the resin. Under moderate salt condition, 
plasmid DNA binds to the resin while proteins, carbohydrates and other impurities are 
washed away with wash buffer. The washing was performed twice with 10 ml of wash 
buffer with high salt concentrations. The plasmid DNA was eluted under low salt condition
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with 5 ml o f elution buffer. The columns were allowed to drain by gravity flow. 3.5 ml of 
isopropanol were added to precipitate the plasmid DNA. The samples were centrifuged at 
4°C for 30 minutes at 15000 x g. The DNA pellet was washed in 3 ml 70% ethanol followed 
by centrifugation at 4°C for 10 minutes at 15000 x g. The supernatant was decanted and the 
tube was allowed to dry horizontally at room temperature. The plasmid DNA was 
resuspended in 50 fi\ of TE buffer. The concentration of DNA was determined 
spectrophotometrically at 260 nm (Genequant, UK).
2.2.8.6 Restriction digest analysis and agarose gel electrophoresis 
5 fi\ of plasmid DNA was digested in 50 /d reaction volume with 20 U ofX ho I plus B am ll 
and 10X Surecut buffer B at 370C for 2 hours and visualised via electrophoresis on 2% 
agarose gel (Figure 2.17). Digested DNA samples were mixed with 10 fil of loading buffer 
and loaded into the wells o f a 2% agarose gel in vertical electrophoresis column (Hoeffer- 
Pharmacia SE280, UK) with IX  EPB as running buffer. A 1 kbp DNA ladder 
(Fermentas/NEB, UK) and a 100 bp ladder (Fermentas/NEB, UK) were also loaded to serve 
as size standards. The column was connected to a Consort E l43 power supply and samples 
electrophoresed at 100 V  for 60-90 minutes. Gels were stained with ethidium bromide (200 
fig/ml) and DNA was visualised using BIORAD U V  transiluminator.
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220 227
t o
1
238
4000 bp 
3000 bp 
2000 bp 
1500 bp
1000 bp 
500 bp
Well(s) ILR # (Plasmid) Size (bp)
1, 4, 7, 10 and 13 1 kbp ladder -
3, 6, 9, 12 and 15 100 bp ladder -
2 217 (N F kB firefly reporter) 5000
5 231 (IFN-p firefly reporter) 2000 + 5000
8 220 (TLR3 expression) 1000 + 5000
11 227 (RIG-I expression) 940 + 5200
14 238 (phRL-TK Renilla reporter) 4000
Figure 2.17: Agarose gel electrophoresis (panel A) and restriction digest analysis (panel B) of 
plasmids used to determine NF-kB and IFN-p promoter activation by Dual-Luciferase® Reporter 
Assay. (ILR # - internal laboratory reference number)
2.2.8.7 Transfection o f HEK293
HEK293 cells (2 x 104 cells/well) were plated into 96 well plate in DMEM with 10% FBS. 
HEK293-TLR3 and HEK-RIG-I cells (2 x 104 cells/well) were plated into 96 well plate in 
DMEM with 10% FBS and 500 pglmX of G418. After 24 hours cells were transfected with 
0.3 fig of NF-kB or IFN-P firefly luciferase reporter plasmids, 0.3 jUgof TLR3 or RIG-I 
expression vectors and 0.03 fig of Renilla luciferase reporter plasmids (at different
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combinations). More precisely, for each transfection, sample complexes were prepared as 
follows:
DNA was diluted in 50 fil of Opti-MEM* I Reduced Serum Medium (Gibco,
UK),
1 /d of transfection reagent FuGENE™ 6 (Roche, UK) was diluted in 50 fil of 
Opti-MEM001 Reduced Serum Medium before incubation for 5 minutes at room 
temperature,
after 5 minutes incubation, the diluted DNA was combined with diluted 
FuGENE™ 6, this solution was incubated for 20 minutes at room temperature,
100 fil of these complexes were added to each well containing cells and
medium.
Cells were incubated for 24 hours at 37°C prior to co-transfection with poly(I-C), as 
described above, or infection with influenza or measles virus. The reporter gene activity was 
assessed 6 (NF-kB) and 12 hours (IFN-P) later.
FuGENE™ 6 is a nonliposomal lipid-based transfection agent. After forming a complex 
with DNA/RNA FuGENE™ 6 interacts with the cell membrane. Unlike the liposomal 
transfection reagents, which envelopes DNA/RNA and then fuse with cell membrane, 
nonliposomal lipids form micelles of different sizes that are taken up by the cells by 
endocytosis and then released in the cytoplasm.
2.2.8.8 Transfection of BEAS-2B cells
Unlike HEK293 cells, BEAS-2B cells were transfected in suspension with 0.3 fig of NF-kB 
firefly luciferase reporter plasmids and 0.03 fig o f Renilla luciferase reporter plasmids or 
IFN-P firefly luciferase reporter plasmids and 0.03 fig of Renilla luciferase reporter 
plasmids. First DNA/FuGENE™ 6 complexes were prepared in 96 well plate and then
BEAS-2B ( lx l  04 cells/well) were plated in F-12K with 10% FBS. Cells were incubated for 
24 hours at 37°C prior to transfection with poly(I-C) or infection with respiratory viruses.
2.2.8.9 Measurement of luciferase activity
Briefly, transfection reactions were removed from the cells and 40 /d of IX  passive lysis 
buffer were dispensed into each culture well. Sufficient quantity of the IX  passive lysis 
buffer was prepared by adding 1 volume of 5X passive lysis buffer (Promega, UK) to 4 
volumes o f enotoxin-free water. The plate was placed on a rocking platform for 15 minutes 
at room temperature. 40 /d of cell lysate were dispensed to a luminometer plate (Nunc, 
Denmark). Two different methods and two different luminometers were applied to 
determine enzymes activity.
100 fil of luciferase assay reagent II were carefully transferred manually into a 
luminometer plate containing cell lysate (to all samples at the same time), the plate was 
placed in the luminometer (Microtiter plate luminometer, Dynex Technologies, UK) and the 
reading was initiated (1 second per each well). The firefly luciferase activity was recorded. 
Luciferase assay reagent II was prepared by resuspending the provided lyophilized 
luciferase assay substrate (Promega, UK) in 10 ml of the supplied luciferase assay buffer II 
(Promega, UK). Luciferase assay reagent II was aliquoted and stored frozen at -70°C. 
Following luciferase activity measurement, the plate was removed from the luminometer 
and 100 fil of Stop &  Glo reagent were added manually as described above. The plate was 
replaced in the luminometer and the reading was initiating (1 second per each well). This 
time the Renilla luciferase activity measurement was recorded. Sufficient quantity of the 
Stop &  Glo reagent was prepared by adding 1 volume of 50X Stop &  Glo substrate 
(Promega, UK) to 50 volumes of Stop &  Glo buffer (Promega, UK) in a glass tube.
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The plate was placed in luminometer (FLUOstar Optima, BMG LABTECH, 
UK) and 100 (i\ of luciferase assay reagent II were injected automatically into each well 
shortly before the measurement. The reading was initiated (10 seconds per each well) and 
the firefly luciferase activity was recorded. Without removing the plate from the machine 
100 fil of Stop &  Glo reagent were injected automatically, again into each well shortly 
before the measurement. The reading was initiated (10 seconds per each well) and the 
Renilla luciferase activity was recorded.
2.2.8.10Effect of poly(I-C) on NF-kB and IFN-/3 promoters activation in HEK293 
cells
HEK293 cells transfected with NF-kB and TLR3, NF-kB and RIG-I, IFN-/3 and TLR3 or 
IFN-/3 and RIG-I were co-transfected with 1 /zg/ml of poly(I-C). The reporter gene activity 
was assessed after 6 (NF-kB) or 12 hours (IFN-P).
2.2.8.11 Effect o f poly(I-C), influenza virus and measles virus on NF- kB and IFN-/3 
promoters activation in BEAS-2B cells
BEAS-2B cells transfected with NF-kB or IFN-/3 reporter plasmid were co-transfected with 
1 fJLg/m\ of poly(I-C), infected with influenza virus at an MOI 1 or infected with measles 
virus at the MOI 0.05. The reporter gene activity was assessed after 6 (NF-kB) or 12 hours 
(IFN-P).
2.2.8.12Effect o f poly(I-C), influenza virus and measles virus on N F- kB promoter 
activation in HEK293, HEK293-TLR3 and H EK 293-R IG -I cells 
HEK293, HEK293-TLR3 or HEK293-RIG cells transfected with N F -k B reporter plasmid 
were co-transfected with 50 /zg/ml of poly(I-C), infected with influenza virus at an MOI 1 or
infected with measles virus at an MOI 0.05. The reporter gene activity was assessed after 6
hours.
2.2.8.13 Effect o f pulmonary surfactant and dexamethasone on measles virus induced 
N F- k B promoter activation and poly(I-C), influenza virus and measles virus induced 
IFN-/3 promoter activation in BEAS-2B cells
BEAS-2B cells transfected with N F -k B reporter plasmid were incubated with 500 fig/ml o f 
Curosurf® (batch # 069097), 500 fig/ml of Survanta® (batch # 41-957-27) or 1 fig/ml of 
dexamethasone for 2 hours. Following incubation, Curosurf®, Survanta® or dexamethasone 
solutions were removed and cell were washed once with F-12K medium before infection 
with measles virus at the MOI 0.05. The reporter gene activity was assessed after 6 hours. 
BEAS-2B cells transfected with IFN-/3 reporter plasmid were incubated with 500 fig/ml of 
Curosurf® (batch # 069097), 500 fig/ml of Survanta® (batch # 41-957-27) or 1 fig/ml of 
dexamethasone for 2 hours. Following incubation, Curosurf®, Survanta® or dexamethasone 
solutions were removed and cell were washed once with F-12K medium before co­
transfection with 1 fig/ml of poly(I-C), infection with influenza virus at the MOI 1 or 
infection with measles virus at the MOI 0.05. The reporter gene activity was assessed after 
12 hours.
2.2.8.14Effect o f Curosurf® and dexamethasone on poly(I-C) and measles virus 
induced N F- kB promoter activation in HEK293-TLR3 and H E K 293-R IG -I cells 
HEK293, HEK293-TLR3 or HEK293-RIG-I cells transfected with N F -kB reporter plasmid 
were incubated with 500 fig/ml of Curosurf® (batch # 069097) or 1 fig/ml of dexamethasone 
for 2 hours. Following incubation, Curosurf® or dexamethasone solutions were removed and 
cell were washed once with DMEM medium before co-transfection with 1 fig/ml of poly(I-
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C) or infection with measles virus at the MOI 0.05. The reporter gene activity was assessed
after 6 hours.
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2.2.9 IT  equipment and software
Immunofluorescence was examined using the fluorescence microscope Olympus BX5I and 
AxioVision software version 4.4. Plates with haemagglutination tests, TCID50 and plaque 
assays were scanned on a flat bed scanner HP Scanjet 5470C, using HP Precisionscan Pro 
software version 3.1 and examined by using COREL00 PHOTO -  PAINT00 X3 software 
version 3. Luciferase activity was measured using Microtiter Plate Luminometer DYNEX  
TECHNOLOGIES and Revelation M LX software version 4.25 or FLUOstar OPTIMA  
Luminometer BMG LABTECH and FLUOstar* OPTIMA software. Statistical analysis was 
performed using SPSS software version 12. Bibliography was created using Reference 
Manager software version 10.
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3 Results
3.1 Generation and quantitation of viral stocks
Viral stocks of A/Swine/1976/31, A/WSN/33 and A/PR/8/34 influenza viruses were 
prepared in 7 day old embryonated chicken eggs (ECEs) of specific pathogen free origin. 
This method was previously reported to yield generally higher titers when compared to 
propagation in cell culture system (Clavijo et al. 2002). All strains of influenza virus used in 
this study grew to high titer as determined by haemagglutination test (Table 3.1). Although 
titers varied between preparations from different eggs, the titer of human influenza virus 
reached a value of 811920 HAU/ml in 9 out of 12 inoculated eggs (A/WSN/33: SPF-11, 
SPF-12, SPF-15 and A/PR/8/34: SPF-2, SPF-3, SPF-4, SPF-6, SPF-9, SPF-10). The titer of 
swine influenza virus was lower but still at a significant quantifiable level of 20480 
HAU/ml, in all eggs from which allantoic fluids were obtained (A/Swine/1976/31: SPF-3, 
SPF-5, SPF-8, SPF-9).
For the first stock preparation of A/Swine/1976/31 amniotic and allantoic fluids were 
collected separately for analysis. The yield of amniotic fluid (1ml on average) was much 
lower than the yield of fluid obtained from allantoic cavity (7 ml on average) therefore 
A/WSN/33 and A/PR/8/34 inoculation infective amniotic fluid was harvested together with 
allantoic fluid for each ECE (4 ml on average for A/WSN/33 strain and 6 ml on average for 
A/PR/8/34 strain) (Table 3.1).
A/WSN/33 and A/PR/8/34 influenza viruses were also propagated in MDCK cells. 
Surprisingly, only the growth of A/WSN/33 was supported by these cells (Table 3.1). Both 
human strains were previously shown to be successfully propagated in MDCK cells 
(Someya et al. 1990;Turan et al. 1996), however the ability of influenza virus to replicate in 
ECEs and cell culture system depends on the origin of virus strain. These results indicate 
that A/PR/8/34 strain (obtained from ECACC) was ECE adapted whereas A/WSN/33 strain
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(also obtain from ECACC) was both ECE and cell culture adapted. As expected, the titer of 
A/WSN/33 isolated in cell culture (5120 HAU/ml) was much lower than the titer of this 
strain grown in ECEs (81920 HAU/ml) (Table 3.1).
The infection of MDCK cells with influenza virus was performed in the presence of high 
purity TrypLE or TPCK-treated trypsin. The addition of trypsin to cell culture medium has 
been shown to stimulate the growth of influenza virus and to enable many influenza virus 
strains to form plaques with high efficiency (Tobita et al. 1975). This was achieved by 
enzymatic cleavage of the precursor HA molecule (HAO) into two subunits (HA1 and HA2) 
and by mediating the fusion of the viral envelope with the endosomal membrane. In our 
hands, the growth ability of A/WSN/33 strain in the presence of high purity TrypLE was 
identical to that in the presence of TPCK-treated trypsin (Table 3.1). Possible explanation 
for the observed result is that HA of ECE adapted A/WSN/33 strain was already activated 
by protease present in allantoic fluid o f embryonated eggs (factor X-like enzyme), which has 
been previously shown for influenza virus (Gotoh et al. 1990), and not by addition of 
exogenous proteases.
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Virus Host Sample Volume
(ml)
HAU/50 HAU/ml
A/Swine/1976/31 ECE SPF-1* 0.5 0 0
SPF-2* 0.7 0 0
SPF-3* 0.8 512 10240
SPF-4* 1.5 64 1280
SPF-8* 0.4 256 5120
SPF-9* 2.6 512 10240
SPF-3** 5 1024 20480
SPF-5** 5 1024 20480
SPF-8** 9 1024 20480
SPF-9** 8 1024 20480
A/WSN/33 SPF-11 *** 4 4096 81920
SPF-12*** 4 4096 81920
SPF-14*** 3 16 320
SPF-15*** 3 4096 81920
SPF-16*** 5 8 160
SPF-17*** 4 2 40
A/PR/8/34 SPF-2*** 5 4096 81920
SPF-3*** 5 4096 81920
SPF-4*** 4 4096 81920
SPF-6*** 8 4096 81920
SPF-9*** 7 4096 81920
SPF-10*** 6 4096 81920
A/WSN/33 MDCK TrypLE 9 256 5120
TPCK 9 256 5120
A/PR/8/34 TrypLE 9 0 0
TPCK 9 0 0
ECE -  embryonated chicken egg
* - amniotic fluid
**  - allantoic fluid
* * *  - amniotic fluid + allantoic fluid
Table 3.1: Characterisation of influenza virus growth in embryonated chicken eggs and 
MDCK cells by haemagglutination test.
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3.2 Characterisation of influenza virus infection in target cell lines by 
TCID50 and immunofluorescence
The biological properties associated with infectivity and pathogenicity of prepared influenza 
virus stocks were examined by immunofluorescence and TCID50, respectively (Table 3.2). 
At different stages of viral life cycle such as uptake by endocytosis (Sieczkarski &
Whittaker 2003), transcription and replication in the cell nucleus (O'Neill et al. 1995) or 
assembly in the cytoplasm (O'Neill et al. 1998; Neumann et al. 2000) influenza virus 
proteins can be detected in different cellular compartments by immunofluorescence staining. 
The number of influenza positive cells correlates with active infection and entry of the virus. 
However, only after the release of new influenza virus the host cell dies and this cytotoxic 
effect which correlates with pathogenicity and virulence of the virus can be evaluated by 
TCID50. Therefore infection and pathogenicity of A/Swine/1976/31, A/WSN/33 and 
A/PR/8/34 viruses were assessed in kidney epithelial cells MDCK and two different lung 
epithelial cell lines BEAS-2B and A549. The MDCK cell line is the most efficient cell 
system for the plaque assay of influenza virus available at the present (Gaush &  Smith 
1968). Human bronchial and alveolar epithelial cells are the primary site for influenza virus 
infection in lungs. Therefore they were tested along with MDCK cells because they would 
constitrute the final airway model.
According to these results, A/WSN/33 grown in embryonated chicken eggs was 
characterised as the strain of highest pathogenicity (1.3xl07TCID50/ml) and infectivity 
(2.5xl07 IC/ml) in MDCK cells. Similarly, virulence (5.6xl04 TCID50) correlated with 
infectivity (9.0x104 IC/ml) o f the same strain of influenza virus derived from cell culture in 
MDCK cells. The high pathogenicity of A/WSN/33 strain was previously reported in 
MDCK cells as well as in mice and was surprisingly associated with NA of this strain. The 
lack of conserved glycosylation sites of N A  determines the virulence of influenza virus
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A/WSN/33 strain (Li et al. 1993). On the other hand, A/Swine/1976/31 and A/PR/8/34 were 
found to exhibit lower pathogenicity (3.2xl03 TCID50/ml and 3.2x104 TCID50/ml, 
respectively) albeit high infectivity (2.7xl06 IC/ml and 1.1 xlO8 IC/ml, respectively) in these 
cells. These results indicate that the life cycle of A/Swine/1976/31 and A/PR/8/34 strains 
was not completed in MDCK cells. The same pattern was observed for bronchial and 
alveolar epithelial cells. All influenza virus strains tested had lower pathogenicity than 
infectivity in these cells, suggesting that viral budding was also impaired in all lung cells 
tested. This might result in the lower yield of the virus at the site of inflammation and the 
suppression of cytokine production associated with the secondary infection of the influenza 
virus.
The infectivity of two human influenza viruses, measured by immunofluorescence, was 
higher than the infectivity found for swine influenza virus in all cell lines used therefore 
A/WSN/33 and A/PR/8/34 were chosen for further experiments. The observed effect could 
be due to receptor preference of different influenza virus strains. Human trachea contains 
sialic acids with a-(2,6) linkages which preferentially bind human strains of influenza virus. 
In addition, the viral titer, measured by immunofluorescence, for all strains used was higher 
in MDCK and BEAS-2B cells than in A549 cells therefore BEAS-2B cells were selected as 
a model for further studies. This result indicates that the main sites of entry for these strains 
of influenza virus in lungs may be bronchioles.
In the light of these results, the effect of pulmonary surfactant on influenza virus A/WSN/33 
and A/PR/8/34 infected human bronchial epithelial cells BEAS-2B was the major focus of 
this work. For the purpose of this study all MOIs given were based on the “infectivity” titers 
determined by the immunofluorescence method.
To exclude any stimulatory effect associated with contamination by LPS, all viral stocks 
were shown to be free from bacterial endotoxins by LAL assay (data not shown).
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Virus M D CK BEAS-2B A549
TCID50/ml IC/ml TCID50/ml IC/ml TCID50/ml IC/ml
A/Swine/1976/31* 3.2xl03 2.7xl06 0 8.0xl05 3.2xl02 3.0xl05
A/WSN/33 
SPF-11
1.3xl07 2.5xl07 3.2xl04 1.6xl07 3.2xl03 5.6xl06
A/PR/8/34
SPF-2
3.2xl04 l.lx lO 8 3.2xl04 4.0xl08 0 5.0xl06
A/WSN/33
TrypLE
5.6xl04 9.0x104 - “ “ “
A/PR/8/34
TPCK
3.2xl02 - “ “ “
* - after Optiprep purification
Table 3.2: Characterisation of influenza virus in target cell lines by TCID50 and 
immunofluorescence.
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3.3 Optiprep™ purification
The titer of A/Swine/1976/31 (20480 HAU/ml) determined by haemagglutination test was 
lower than the titer of A/WSN/33 and A/PR/8/34 (81920 HAU/ml) therefore this strain was 
further subjected to density gradient centrifugation to concentrate low titer virus from ECE 
fluids. As an alternative to sucrose, iodixanol was investigated as the density gradient 
medium. Iodixanol was successfully used previously for purification of various viruses, 
including respiratory syncytial virus (RSV) (Gias et al. 2007), human immunodeficiency 
virus type 1 (HIV-1) (Dettenhofer &  Yu 1999), recombinant adeno associated virus (rAAV) 
(Hermens et al. 1999), Moloney murine leukemia virus (MoMLV)-derived retrovirus 
particles (Moller-Larsen &  Christensen 1998; Segura et al. 2006) and hepatitis C virus 
(HCV) (Nielsen et al. 2006).
Allantoic fluid was underlayed with 10 ml of 15%, 8 ml of 25% and 7 ml of 40% iodixanol. 
After centrifugation, the gradient was collected by gravity flow into twenty 1 ml fractions. 
The titer of influenza virus in each fraction was determined by haemagglutination test 
(Table 3.3). A haemagglutination peak higher than the input titer was observed only in 
Optiprep™ gradient number 1, fraction 8 (40960 HAU/ml). The haemagglutination peaks 
equal to the input concentration were obtained in Optiprep™ gradient number 2, fractions 6 
and 7 (20480 HAU/ml) (Figure3.1). The gradient fractions containing the most concentrated 
virus band were pooled and analysed by immunofluorescence and TCID50. Detection of 
influenza virus strain A/Swine/1976/31 after gradient centrifugation by immunofluorescence 
proved that purified particles were still infective. The apparent peaks seen in Optiprep™ 
gradients number 1 and 2 did not occur in other gradients therefore high concentrations 
obtained in two first gradients were not reproducible. In all ten gradients performed 
influenza virus was distributed through all density steps (15%, 25% and 40%) therefore 
concentration of influenza virus in a small volume of the iodixanol was also not achieved.
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The presence of influenza virus in iodixanol medium at the lowest dilution (40%) showed 
that layer(s) of less diluted or undiluted Optiprep™ should also be included in this method 
in the future. In addition, an increased gradient centrifugation time might be more efficient 
than one hour gradients in the process of influenza virus purification. Interestingly, in 
Optiprep™ gradients number 4, 7, 8 and 9 two separated peaks were observed which might 
suggest the presence of two different morphological forms of this virus. Additional electron 
microscopy studies would be required to ascertain if  this is the case.
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Fraction Optiprep gradient number
number 1 2 3 4 5 6 7 8 9 10
HAU/50 p\
1 1 0 2 1 1 1 2 2 1 2
2 0 0 2 1 4 2 2 2 1 4
3 0 4 1 8 64 8 1 2 16 64
4 0 32 8 128 128 32 1 8 128 256
5 0 128 128 256 256 128 8 128 256 256
6 4 1024 256 512 256 128 512 512 512 256
7 256 1024 256 512 256 256 512 256 512 256
8 2048 512 256 256 256 256 256 256 256 256
9 512 512 256 256 256 512 256 512 512 512
10 256 512 256 512 256 512 256 512 512 512
11 256 256 256 512 256 512 256 512 512 256
12 128 256 512 256 256 512 256 512 512 256
13 128 128 256 128 128 512 512 256 256 256
14 128 64 128 128 128 256 256 256 256 256
15 128 64 128 128 128 256 256 256 128 256
16 128 64 128 128 128 256 256 256 128 128
17 128 64 128 128 128 256 256 256 128 128
18 128 64 128 128 128 128 256 256 128 128
19 128 128 128 128 64 128 256 128 128 128
20 64 64 128 64 64 128 256 128 128 64
Table 3 3 : Characterisation of fractions from 10 different Optiprep™ gradients.
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Figure 3.1: Characterisation o f fractions from Optiprep™ gradient 1 and 2
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3.4 Pulmonary surfactant is generally non-toxic in human airway 
epithelial cells
Prior to assessing the effect of pulmonary surfactant on inflammatory responses and cell 
signalling pathways induced in influenza virus treated airway epithelial cells it was essential 
to determine whether surfactant had any effect on cellular viability or viral entry in these 
cells.
Cell viability was assessed using the CellTiter96® A Q ue0us one solution cell proliferation 
assay. Three different batches of Curosurf® (batch # 061350, 066120 and 069097) and two 
different batches of Survanta® were tested (batch # 40-705-27 and 41-957-27). The 
following concentrations of pulmonary surfactant preparations were tested; 500, 250 and 
125 /ig/ml reflecting the physiological concentrations of pulmonary surfactant in lungs 
(Griese 1999). Briefly, BEAS-2B cells were incubated with Curosurf® or Survanta® for 2 
hours before washing. Cell viability was determined at different time points (24, 48 and 72 
hours).
The viability of BEAS-2B cells treated with Curosurf® (batch # 066120 and 069097) and 
Survanta® (batch # 40-705-27 and 41-957-27) was not significantly different from control 
cells with respect to reduction of novel tetrazolium salt. Across a wide range of 
concentrations of these pulmonary surfactant preparations were not toxic for BEAS-2B cells 
and viability of cells remained at greater than 90% under the various conditions assessed 
(Figure 3.2 and 3.3).
Surprisingly, Curosurf® batch #061350 showed a strong cytotoxic effect on BEAS-2B 
cells, this was seen to be dose dependent. Viability of these cells incubated with 500 (jlg/ml 
of Curosurf® batch # 061350 for 2 hours was reduced to 47 and 43% after 48 and 72 hours, 
respectively. In addition, Curosurf® batch # 061350 also had a cytotoxic effect on A549 
cells, however viability of these cells did not fall below 80% (Figure 3.4).
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Figure 3.2: Effect of Curosurf® (batch # 066120 -  panel A and batch # 069097 -  panel 
B) on BEAS-2B cell viability. BEAS-2B cells were incubated w ith different concentrations 
o f Curosurf0 (500, 250, 125, 62.5 and 31.25 jwg/ml) for 2 hours. Cell v iab ility  was 
determined at different time points (24, 48 and 72 hours). Each experimental condition was 
tested in quadruplicate. Results are expressed as mean ±  1 SD o f 3 separate experiments. * P 
< 0.05 using unpaired t-test comparison.
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Figure 33: Effect of Survanta® (batch # 40-705-27 -  panel A and batch # 41-957-27 -  
panel B) on BEAS-2B cell viability. BEAS-2B cells were incubated w ith different 
concentrations o f  Survanta00 (500, 250, 125, 62.5 and 31.25 /zg/ml) for 2 hours. Cell v iab ility  
was determined at different time points (24, 48 and 72 hours). Each experimental condition 
was tested in quadruplicate. Results are expressed as mean ± 1 SD o f 3 separate 
experiments. * P < 0.05 using unpaired t-test comparison.
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Figure 3.4: Effect of Curosurf® (batch # 061350) on BEAS-2B (panel A) and A549 cell 
(panel B) viability. BEAS-2B and A549 cells were incubated with different concentrations 
of Curosurf0 (500, 250, 125, 62.5 and 31.25 /zg/ml) for 2 hours. Cell viability was 
determined at different time points (24, 48 and 72 hours). Each experimental condition was 
tested in quadruplicate. Results are expressed as mean ±1  SD of 3 separate experiments. * P 
< 0.05 using unpaired t-test comparison.
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3.5 Pulmonary surfactant does not affect infectivity of influenza virus 
in bronchial epithelial cell
As shown in the last experiment, the toxicity of pulmonary surfactant in human airway 
epithelial cells appeared to be batch dependent. For that reason, only batches of Curosurf00 
and Survanta00 which were previously shown to be non-toxic, were used in further 
experiments. The effect of Curosurf00 (batch # 066120) and Survanta00 (batch # 41-957-27) 
on influenza virus infectivity in BEAS-2B cells was investigated by plaque assay. 
Pulmonary surfactant preparations were tested at three different concentrations (500, 250 
and 125 fig/ml). BEAS-2B cells were incubated with pulmonary surfactant for 2 hours and 
then, after washing, infected with influenza virus. The number of plaques was determined 
after 24 hours. Neither pre-incubation with Curosurf00 nor pre-incubation with Survanta00 
changed the titer of influenza virus strains A/WSN/33 and A/PR/8/34 (Figure 3.5) as 
determined by plaque assay.
The results from plaque assays showed that infection of cells by influenza virus was not 
affected by pulmonary surfactant treatment.
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Figure 3.5: Effect of Curosurf® (batch # 066120) and Survanta® (batch # 41-957-27) on 
A/WSN/33 (panel A) and A/PR/8/34 (panel B) infectivity in BEAS-2B cells. BEAS-2B 
cells were incubated with different concentrations of Curosurf® or Survanta® (500, 250 and 
125 /Ltg/ml) for 2 hours, washed and then infected with influenza virus strain A/WSN/33 or 
A/PR/8/34. The number of plaques was determined after 24 hours. Results are expressed as 
mean ±1 SD of 3 separate experiments.
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3.6 Pre-treatment with Survanta does not change influenza virus 
induced cytotoxicity in bronchial epithelial cells
Although the rate of influenza virus entry did not change significantly in the presence of 
pulmonary surfactant in plaque assay, it seemed worth while extending our investigation to 
the effect of surfactant on influenza virus infected cell viability/proliferation. Assembly and 
budding of influenza virus is followed by the death of host cell, therefore these experiments 
were undertaken using CellTiter96® A Q ue0Us one solution cell proliferation assay, previously 
used to assess cell viability/proliferation in the presence of pulmonary surfactant alone. This 
colorimetric method was used to determine the effect of Survanta® (batch # 40-705-27) pre­
treatment on influenza virus infected bronchial epithelial cells. As a result of influenza virus 
infection, alveolar macrophages were previously shown to die predominantly by apoptosis, 
whereas epithelial cells were reported to undergo necrotic cell death (Fesq et al. 1994), 
which would be indicated by reduced cell proliferation and viability.
Briefly, BEAS-2B cells were incubated with different concentration of Suvanta® for 2 hours 
and then, after washing, infected with influenza virus. Cells viability was measured after 24, 
72 and 120 hours. This study examined a wider concentration range of Survanta® (five 
double dilutions from 500 to 31.25 jttg/ml). As shown before, the viability of BEAS-2B cells 
treated with Survanta® batch # 40-705-27 was not significantly different from the viability 
of untreated cells with respect to their reductive capacity of tetrazolium compound.
Different concentrations of this batch of pulmonary surfactant were not toxic for BEAS-2B 
cells and viability of these cells was greater than 90% at all time points tested (Figure 3.6 
and 3.7).
In contrast, influenza virus strain A/WSN/33 and A/PR/8/34 showed a strong cytotoxic 
effect on BEAS-2B cells which was clearly time dependent. Although the titer determined 
by TCID50 was the same for both strains in BEAS-2B cells (3.2xl04 TCID50/ml) (Table
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3.2), this effect was more pronounced for strain A/WSN/33. This result suggests that 
CellTiter96® A Q ueous one solution cell proliferation assay is a more sensitive method 
measuring the cytopathic effect of influenza virus than TCID50. Viability of BEAS-2B cells 
incubated with A/WSN/33 strain at the MOI of 2 was reduced to 80, 45 and 27% after 24,
72 and 120 hours, respectively (Figure 3.6). Viability of BEAS-2B cells incubated with 
A/PR/8/34 strain at the MOI 2 was reduced to 92, 66 and 65% after 24, 72 and 120 hours, 
respectively (Figure 3.7).
Pre-incubation with Survanta®, at all concentrations tested, did not change reduced 
proliferation rates induced by influenza virus induced death of BEAS-2B cells (Figure 3.6 
and 3.7).
In summary, neither the rate of the virus infectivity (higher for A/PR/8/34 strain, as shown 
by plaque assay) nor the negative effect of virus on cell proliferation (higher for A/WSN/33, 
as shown by proliferation assay) were affected by pulmonary surfactant treatment therefore, 
in the next step, the main attention was directed to investigate the effect of pulmonary 
surfactant on the production of inflammatory mediators during influenza virus infection.
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Figure 3.6: Effect of Survanta® (batch # 40-705-27) on BEAS-2B cell viability upon 
A/WSN/33 infection. BEAS-2B cells were incubated with different concentrations o f 
Survanta (500, 250125. 62.5 and 31.25 /tg/ml) for 2 hours and then infected w ith influenza 
virus strain A/WSN/33 at MOI 2. Cell v iab ility  was determined after 24 (panel A), 72 (panel 
B) and 120 hours (panel C). Each experimental condition was tested in quadruplicate.
Results are expressed as mean ± 1  SD o f 2 separate experiments.
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Figure 3.7: Effect of Survanta® (batch # 40-705-27) on BEAS-2B cell viability upon 
A/PR/8/34 infection. BEAS-2B cells were incubated w ith different concentrations o f 
Survanta® (500, 250125. 62.5 and 31.25 /xg/ml) for 2 hours and then infected with influenza 
virus strain A/PR/8/34 at MOI 2. Cell v iab ility  was determined after 24 (panel A), 72 (panel 
B) and 120 hours (panel C). Each experimental condition was tested in quadruplicate. 
Results are expressed as mean ± 1 SD o f  2 separate experiments.
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3.7 Influenza virus strain A/WSN/33 strain is a more potent inducer 
of cytokine production than A/PR/8/34 strain in bronchial epithelial cells
In order to investigate the effect of pulmonary surfactant on cytokine production in 
influenza virus infected human bronchial epithelial cells, a comparison of the activation of 
BEAS-2B cells by influenza virus strains A/WSN/33 and A/PR/8/34 was performed. 
Monolayers of BEAS-2B cells were challenged for various times (12, 24 and 48 hours) with 
increasing concentrations of influenza virus (MOI 0.0001, 0.001, 0.01, 0.1 and 1). 
Supernatant fluids from these cells were tested for IL-8, RANTES and IL-6 by ELISA. Both 
A/WSN/33 and A/PR/8/34 triggered secretion of IL-8 and RANTES in a MOI and time 
dependent manner, as previously described for influenza virus A/Scotland/20/74 (H3N2) in 
BEAS-2B cells (Guillot et al. 2005). When BEAS-2B cells were infected with A/WSN/33 
strain IL-8 and RANTES secretion was detected after 24 hours with a MOI of 0.1, reaching 
the maximum 48 hours after infection at the MOI of 1. Upon infection with A/PR/8/34 
cytokine production was delayed by 24 hours in comparison with that for A/WSN/33 
challenged BEAS-2B cells. IL-8 and RANTES production were significantly induced only 
48 hours after infection at the MOI of 1 (Figure 3.8 and 3.9). In the absence of influenza 
virus RANTES production was not detectable in BEAS-2B cells, although these cells 
demonstrated some background IL-8 release. BEAS-2B cells infected with influenza virus 
A/WSN/33 strain at the MOI 1 also produced higher level o f IFN-/3 than BEAS-2B cells 
infected with influenza virus A/PR/8/34 strain at the same MOI, 24 hours post-infection 
(Figure 3.10). Surprisingly in contrast to influenza virus A/Scotland/20/74 strain, none of 
the influenza virus strains used in this study induced IL-6 production in BEAS-2B cells 
(data not shown). Influenza virus strain A/WSN/33 was a more potent inducer of IL-8, 
RANTES and IFN-|8 production than A/PR/8/34 strain in BEAS-2B cells which might be
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associated with higher cytopathogenicity of this strain, as shown by us in CellTiter96® 
AQueous one solution cell proliferation assay (section 3.6).
During influenza virus infection, dsRNA has been previously shown to accumulate and 
induce inflammatory and antiviral response within infected cells (Jacobs & Langland 1996; 
Majde 2000). For that reason it was important to determine whether influenza virus induced 
activation of bronchial epithelial cells resembles that stimulated by a synthetic dsRNA such 
as poly(I-C). In BEAS-2B cells, 50 /-ig/ml of poly(I-C) triggered higher levels of secretion of 
IL-8 and RANTES than influenza virus at the MOI of 1 after 24 hours (Figure 3.10). IL-8 
and RANTES production peaked after 48 hours after influenza virus infection, suggesting 
that more time is required to generate dsRNA within the infected cells, during the 
replication of the virus, which is necessary for induction of these chemokines. These results 
are in agreement with previous data which indicates that poly(I-C) induced the secretion of 
IL-8 within 3 hours and accumulated up to 24 hours whereas the secretion of RANTES was 
induced within 6 hours and also accumulated in the culture medium up to 24 hours (Guillot 
et al. 2005). The same group showed that upon poly(I-C) stimulation IFN-/3 production 
reached the maximum level 6 hours post-stimulation but was not detected after 24 hours. 
Referring to these observations in our experiments, the production of IFN-/3 in poly(I-C) 
stimulated BEAS-2B cells was scarce in comparison to influenza virus treated cells after 24 
hours (Figure 3.10).
Finally, influenza virus and poly(I-C) induced cytokine production was compared to that 
caused by measles virus Edmonston strain. Measles virus at the MOI as low as 0.01 
triggered a stronger IL-8 production than influenza virus with MOI of 1 and 50 fig/ml of 
poly(I-C) after 24 hours in BEAS-2B cells (Figure 3.10). These results are in agreement 
with data by Sato and co-workers, who showed that in contrast to influenza virus, 
replication of measles virus Edmonston strain was not required for induction of IL-8 protein,
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in alveolar epithelial cells A549 (Sato et al. 2005). Induced synthesis of IL-8 is probably 
caused by interaction of measles virus with cell surface TLRs and/or incorporation of viral 
particles. This also affects RANTES production since measles virus at the MOI 0.01 
triggered lower RANTES production than 50 /ig/ml of poly(I-C) after 24 hours in BEAS-2B 
cells (Figure 3.10). Measles virus did not induce IFN-jS in BEAS-2B, 24 hours post infection 
(P-i)-
Two receptors have been proposed to be involved in inflammatory and anti-viral response in 
influenza infected BEAS-2B cells (Le Goffic et al. 2007). TLR3 has been shown to mediate 
NF-kB dependent gene expression whereas RIG-I has been shown to mediate both pro- 
inflammatory and anti-viral signalling pathways.
In summary, the best ELISA MOI for IL-8 and RANTES induction by the two influenza 
virus strains used was an MOI of 1. The best time was 24 hours p.i. for A/WSN/33 and 48 
hours p.i. for A/PR/8/34.
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Figure 3.8: Effect of A/WSN/33 (panel A) and A/PR/8/34 (panel B) on BEAS-2B cell 
IL-8 production. BEAS-2B cells were infected w ith influenza virus strain A/WSN/33 or 
A/PR/8/34 at different MOIs (1, 0.1, 0.01, 0.001 and 0.0001). Cell IL-8 production was 
determined after 12, 24 and 48 hours. Each experimental condition was tested in duplicate. 
Results are expressed as mean ±  1 SD o f representative o f 3 separately performed 
experiments w ith similar results.
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Figure 3.9: Effect of A/WSN/33 (panel A) and A/PR/8/34 (panel B) on BEAS-2B cell 
RANTES production. BEAS-2B cells were infected with influenza virus strain A/WSN/33 
or A/PR/8/34 at different MOIs (1, 0.1, 0.01, 0.001 and 0.0001). Cell RANTES production 
was determined after 12, 24 and 48 hours. Each experimental condition was tested in 
duplicate. Results are expressed as mean ± 1 SD of representative of 3 separately performed 
experiments with similar results.
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Figure 3.10: Effect of poly(I-C), LPS, measles virus and influenza virus on BEAS-2B 
cell IL-8, RANTES and IFN-jS production. BEAS-2B cells were stimulated with poly(I-C) 
(50 /-ig/ml) or LPS (1 jig/ml) or infected with measles virus (MOI 0.01) or influenza virus 
(MOI 1). Cytokine production was determined after 24 hours. Results are expressed as mean 
± 1 SD of 3 separate experiments.
159
3.8 Curosurf® is a more potent inhibitor of key inflammatory 
cytokines than Survanta® in bronchial epithelial cells
Following optimisation of conditions for assessing cytokine generation in BEAS-2B cells, 
the effect of Curosurf® and Survanta® on cytokine production induced by influenza virus 
was determined at 24 and 48 hours for A/WSN/33 at the MOI of 1 and 0.1 and after 48 
hours for A/PR/8/34 at the MOI 1. Pulmonary surfactant preparations were tested at three 
different concentrations (500, 250 and 125 /ig/ml). After 24 hours the release of IL-8 in 
A/WSN/33 infected BEAS-2B cells was significantly inhibited by pre-incubation with 
Curosurf® 20-30% (500 /ig/ml) and 12% (250 /ig/ml) (P < 0.05) (Figure 3.11). Pre-treatment 
with Curosurf® at all concentration used also decreased the production of IL-8 in A/PR/8/34 
challenged BEAS-2B cells by 25% after 48 hours (P < 0.05) (Figure 3.11). Similarly 
Curosurf® studied down-regulated the release of RANTES in A/WSN/33 treated BEAS-2B 
cells after 24 hours by 35% (500 /ig/ml), 12% (250 /ig/ml) and 22% (125 /ig/ml) (P < 0.05) 
(Figure 3.12). Survanta® only at the lowest concentration (125 /ig/ml) reduced IL-8 
production after 24 hours and RANTES production after 48 hours by 15 % and 25%, 
respectively, in A/WSN/33 infected BEAS-2B cells (P < 0.05) (Figure 3.13 and 3.14). The 
IL-8 inhibitory activity is already disappearing in the case of A/WSN/33 infected cells by 48 
hours p.i. A significant effect on RANTES could only be shown for A/WSN/33 infected 
BEAS-2B cells.
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Figure 3.11: Effect of Curosurf® (batch # 066120) on BEAS-2B cell IL-8 production 
upon A/WSN/33 and A/PR/8/34 infection. BEAS-2B cells were incubated w ith different 
concentrations o f Curosurf0 (500, 250 and 125 /ig/m l) for 2 hours, washed and then infected 
with influenza virus strain A/WSN/33 or A/PR/8/34. IL-8 production was determined after 
24 (panel A) and 48 hours (panel B). Each experimental condition was tested in duplicate. 
Results are expressed as mean ± 1 SD o f 3 separate experiments. * P < 0.05 using unpaired 
t-test comparison.
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Figure 3.12: Effect of Curosurf® (batch # 066120) on BEAS-2B cell RANTES 
production upon A/WSN/33 and A/PR/8/34 infection. BEAS-2B cells were incubated 
w ith different concentrations o f  Curosurf® (500, 250 and 125 [ig/ml) for 2 hours, washed 
and then infected with influenza virus strain A/WSN/33 or A/PR/8/34. RANTES production 
was determined after 24 hours. Each experimental condition was tested in duplicate. Results 
are expressed as mean ± 1 SD o f 3 separate experiments. * P < 0.05 using unpaired t-test 
comparison.
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Figure 3.13: Effect of Survanta® (batch # 41-957-27) on BEAS-2B ceil IL-8 production 
upon A/WSN/33 and A/PR/8/34 infection. BEAS-2B cells were incubated w ith different 
concentrations o f  Survanta* (500, 250 and 125 ^ig/ml) for 2 hours, washed and then infected 
w ith influenza virus strain A/WSN/33 or A/PR/8/34. IL-8 production was determined after 
24 (panel A  and 48 hours (panel B). Each experimental condition was tested in duplicate. 
Results are expressed as mean ± 1 SD o f  3 separate experiments. * P < 0.05 using unpaired 
t-test comparison.
MeM u
600 i
500 
1  400
'SU
a  300 ^
oo
j  200 
100 
0
163
A800 
1  700
ob 600 
&  500
S3 400
£  300 
<; 200 
«  100 
0 m Hfi
Cells abne A/W SN/33 M O I 1 BEAS-2B +  
A/WSN/33 M O I 
0.1
24 hours
■  Survanta 0 ug'ml
■  Survanta 500 ug'ml
□  Survanta 250 ug^ ml
□  Survanta 125 ug/ml
B
800 
700 
600 
500 
400 
300 H
C/5 UJ H
|  200 -j 
100 -  
0
Cells abne A/WSN/33  
M O I 1
A/WSN/33 
M O I 0.1
A/PR/8/34 
M O I 1
48 hours
Figure 3.14: Effect of Survanta® (batch # 41-957-27) on BEAS-2B cell RANTES 
production upon A/WSN/33 and A/PR/8/34 infection. BEAS-2B cells were incubated 
with different concentrations o f  Survanta® (batch # 41-957-27) (500, 250 and 125 ^g/m l) for 
2 hours, washed and then infected w ith  influenza virus strain A/WSN/33 or A/PR/8/34. 
RANTES production was determined after 24 (panel A) and 48 hours (panel B). Each 
experimental condition was tested in duplicate. Results are expressed as mean ± 1 SD o f 3 
separate experiments. * P < 0.05 using unpaired t-test comparison.
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3.9 Dexamethasone inhibits IL-8 but not RANTES or IFN-/3 
production in bronchial epithelial cells
N F-kB is a transcription factor involved in the production of various inflammatory 
cytokines including IL-8 (Kunsch &  Rosen 1993; Kang et al. 2007) and RANTES 
(Moriuchi et al. 1997). To test whether N F-kB mediates transcription of these cytokines 
upon influenza virus A/WSN/33 and A/PR/8/34 in BEAS-2B cells, the effect of N F -kB 
specific inhibitor dexamethasone on the release of IL-8, RANTES and IFN-/3 was 
investigated in these cells. Dexamethasone is a corticosteroid which is widely used as an 
anti-inflammatory agent. It is able to down-regulate the cellular release of different 
cytokines involved in inflammatory responses. The mechanism underlying the suppression 
of N F-kB dependent gene expression by this corticosteroid was associated with the direct 
binding of the dexamethasone to cis-regulatory element of N F -kB (Mukaida et al. 1994).
In a similar manner to pulmonary surfactant treatment, BEAS-2B cells were incubated with 
1 /^g/ml of dexamethasone for 2 hours and then exposed to poly(I-C) (50 /ig/ml), LPS (1 
/ig/ml), measles virus (MOI 0.01) or two different strains of influenza virus (MOI 1) 
(A/WSN/33 and A/PR/8/34). The concentration of dexamethasone which showed the 
strongest inhibitory effect on LPS induced IL-8 production in BEAS-2B cells without 
showing any toxic effect in these cells was used in this experiment (data not shown). Only 
IL-8 production, triggered by all stimulants, was significantly inhibited by pre-incubation 
with 1 /ig/ml of dexamethasone (by 37, 30, 26, 33 and 49%, respectively) (P < 0.05) (Figure 
3.15). In all cases, the inhibition was not complete, suggesting participation of other 
transcription factors in IL-8 production. No effect of dexamethasone pre-treatment on 
RANTES and IFN-/3 release was observed (Figure 3.15), suggesting that different 
transcription factors are involved in expression of these cytokines expression. Interestingly,
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the range of inhibition found in the presence of dexamethasone was similar to that found in 
the presence of Curosurf®.
166
A_  40000 -
1, 30000 
3  20000 H
2  10000
0
u
u
"oOh
o
ono. |>
I
O
2 s  
> © 
2
Cells alone
Dexamethasone 1 ug/ml
T~ I
So ^
e2 O 
<
B
-£  1200 
§  1000 
800 
600 
400
uU
u  s
d  ^  ^  3
I  R
mCQ
Zon
m
OO _
£  o  ^ s  
<
I o
D
100
2<L>X! 50
Z 0
<u
U
"o © (£ «o
-I------------------- r
S oT \  C/J \ 2
w  5P CU M s
Z ' hJ 3 .
l i t
cn r^rn
-H O  Z "  9s
>  © £ O c2 O 
<  <
Figure 3.15: Effect of dexamethasone on BEAS-2B cell IL-8, RANTES and IFN-0  
production. BEAS-2B cells were incubated w ith 1 /ig/m l o f  dexamethasone for 2 hours and 
then stimulated with poly(I-C) (50 /ig/m l) or LPS (1 /ig/m l) or infected w ith measles virus 
(MOI 0.01) or influenza virus (MOI 1). Cytokine production was determined after 24 hours. 
Results are expressed as mean ±  SD o f 3 separate experiments. * P < 0.05 using unpaired t- 
test comparison.
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3.10 Curosurf® and Survanta® differ in phospholipid content
Curosurf® and Survanta® showed different modulatory activity in BEAS-2B cells therefore 
Curosurf® batch # 069097 and Survanta® batch # 41-957-27 phospholipid content was 
compared by liquid chromatography (LC) since phospholipids are the major components of 
pulmonary surfactant used in these studies. Individual classes o f phospholipids were also 
assessed by mass spectrometry (MS) and some differences in fatty acids profiles were 
detected. Analysis of LC-MS profiles indicates that phosphatidylcholine (PC), phosphatidic 
acid (PA) and phosphatidylglycerol (PG) were present in both types pulmonary surfactant 
preparations (Figure 3.16 and 3.17) whereas phosphatidylethanolamine (PE) 
phosphatidylinositol (PI) were found only in Curosurf® (Figure 3.18 and 3.19), suggesting 
that these phospholipids might be involved in IL-8 and RANTES inhibition in influenza 
virus infected BEAS-2B cells. Previously, PC, PG and PI were shown to be the key 
phospholipids of pulmonary surfactant suppressing lymphocytes response to 
phytohaemagglutinin (PHA) (Wilsher et al. 1988b). Pulmonary surfactant preparations 
studied here might also differ in concentration of PC and PG however additional high 
performance liquid chromatography (HPLC) analysis would be necessary to conclude if this 
is the case. Neither Curosurf® nor Survanta® contained sphingomyelin (SM) (Figure 3.16).
In addition phospholipids profile of Curosurf® batch # 061350 which showed strong 
cytotoxic effect on BEAS-2B cells was compared to non-toxic Curosurf® batch # 069097, 
however no differences between these preparations were observed (Figure 3.16, 3.17, 3.18 
and 3.19).
The observed variations in phosholipid composition between Curosurf® and Survanta® might 
be caused by different source of pulmonary surfactant (porcine versus bovine) or different 
preparation methods. Production of Curosurf® includes removing of neutral lipids by gel-
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liquid chromatography whereas Survanta® is supplemented with DPPC, triglicerides and 
palmitic acid.
Identification o f components responsible for observed differences would require significant 
chemical investigation and assessment o f individual components biological activities which 
is beyond scope of this study.
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Figure 3 .16: Mass spectrometry of Curosurf00 (batch # 061350) (panel A), Curosurf00 (batch
# 069097) (panel B) and Survanta00 (batch # 41-957-27) (panel C) -  phosphatidylcholine
(PC) / sphingomyelin (SM).
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Figure 3.17: Mass spectrometry of Curosurf0 (batch # 061350) (panel A), Curosurf00 (batch
# 069097) (panel B) and Survanta40 (batch # 41-957-27) (panel C) -  phosphatidic acid (PA) /
phosphatidylglycerol (PG).
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Figure 3.18: Mass spectrometry of Curosurf40 (batch # 061350) (panel A), Curosurf00 (batch
# 069097) (panel B) and Survanta00 (batch # 41-957-27) (panel C) -
phosphatidylethanolamine (PE).
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Figure 3.19: Mass spectrometry o f Curosurf0 (batch # 061350) (panel A), Curosurf00 (batch 
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(PI).
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3.11 Characterisation o f signalling pathways involved in cytokine and 
chemokine production in virus infected HEK293 and BEAS-2B cells
3.11.1 TLR3 mediates IFN-/3 promoter activation induced by dsRNA whereas 
RIG-I mediates IFN-/3 promoter activation induced by dsRNA and influenza 
virus in HEK293 cells
In our previous experiments, influenza virus was shown to induce IL-8, RANTES and IFN-jS 
production in bronchial epithelial cells. The production of IL-8 and RANTES was 
significantly inhibited in the presence o f pulmonary surfactant which was assessed at the 
protein level by ELISA. In order to explore possible mechanism the activation of NF-kB and 
IFN-/3 promoters in TLR3 and R IG -I transfected cells was assessed using the Dual- 
Luciferase^ Reporter Assay System. TLR3 and RIG -I receptors play an important role in 
innate immunity and have been previously shown to be involved in ssRNA and dsRNA 
induced pro-inflammatory and anti-viral responses (Le Goffic et al. 2007), whereas in this 
study, activation o f NF-kB transcription factor was found to be directly involved in the 
production of IL-8 in influenza virus infected bronchial epithelial cells.
The activity o f pulmonary surfactant in this assay was assessed in comparison to the activity 
of dexamethasone in influenza virus as well as measles virus and dsRNA treated cells. 
Synthetic dsRNA was found to be a more potent inducer of IL-8 and RANTES production 
than influenza virus (A/WSN/33 and A/PR/8/34 strains) in BEAS-2B cells, as measured by 
ELISA. For that reason poly(I-C) was used initially to investigate NF-kB and IFN-jS 
promoter activation, both TLR3 and RIG -I mediated, in transiently transfected HEK293 
cells. Briefly, HEK293 cells were transfected with 300 ng of expression vectors for TLR3 or 
RIG-I, 300 ng of NF-kB or IFN-/5 luciferase reporter gene and 30 ng o f Renilla luciferase 
internal control. After 24 hours cells were co-transfected with poly(I-C) (1 /zg/ml). In
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comparison to Genejuice and Metafectene, FuGENE 6 was shown to be the most efficient 
transfection agent (data not shown) therefore this reagent was selected for all transfection 
experiments, including synthetic dsRNA administration. A comparison study shown that 
IFN-/3 promoter activation was stronger in HEK293 cells co-transfected with poly(I-C) than 
in HEK293 cells stimulated with poly(I-C) (4 folds vs.l fold o f induction via TLR3 and 10 
folds vs. 4 folds o f induction via R IG -I) (data not shown).
Luciferase activity was measured 6 (NF-kB) and 12 (IFN-/3) hours later. Firefly luciferase 
values were divided by Renilla luciferase values to normalise for transfection efficiency. For 
this series of experiments the results were presented as firefly luciferase values divided by 
Renilla luciferase values presented as fold induction over mock.
Surprisingly, in this luciferase reporter assay, neither TLR3 nor R IG -I expression mediated 
NF-kB promoter activity in HEK293 cells after poly(I-C) co-transfection. However, both 
TLR3 and RIG -I expression mediated IFN-P promoter activation in these cells upon 
transfection with poly(I-C) (Figure 3.20). Induction of IFN-P by dsRNA was both TLR3- 
and RIG-I-mediated however in the presence of R IG-I, IFN-P promoter activation was 
stronger (14 folds vs. 12 folds of induction) which was in agreement with earlier studies by 
Opitz and co-workers (Opitz et al. 2007). The same pattern of activation was observed using 
influenza virus A/WSN/33 strain as a stimulant. Although it was shown that this strain 
induced significant amounts of IL-8, NF-kB promoter was not activated in this assay. Only 
transient expression of RIG-I but not TLR3 mediated IFN-P promoter activation upon 
A/WSN/33 infection (2 folds o f induction) in HEK293 cells (data not shown). Detectable 
luciferase activity from IFN-/3 reporter plasmid in the presence of A/WS/33 suggests that 
HEK293 cells are permissive for influenza virus infection. No effect was observed with 
influenza virus A/PR/8/34 strain (data not shown). Lack o f the signal from NF-kB luciferase 
reporter gene might be associated with the method o f transfection. In transient transfection,
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certain plasmids might be lost from the cells during cell mitosis. It was decided to use stably 
transfected cell lines as an alternative option. In addition, functionality of this reporter might 
have been impaired therefore additional studies with different cell lines were also included 
in the next stage of this work.
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Figure 3.20: Effect of poly(I-C) on HEK293 cells N F -kB promoter and IFN-/5 promoter 
activation. HEK293 cells were transfected w ith 1 /tg/ml o f  poly(I-C). NF-kB promoter and 
IFN-/3 promoter activation were measured after 6 and 12 hours, respectively. Results are 
expressed as mean ±  1 SD o f 2 separate experiments.
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3.11.2 dsRNA and influenza virus induce IFN-/3 promoter promoter activation 
whereas measles virus induces NF-kB and IFN-/3 promoter activation in 
BEAS-2B cells
Signalling events involved in cytokine and chemokine production were also investigated in 
BEAS-2B cells. Previously Guillot and co-workers showed that TLR3 and R IG -I receptors 
are constitutively expressed in resting BEAS-2B cells (Guillot et al. 2005; Le Goffic et al. 
2007) therefore these cells were only transfected with 300 ng of N F -kB or IFN-/3 luciferase 
reporter gene and 30 ng of Renilla luciferase internal control. After 24 hours cells were 
infected with measles virus (M OI 0.05) or influenza virus strain A/WSN/33 (M OI 1) or co­
transfected with poly(I-C) (1 /tg/ml). Luciferase activity was measured 6 (N F-k B) and 12 
(IFN-/3) hours later using the Dual-Luciferase4* Reporter Assay System. Like in HEK293 
cells, poly(I-C) significantly induced only IFN-P (190 folds o f induction) but not N F -k B 
promoter activation in BEAS-2B cells (Figure 3.21). However, the luciferase activity from 
N F -kB reporter plasmid was measured in the presence of measles virus in BEAS-2B cells 
(13 folds of induction) (Figure 3.21) and in A549 cells (5 folds of induction) (data not 
shown) and upon addition of LPS (10 /zg/ml) to HEK293 cells, transiently expressing TLR2 
(4 folds of induction) or TLR2 together with CD14 (3 folds of induction) (data not shown). 
In addition, measles virus was a potent inducer of the IFN-p promoter in BEAS-2B (16 folds 
of induction) (Figure 3.21). Again like in HEK293 cells, influenza virus A/WSN/33 strain 
induced IFN-P (10 folds of induction) but not N F-kB promoter activation in BEAS-2B cells 
(Figure 3.21).
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Figure3.21: Effect of poly(I-C) on BEAS-2B cells NF-kB promoter and IFN-/S 
promoter activation. BEAS-2B cells were infected with measles virus at the M OI 0.05 or 
influenza virus at the MOI 1 or transfected with 1 /xg/ml o f  poly(I-C). NF-kB promoter and 
IFN-/3 promoter activation were measured after 6 and 12 hours, respectively. Results are 
expressed as mean ± 1 SD o f o f  2 separate experiments.
179
3.11.3 Measles virus and dsRNA induce NF-kB promoter activation in 
HEK293-TLR3 and HEK293-RIG-I cells
Although transient transfected HEK293 cells were useful to assess signalling pathways 
involved in anti-viral responses, no activation of NF-kB promoter was observed in these 
cells. For that reason activation of this reporter vector, which effectiveness was proved in 
BEAS-2B cells, was further investigated in stably transfected HEK293-TLR3 and HEK293- 
RIG cells.
Like BEAS-2B cells, these cells were transfected with 300 ng of NF-kB luciferase reporter 
and 30 ng of Renilla luciferase internal control. After 6 hours, as presented below (Figure 
3.22), HEK293 cells infected with influenza virus (M OI 1), infected with measles virus 
(M OI 0.05) or transfected with poly(I-C) (50 /-ig/ml) showed only weak induction o f NF-kB 
promoter in the presence of measles virus (2 folds o f induction). This activation was clearly 
enhanced in HEK293-TLR3 (17 folds of induction) and in HEK293-RIG-I cells (5 folds of 
induction). In addition, NF-kB promoter was activated to the same extent in HEK293-TLR3 
and HEK293-RIG cells upon poly(I-C) transfection (3 folds of induction). Again, none of 
the influenza virus strains used in this study showed significant effect on NF-kB promoter 
induction in stably transfected cells.
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Figure 3.22: Effect of measles virus, influenza virus and poly(I-C) on HEK293, HEK- 
293-TLR3 and HEK293-RIG-I cells NF-kB promoter activation. Cells were infected 
with measles virus at the MOI 0.05 or influenza virus at the MOI 1 or transfected with 1 
/zg/ml o f  poly(I-C). NF-kB promoter promoter activation was measured after 6 hours. 
Results are expressed as mean ±  1 SD o f 2 separate experiments.
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3.11.4Characterisation of signalling pathways involved in cytokine and 
chemokine production in virus infected HEK293 and BEAS-2B cells - 
summary
Synthetic dsRNA activated NF-kB and IFN-/3 promoters in TLR3 and RIG -I 
dependent manner, as shown in transient and stably transfected HEK293 cells. In both cases 
response was stronger with the presence of RIG-I receptor. The same pattern was previously 
described for and IFN-/3 promoter by others (Opitz et al. 2007), suggesting critical role of 
this cytoplasmic receptor in both pro-inflammatory and anti-viral response caused by 
replicative intermediates of ssRNA viruses.
Involvement of R IG -I was also reported for influenza virus induced antiviral 
activity (Pichlmair et al. 2006; Opitz et al. 2007), where RIG -I was shown to be activated by 
viral genomic ssRNA bearing 5'-phosphates group. Referring to this result, influenza virus 
A/WSN/33 strain, also in our hands, triggered IFN-/3 promoter activation via R IG -I in 
transient transfected HEK293 cells. Activation of NF-kB however was not observed, 
indicating that at the 6 hours time point there was not sufficient amount o f dsRNA generated 
to initiate NF-kB mediated pro-inflammatory response. Hence, the inflammatory response to 
influenza virus infection seemed to be replication dependent which is in agreement with 
previous work (Guillot et al. 2005).
After 6 hours NF-kB promoter activation was clearly detected in measles virus 
infected TLR3 and RIG-I stably transfected HEK293 cells, suggesting that production of 
inflammatory mediators in response to measles virus infection occurred in the absence of 
multiplication of this pathogen which was also shown at the protein level in this work. In 
addition, NF- kB promoter activation was induced in non-transfected HEK293 cells, 
suggesting that additional signalling pathways were involved in measles virus induced pro- 
inflammatory mediato production. Interaction of measles virus with cell surface receptors
pathogen detection was suggested in pro-inflammatory cytokine production by Sato and co­
workers (Sato et al. 2005). The role of TLR3 and RIG -I receptors in measles virus induced 
IFN-/3 production should be investigated further.
•  A similar pattern of activation was achieved in BEAS-2B cells where NF- k B
promoter activation was observed in the presence of measles virus, whereas IFN-/3 promoter 
activation was observed in the presence of poly(I-C), influenza virus and measles virus.
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3.12 The effect of pulmonary surfactant on signalling pathways 
involved in cytokine and chemokine production in virus infected HEK293 
and BEAS-2B cells
3.12.1 Survanta®, Curosurf® and dexamethasone inhibit NF-kB promoter 
activation induced by measles virus whereas Survanta® and Curosurf® inhibit 
IFN-/3 promoter activation induced by dsRNA and influenza virus in BEAS-2B 
cells
Referring to the previous experiment the effect of pulmonary surfactant preparations 
(Survanta® batch # 41-957-27 and Curosurf® batch # 069097) at the concentration of 500 
/xg/ml and dexamethasone at the concentration 1 /zg/ml on NF-kB and IFN-/3 promoter 
activation was investigated in bronchial epithelial cells.
After 6 hours, Survanta® and Curosurf® and dexamethasone down-regulated NF-kB 
promoter activation in measles virus infected BEAS-2B cells (by 27, 48 and 60%, 
respectively) (Figure 3.25).
After 12 hours, also IFN-/3 promoter activation in poly(I-C) (Figure 3.23) and influenza 
virus (Figure 3.24) treated cells was clearly inhibited by pre-incubation with 500 /ig/ml of 
Survanta® (by 63 and 67%, respectively) as well as by pre-incubation with 500 /zg/ml of 
Curosurf® ( by 49 and 72%, respectively). In contrast, no effect of pulmonary surfactant 
preparations was observed on IFN-/3 promoter activation in measles virus (Figure 3.26) 
challenged cells. NF-kB specific inhibitor dexamethasone did not affect IFN-/3 induction in 
all conditions tested here.
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Figure 3.23: Effect of pulmonary surfactant and dexamethasone on poly (I-C ) induced 
BEAS-2B cells IFN -# promoter activation. BEAS-2B cells were incubated w ith 500 
fJLg/m\ o f Survanta00, 500 /tg/ml o f  Curosurf*® or 1 /tg/ml o f  dexamethasone for 2 hours and 
then transfected with 50 /tg/ml o f  poly(I-C). IFN-/3 promoter activation was measured after 
12 hours. Results are expressed as mean ±  1 SD o f 3 separate experiments. * P < 0.05 using 
unpaired t-test comparison to cells without pulmonary surfactant/dexamethasone treatment.
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Figure 3.24: Effect of pulmonary surfactant and dexamethasone on A/WSN/33 induced 
BEAS-2B cells IFN-/5 promoter activation. BEAS-2B cells were incubated w ith 500 
Hg/m\ o f Survanta10, 500 /zg/ml o f  Curosurf0 or 1 /xg/ml o f  dexamethasone for 2 hours and 
then infected with influenza virus A/WSN/33 strain at the M OI 1. IFN-/3 promoter activation 
was measured after 12 hours. Results are expressed as mean ± 1  SD o f 3 separate 
experiments. * P < 0.05 using unpaired t-test comparison to cells without pulmonary 
surfactant/dexamethasone treatment.
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Figure 3.25: Effect of pulmonary surfactant and dexamethasone on measles virus 
induced BEAS-2B cells NF-kB promoter activation. BEAS-2B cells were incubated w ith 
500 /zg/ml o f Survanta30, 500 /ig/ml o f  Curosurf00 or 1 /zg/ml o f  dexamethasone for 2 hours 
and then infected w ith measles virus at the MOI 0.05. NF-kB promoter activation was 
measured after 6 hours. Results are expressed as mean ± 1 SD o f 3 separate experiments. * P 
< 0.05 using unpaired t-test comparison to cells without pulmonary 
surfactant/dexamethasone treatment.
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Figure 3.26: Effect of pulmonary surfactant and dexamethasone on measles virus 
induced BEAS-2B cells IFN-/? promoter activation. BEAS-2B cells were incubated w ith 
500 /ig/ml o f  Survanta90, 500 /-ig/ml o f Curosurf00 or 1 /rg/ml o f  dexamethasone for 2 hours 
and then infected with measles virus at the MOI 0.05. IFN-/3 promoter activation was 
measured after 12 hours. Results are expressed as mean ± 1  SD o f 3 separate experiments.
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3.12.2 Curosurf® and dexamethasone inhibit NF-kB promoter activation upon 
measles virus and poly(I-C) in HEK293-TLR3 and HEK-RIG-I cells 
The effect of pulmonary surfactant and dexamethasone on cytokine and chemokine 
production was further investigated in stably transfected HEK293-TLR3 and HEK293-RIG- 
I cells.
After 6 hours NF-kB promoter activation in measles virus and poly(I-C) treated HEK293- 
TLR3 cells was inhibited by pre-incubation with 500 jUg/ml o f Curosurf (by 29 and 47%, 
respectively) and by pre-incubation with 1 ng/m\ o f dexamethasone (by 52 and 65% 
respectively) (Figure 3.27).
The same effect was observed in HEK293-RIG-I cells. After 6 hours NF-kB promoter 
activation in measles virus and poly(I-C) treated HEK293-RIG-I cells was down-regulated 
by pre-incubation with 500 fJLg/m\ o f Curosurf (by 21 and 31%, respectively) and by pre­
incubation with 1 /xg/ml o f dexamethasone (by 32 and 72% respectively) (Figure 3.28).
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Figure 3.27: Effect of Curosurf01 and dexamethasone on HEK293-TLR3 cells NF-kB  
promoter activation. Cells were incubated w ith 500 /tg/ml o f  Curosurf*0 or 1 /xg/ml o f  
dexamethasone for 2 hours and then infected with measles virus at the MOI 0.05 or 
transfected w ith 50 /xg/ml o f poly(I-C). NF-kB promoter activation was measured after 6 
hours. Results are expressed as mean ±  1 SD o f 3 separate experiments. * P < 0.05 using 
unpaired t-test comparison to cells without pulmonary surfactant/dexamethasone treatment.
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Figure 3.28: Effect of Curosurf* and dexamethasone on HEK293-RIG-I cells NF-kB  
promoter activation. Cells were incubated w ith 500 fig/m\ o f  Curosurf90 or 1 pig/ml o f  
dexamethasone for 2 hours and then infected with measles virus at the MOI 0.05 or 
transfected with 50 ^g/m l o f poly(I-C). N F - k B promoter activation was measured after 6 
hours. Results are expressed as mean ± 1 SD o f 3 separate experiments. * P < 0.05 using 
unpaired t-test comparison to cells without pulmonary surfactant/dexamethasone treatment.
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3.12.3 The effect of pulmonary surfactant on signalling pathways involved in 
cytokines and chemokines production in virus infected HEK293 and BEAS-2B 
cells - summary
• Pulmonary surfactant and dexamethasone inhibited dsRNA induced TLR3 and
RIG-I dependent NF-kB promoter activation, as shown in stably transfected HEK293 cells.
In addition, pulmonary surfactant inhibited dsRNA induced IFN-/3 promoter activation in 
BEAS-2B cells, which was not affected in the presence of dexamethasone. This result 
clearly shows that although anti-inflammatory activity o f pulmonary surfactant is 
comparable to that of dexamethasone, pulmonary surfactant preparations may also 
unspecifically contribute to the reduction of anti-viral responses.
•  Pulmonary surfactant but not dexamethasone inhibited IFN-/3 promoter
activation in influenza infected BEAS-2B cells.
•  Pulmonary surfactant and dexamethasone inhibited measles virus induced
TLR3 and RIG -I dependent NF-kB promoter activation, as shown in stably transfected 
HEK293 cells. This inhibition was confirmed in BEAS-2B cells. In contrast to dsRNA and 
influenza virus, pulmonary surfactant did not inhibit measles virus induced IFN-/3 promoter 
activation in BEAS-2B cells, suggesting that signalling pathways involved in anti-viral 
response in the presence of measles virus differ from that activated in the presence of 
influenza virus or replicative intermediates of ssRNA viruses.
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4 Discussion
Influenza virus has a worldwide distribution and causes annual epidemics of variable 
intensity. In the 20th century three pandemics of influenza virus have occurred, characterised 
by a large portion of influenza related deaths (>99% in 1918, 36% in 1957 and 48% in 
1968) (Simonsen et al. 1998), caused by H1N1, H2N2 and H3N2 subtypes, respectively.
The possibility o f re-emergence of a highly pathogenic influenza virus was brought to public 
attention in 1997, by the sudden appearance of lethal avian influenza virus H5N1 in Asia 
(Hsieh et al. 2006), able to transmit directly from birds to humans.
Influenza virus infection results in a range of clinical syndromes which can manifest locally 
in the upper (common cold or pharyngitis) and lower (croup, bronchiolitis or pneumonia) 
respiratory tract or less often systemically (Richman et al. 2002). Clinical outcomes caused 
by influenza virus infection include chronic respiratory diseases (asthma, chronic 
obstructive pulmonary disease or acute respiratory distress syndrome), are often associated 
with excessive host inflammatory response (Van Reeth 2000). The initial release of 
inflammatory mediators by influenza virus infected airway epithelial cells and alveolar 
macrophages results in the recruitment of neutrophils, lymphocytes and macrophages from 
the peripheral blood to the infected lung tissue which is associated with massive production 
of cytokines (IFN-a//3, TNF-a, IL-1/3 and IL-6) and chemokines (IL-8, RANTES, MCP-1 
and M IP-1) at the site of infection (Julkunen et al. 2000).
Currently, the principal method to control influenza virus infection is vaccination, however, 
vaccine induced immunity decreases over time and annual re-immunisation is necessary 
even if the vaccine antigens remain unchanged (Centers for Disease Control and 
Prevention). The target group for immunisation is limited and includes persons at increased 
risk of influenza related complications (persons aged 50 years and older, patients with
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chronic cardiovascular and pulmonary disorders or residents of nursing homes) and persons 
who are in close contact with high risk individuals, including health care workers (Richman 
et al. 2002). Uncomplicated influenza does not require specific anti-viral therapy, but such 
therapy needs to be considered when complications of influenza occur, including bacterial 
infections (Schwarzmann et al. 1971), viral pneumonia (Kaiser & Hayden 1999), cardiac 
and other systems abnormalities (Hayase &  Tobita 1997).
A few specific anti-viral drugs are used to treat infection caused by influenza virus, 
including replication inhibitors (amantadine and rimantadine) (Wintermeyer &  Nahata 
1995) and neuraminidase inhibitors (oseltamivir and zanamivir) (Monto et al. 1999). The 
appearance of drug resistant influenza virus strains has significantly limited the 
effectiveness of these drugs (Deyde et al. 2007). Another inhibitor of influenza virus 
replication is a nucleoside analog ribavirin (Oxford 1975), however intravenous 
administration of ribavirin may cause dose dependent hemolytic anemia whereas aerosolised 
administration may cause broncho-spasm (Ison & Hayden 2001). Clearly, alternative anti­
viral drugs are needed. Recently the anti-malarial drug, chloroquine, was reported to 
significantly inhibit pH dependent influenza virus replication in vitro (Ooi et al. 2006). 
Moreover, chloroquine was shown to exhibit an immunomodulatory activity in vitro, 
suppressing the production of TNF-a (Jeong &  Jue 1997), IL -1/3 (Bondeson &  Sundler 
1998), IL-6 (Karres et al. 1998) and IFN-y (van den Bome et al. 1997) in monocytes and 
macrophages stimulated with various bacterial components. The anti-inflammatory action of 
chloroquine could potentially reduce influenza virus associated inflammation and thus 
reduce pathogenic effects. Similar to chloroquine, animal derived pulmonary surfactant 
preparations are clinically approved products which have been shown to have 
immunomodulatory activity in vitro (Walti et al. 1997), indicating potential beneficial
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effects in the treatment of influenza virus infection. Previous clinical use of chloroquine and 
pulmonary surfactant preparations may shorten the duration required for the various phases 
of clinical trials.
Pulmonary surfactant is a phospholipid rich material that plays an essential role in 
pulmonary homeostasis. The composition of pulmonary surfactant may be altered, 
specifically with regard to quantity and composition, in a range of pulmonary diseases, 
including infant respiratory distress syndrome (IRDS) (Shelley et al. 1979) and in some 
which may develop secondary to or be exacerbated by influenza virus infection, such as 
acute respiratory distress syndrome (ARDS) (Nakos et al. 1998), pneumonia (Griese 1999), 
chronic obstructive pulmonary diseases (COPD) (Griese 1999) and asthma (Heeley et al. 
2000). Administration of pulmonary surfactant preparations, also known as exogenous 
replacement therapy, was found to be an effective treatment in IRDS (Berggren et al. 1984) 
and has been assessed in clinical trials in ARDS with limited success, mainly because of the 
complexity of this disorder. Although surfactant replacement therapy was shown to improve 
oxygenation (Spragg et al. 2004) and lung compliance (Perez-Benavides et al. 1995), and to 
reduce the need for ventilatory support (Perez-Benavides et al. 1995) in patients with 
ARDS, it was unclear whether administration o f pulmonary surfactant reduced ARDS 
associated mortality. The possible explanation for that is that deaths in ARDS may be due to 
multiple organ disfunction syndrome (MODS) and systemic pathology rather than 
respiratory failure. Previous in vitro studies have also indicated the modulatory action of 
commercially available pulmonary surfactant and its lipid components in inflammatory 
responses. Surfactant phospholipids were shown to suppress proliferation of lymphocytes 
(Wilsher et al. 1988b) and cytotoxicity of natural killer cells (Wilsher et al. 1988c), and to 
attenuate the production of various inflammatory mediators, including cytokines (TNF-o:)
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(Morris et al. 2000), lipid mediators (PAF and PGE2) (Tonks et al. 2003) and reactive 
oxygen intermediates (ROIs) (Tonks 2001; Tonks et al. 2005) in human monocytes 
stimulated with LPS from gram negative bacteria. Similarly, animal derived pulmonary 
surfactant preparation was also reported to inhibit the production cytokines (TNF-a), 
arachidonic acid metabolites (PGE2, TxB2 and LTC4) and superoxide anions in human 
monocytes stimulated with various bacterial components (Walti et al. 1997).
These observations led us to investigate the effect of pulmonary surfactant on the release of 
inflammatory mediators in response to influenza virus infection in human airway epithelial 
cells, and the mechanism by which pulmonary surfactant may affect this release. 
Furthermore, the effect of pulmonary surfactant on cellular viability and entry o f influenza 
virus into human airway epithelial cells was assessed.
The data generated in the current study have shown that:
(i) influenza virus strain A/WSN/33 is a more potent inducer of cytokine production than 
strain A/PR/8/34 in bronchial epithelial cells,
(ii) pulmonary surfactant preparations reduce inflammatory cytokine production in bronchial 
epithelial cells, and that this anti-inflammatory activity is comparable to that of 
dexamethasone,
(iii) reduction of cytokine production is not a consequence of altered cell viability since 
pulmonary surfactant is non-toxic in human airway epithelial cells,
(iv) reduction of cytokine production is not a consequence of altered infectivity of influenza 
virus since pulmonary surfactant does not affect infectivity of influenza virus in bronchial 
epithelial cells,
(v) pulmonary surfactant inhibits N F-kB and IFN-jS promoter activation in a variety of cell 
types whereas dexamethasone inhibits only NF-kB promoter activation.
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Influenza virus strain A/WSN/33 is a more potent inducer o f  cytokine production than 
A/PR/8/34 strain in bronchial epithelial cells
Various experimental in vitro approaches and different animal models have been used to 
determine cytokine transcription and secretion profile during influenza virus infection 
(Julkunen et al. 2000).
Human airway epithelial cells were previously reported to produce significant amounts of 
mononuclear cell attracting CC chemokines (RANTES and MCP-1) and polymorphonuclear 
leukocytes chemoattractant CXC (IL-8) in response to influenza virus infection in vitro 
(Matsukura et al. 1996; Adachi et al. 1997) whereas the production of IFN<V/3, IL-1/3, IL-6  
and TNF-a was shown to be limited in these cells (Ronni et al. 1997). Utilising a human 
bronchial epithelial cell line, Guillot and co-workers found these cells to be a good in vitro 
lung model which produced IL-8, RANTES, IL-6 and IFN-/3 following influenza virus strain 
A/Scotland/20/74 (H3N2) infection (Guillot et al. 2005). Therefore, we infected BEAS-2B 
with influenza virus strain A/WSN/33 and A/PR/8/34 and the cytokine profile was assessed. 
In our model influenza virus infected BEAS-2B cells also produced range of inflammatory 
mediators, including IL-8, RANTES as well as IFN-/3 and the production of these cytokines 
was found to be concentration and time dependent. Interestingly, in the present study 
influenza virus strain A/WSN/33 was a more potent inducer o f IL-8, RANTES and IFN-/3 
production than A/PR/8/34 strain which may be due to higher pathogenicity o f this strain, as 
shown by CellTiter960l) A Q ueous one solution proliferation assay in BEAS-2B cells and by 
TCID50 in MDCK and A549 cells.
The pathogenicity of A/WSN/33 has also been reported previously in mice (Sugiura &  Ueda 
1980) and in MDCK cells (Schulman &  Palese 1977) and was found to be related to the lack 
of a conserved glycosylation site at the position 130 of virus neuraminidase (Li et al. 1993).
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The role of A/WSN/33 neuraminidase in the removal of sialic acid from haemagglutinin and 
facilitating the cleavage of haemagglutinin by endogenous proteases was suggested by 
Schulman and Palese (Schulman &  Palese 1977). The glycosylation of neuraminidase at the 
position 130 could possibly inhibit the removal of sialic acid form haemagglutinin by 
neuraminidase of A/WSN/33. As reported by Guillot and others (Guillot et al. 2005), 
influenza virus induced cytokine release was delayed in comparison to the dsRNA 
stimulated response, suggesting that the observed production of inflammatory mediators was 
replication dependent. Our experiments with synthetic dsRNA also indicate that replication 
of influenza virus may be necessary for the observed cytokine biosynthesis, however 
experiments with UV treated virus or inhibitors of influenza virus replication (amantadine or 
rimantadine) would be required to ascertain if  this is the case.
The present study provides evidence that influenza virus and dsRNA induced IL-8 
production is partially mediated by N F -kB in BEAS-2B cells whereas different transcription 
factors are probably involved in RANTES and IFN-/3. In our experiments, IL-8 but not 
RANTES and IFN-/3 production was inhibited by dexamethasone, specific inhibitor of NF- 
kB dependent gene expression (Mukaida et al. 1994). This is supported by findings of 
Bemasconi and others (Bemasconi 2005) who reported that activation of N F -kB is essential 
for A/WSN/33 mediated IL-8 production in alveolar epithelial cells A549. RANTES (Lin et 
al. 1999; Genin et al. 2000) and IFN-/3 (Sato et al. 1998; Sato et al. 2000) were previously 
shown to be regulated mostly by IRF3 and IRF7, although additional transcription factors 
may also play a role, including N F -kB. Nucleic acids of influenza virus are sensed by Toll­
like receptors (TLRs) and RIG-like receptors (RLRs), well known pathogen recognition 
receptors (PRRs). Among them, TLR3 (Alexopoulou et al. 2001), TLR7 (Diebold et al. 
2004) and R IG -I (Pichlmair et al. 2006) have been shown to be involved in the recognition
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of ssRNA whereas TLR3 (Marshall-Clarke et al. 2007) and RIG -I (Yoneyama et al. 2004) 
were also reported to recognise dsRNA. Different receptors have been proposed to be 
involved in IL-8 and RANTES/IFN-j3 production in influenza virus infected BEAS-2B cells 
which may ultimately result in the activation of different transcription factors. Le Goffic and 
co-workers showed that the secretion of IL-8 was severely impaired in influenza virus 
infected BEAS-2B cells expressing an altered form of TLR3 whereas the secretion of 
RANTES and IFN-j8 was only partially inhibited (Le Goffic et al. 2007). This data indicate 
a critical role of TLR3 in the expression of IL-8 but not RANTES or IFN-/3 in bronchial 
epithelial cells infected by influenza virus. Influenza virus activates various signalling 
pathways, including dynamic protein phosphorylations (Wang et al. 2001) and 
ubiquitinations (Deng et al. 2000), which control the induction of pro-inflammatory and 
antiviral responses. The kinases involved in phosphorylation incude extracellular signal 
regulated kinase 1/2 (ERK1/2) (Pleschka et al. 2001), p38 mitogen activating protein (MAP) 
kinase (p38) (Kujime et al. 2000), phosphatidylinositol 3 kinase (PI3K) (Ehrhardt et al.
2006), dsRNA dependent protein kinase (PKR) (Balachandran et al. 2000) c-jun-NH2- 
terminal kinase (JNK) (Kujime et al. 2000) and others. As reported by Guillot and co­
workers, influenza virus and dsRNA use a more complex signalling mechanism to induce 
IL-8 production than to induce RANTES in BEAS-2B cells (Guillot et al. 2005), which may 
also result in the activation o f different transcription factors. They found that in influenza 
infected BEAS-2B cells, IL-8 production required ERK1/2, p38 and PI3K activation 
whereas RANTES secretion required p38 and PI3K signal transducing molecules activation. 
Similarly in dsRNA stimulated cells, IL-8 production was mediated by all o f these kinases 
whereas RANTES release was PI3K dependent (Guillot et al. 2005).
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The results obtained in the present study indicate that BEAS-2B cells provide a relevant in 
vitro model to study influenza virus infection. Although in vitro data allows us to make 
assumptions about the in vivo situation, the in vitro cytokine responses are greatly 
influenced by the cell type used. This limitation results from the lack of complex 
interactions between different cell types and cellular mediators, therefore our in vitro study 
should be validated in an animal model in the future.
Previous studies indicated the involvement o f TLR3 and RIG-I receptor in pro-inflammatory 
and anti-viral immune responses to influenza virus and dsRNA. The TLR3 and its adaptor 
molecule TRIF were shown to be essential for dsRNA and influenza virus induced NF-kB 
activation, and dsRNA induced IRF/IRSE activation in BEAS-2B cells (Guillot et al. 2005; 
Le Goffic et al. 2007). IRFs are regulators of the IFN-a//3 gene promoters (Nguyen et al.
1997) whereas ISRE can regulate various IFN stimulated genes (Williams 1991). TLR3 was 
reported not to be involved in IRF3 (Le Goffic et al. 2007) and IFN -(3 (Siren et al. 2006) 
activation in influenza virus infected BEAS-2B and HEK293 cells, respectively.
Cytoplasmic RIG-I receptor and its adaptor molecule CARDIF were shown to mediate NF- 
kB and IRF3 activation in BEAS-2B cells infected with influenza virus. A critical role of 
RIG-I receptor in anti-viral responses to influenza virus was reported by Pichlmair and co­
workers who showed that influenza virus genomic ssRNA bearing 5’-phosphates group is a 
ligand for RIG-I receptor (Pichlmair et al. 2006). Moreover, RIG-I was shown to mediate 
signals triggered by dsRNA, resulting in activation of N F -kB and IRF3 (Yoneyama et al. 
2004).
In agreement with previous work the present study showed that TLR3 and RIG-I are 
essential for dsRNA induced NF-kB and IFN-/3 promoter activation, and that R IG -I but not 
TLR3 triggers IFN-/3 promoter activation in the presence of influenza virus strain 
A/WSN/33, as assessed in HEK293 cells by Dual Luciferase00 Reporter Assay. Surprisingly,
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in our experiments, neither TLR3 nor R IG -I expressing cells infected with influenza virus 
showed NF-kB promoter activation, suggesting the involvement of different receptors, 
possibly TLR7. Our results indicate a critical role of TLR3 and RIG -I in pro-inflammatory 
and anti-viral response to dsRNA and the importance of RIG-I receptor in anti-viral 
response to influenza virus strain AAVSN/33. This will be discussed in greater detail below.
Pulmonary surfactant preparations reduce cytokine production in bronchial epithelial cells 
Clinically approved animal derived pulmonary surfactant undergoes extraction and 
purification procedures which remove hydrophilic proteins SP-A and SP-D and preserve the 
presence of phospholipids and hydrophobic proteins SP-B and SP-C (Blanco &  Perez-Gil 
2007). Phospholipids, especially DPPC, are the surface tension reducing components at the 
air liquid interface in the alveolus (Klaus et al. 1961) whereas surfactant hydrophobic 
proteins promote rapid adsorption o f phospholipids at the air liquid interface (Curstedt et al. 
1987), which is important for IRDS treatment. Commercially available SP-A and SP-D 
depleted pulmonary surfactant preparations (Speer et al. 1991) and surfactant associated 
lipids (Wilsher et al. 1988b) have been shown to have immunomodulatory activity in vitro. 
These studies reported diverse findings depending on the stimulus and the cell type 
considered. The vast majority of work to date focused on modulatory function of pulmonary 
surfactant in human monocytes and macrophages stimulated with bacterial components 
(Speer et al. 1991).
The present study provides evidence that pulmonary surfactant modulates the biosynthesis 
of IL-8 and RANTES in human bronchial epithelial cells infected with influenza virus. In 
the presence of physiological concentrations of Curosurf00 (500 /zg/ml), IL-8 and RANTES 
responses of BEAS-2B cells to infection with influenza virus strain A/WSN/33 were 
reduced by 30 and 35%, respectively. This is of relevance to the pathogenesis o f influenza
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virus infection since in vivo IL-8 is a potent chemoattractant for neutrophils (Mukaida 2003) 
and the production of IL-8 during influenza virus infection in vivo was shown to correlate 
with systemic (muscle aches, fatigue, headache and fever) and lower respiratory symptoms 
(cough, breathing difficulty, hoarseness and chest discomfort) (Hayden et al. 1998), 
indicating that pulmonary surfactant could be a good treatment option for severe influenza 
infection in lower respiratory tract. RANTES recruits monocytes, T lymphocytes, basophils 
and eosinophils (Schall 1991) however the role of RANTES in the pathology of influenza 
virus infection is unknown.
Our present study demonstrates the greater ability of porcine Curosurf®, compared with 
bovine Survanta®, to reduce production o f pro-inflammatory cytokines. The wide spectrum 
of anti-inflammatory activity o f Curosurf® has been reported previously. Speers and co­
workers reported that in the presence of Curosurf® phagocytosis of Staphylococcus aureus 
was impaired and that this porcine preparation effectively suppressed the production of 
TNF-a in LPS stimulated human monocytes. Decreased TNF-a production was later 
associated with significantly reduced TNF-a mRNA expression by Curosurf® (Baur et al. 
1998). Walti and co-workers showed that in addition to TNF-a production, Curosurf® 
attenuated the production of reactive oxygen intermediates (ROIs) and lipid mediators, 
including PGE2, TxB2 and LTC4 induced by various bacterial components in human 
peripheral blood monocytes (Walti et al. 1997). Natural porcine surfactant was also shown 
to modulate the expression of heat shock proteins and the production of superoxide anions 
caused by tobacco smoke (Pinot et al. 1999).
Our liquid chromatography/mass spectrometry (LC/MS) phospholipid analysis revealed 
variations between these two types of commercially available pulmonary surfactant
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preparation, indicating that the differences in potency may be due, at least in part, to 
differences in phospholipid composition. This is supported by findings of Wilsher co­
workers who reported that the immunosuppressive properties of pulmonary surfactant are 
influenced by variations of the phospholipid composition profile (Wilsher et al. 1988). They 
showed that phosphatidylcholine (PC), phosphatidylglycerol (PG) and phosphatidylinosytol 
(PI) were the most potent inhibitors of the lymphoproliferative response to 
phytohaemagglutinin (PHA). Differences in the chemical composition of these surfactants 
could be due to differences in source and the method used to extract and purify the 
surfactant material. Curosurr undergoes neutral lipid extraction by gel-liquid 
chromatography whereas production of Survanta® includes supplementation with DPPC, 
triglycerides and palmitic acid (Suresh & Soil 2002). Applied methods of extraction and 
purification may also result in incomplete removal of pulmonary surfactant associated 
proteins SP-A and SP-D. White and co-workers showed that when neutrophils were 
incubated with SP-D before influenza virus was added, the oxidative response to the virus 
was reduced (White et al. 2005). One argument that residual SP-A and SP-D are not the 
reason for the observed effect of Curosurf® is that SP-A and SP-D depleted pulmonary 
surfactant should not affect entry of influenza virus in bronchial epithelial cells. This was 
shown by us in an influenza plaque assays (discussed later). Both SP-A and SP-D were 
shown to reduce influenza virus infectivity in vitro (Benne et al. 1995) and in vivo (Li et al. 
2002). It is possible that material extracted from porcine lung tissue is better tolerated by 
human cells than surfactant complexes obtained from bovine lung minces. Compatibility of 
swine and human tissues is used in xenotransplantation to prevent rejection problems 
(Trucco et al. 2007).
203
Interestingly, our in vitro study is also consistent with previous in vivo studies, which 
demonstrate that porcine Curosurf*0 has higher clinical effectiveness than bovine Survanta® 
in the treatment of IRDS (Speer et al. 1995; Baroutis et al. 2003; Ramanathan et al. 2004). 
Premature infants treated with Curosurf® have shorter ventilation, oxygen administration 
and hospitalisation, when compared to those treated with Survanta®. The identification of 
components responsible for observed differences between Curosurf® and Survanta® in vitro 
was beyond the scope of this study, but is planned for the future. This study would require 
significant chemical investigation and assessment of individual components biological 
activities. The role of pure phospholipids of the major type found in pulmonary surfactant 
preparations, such as phosphatidylcholine (PC), phosphatidic acid (PA), 
phosphatidylglycerol (PG), phosphatidylethanolamine (PE) and phosphatidylinositol (PI), 
and the role of pure surfactant associated hydrophobic proteins SP-B and SP-C in the 
reduction of cytokine production in influenza virus infected bronchial epithelial cells should 
be assessed in the future. Our analysis of LC/MS profiles showed that PC, PA and PG were 
present in both types of pulmonary surfactant preparation whereas PE and PI were found 
only in Curosurf®, suggesting that these phospholipids might be involved in IL-8 and 
RANTES inhibition in influenza virus infected BEAS-2B cells.
Reduction o f influenza virus induced cytokine production is not a consequence o f  altered 
cell viability
The results obtained in the present study show that SP-A and SP-D depleted pulmonary 
surfactant preparations affect influenza virus induced cytokine production at the protein 
level in bronchial epithelial cells BEAS-2B. The observed reduction could be possibly due 
to: (i) reduced viability of BEAS-2B cells treated with pulmonary surfactant, (ii) reduced 
entry of influenza virus into BEAS-2B cells treated with pulmonary surfactant or (iii) due to
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the effect of pulmonary surfactant on cellular responses of BEAS-2B cells induced by 
influenza virus.
The effect of pulmonary surfactant on the viability o f human airway epithelial cells was 
assessed by CellTiter96® A Q ueous one solution proliferation assay. Although the kit is called 
proliferation assay, what it actually measures is the cellular reductive capacity o f a 
tetrazolium salt (MTS) to a coloured formazan product. Bioreduction of MTS has been 
shown to occur extramitochondrially, in the presence of two reducing agents N A D H  and 
N A D P H  (Berridge &  Tan 1993), and to be dependent on the mitochondrial dehydrogenase 
enzymes found only in metabolically active cells (Cory et al. 1991), therefore CellTiter96® 
AQueous one solution proliferation assay can be use as an indirect method to evaluate cell 
viability if  cell densities are standardised at the outset.
Curosurf® and Survanta® are the two major pulmonary surfactant preparations 
recommended in the UK (British National Formulary (BNF) BNF54-2007) which have been 
proven to be effective in the treatment of infant respiratory distress syndrome (IRDS) (Speer 
et al. 1995; Ramanathan et al. 2004). Although these animal products are subjected to 
chemical quality controls, aiming to standardise each batch by phosphatidylcholine (PC) 
content, important in reducing surface tension (Klaus et al. 1961), it is unclear which 
biological quality controls are performed before approval of final product release.
Our study indicates that pulmonary surfactant is predominantly non-toxic in human airway 
epithelial cells. Four out of five batches of pulmonary surfactant analysed, including batches 
which affected influenza virus induced chemokine production in BEAS-2B cells, were not 
cytotoxic and the viability of cells in the presence of surfactants was not significantly 
different from the viability of control cells with respect to reduction of MTS. These results 
indicate that reduction of influenza virus induced cytokine production observed was not a
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consequence of altered cell viability by pulmonary surfactant treatment. Only one batch of 
pulmonary surfactant (Curosurf*0 batch # 061350) showed a strong cytotoxic effect in 
bronchial epithelial cells and this was seen to be time and dose dependent, suggesting that 
toxicity of pulmonary surfactant here may be batch related. The role o f Curosurf40 in 
pulmonary defence has been previously studied in vitro in human monocytes and 
macrophages (Speer et al. 1991; Hidi et al. 1997; Walti et al. 1997), however toxicity of this 
pulmonary surfactant preparation has not been reported. Also in vivo studies regarding 
Curosurf® treatment in various respiratory conditions, including impaired mucus clearance 
in a dog model (De Sanctis et al. 1994), bacterial pneumonia in a rabbit model (Herting et 
al. 1997) and acute respiratory distress syndrome (ARDS) in a rat model (van Helden et al.
1998) have not revealed any evidence of toxicity of this preparation of porcine origin. 
Administration of exogenous pulmonary surfactant could potentially cause lung injury, 
leading to subsequent leakage of pulmonary surfactant associated proteins SP-B and SP-C 
into the vascular space and formation of immune complexes between surfactant proteins and 
antibodies. The immunogenicity of Curosurf® has been tested in rabbit model (Precioso et 
al. 2006) where Curosurf® has been shown not to trigger antibody dependent immune 
response against its components, indicating that Curosurf® treatment is safe and does not 
produce lung injury. On the other hand, endotoxin (Whitelaw 1996) and platelet activating 
factor (PAF) (Moya et al. 1993) contaminations were identified in other natural surfactants, 
which could possibly act as stimulants, leading to reduced cell viability. There is also 
concern regarding the hypothetical risk of prions transmission from bovine sources (Ryou
2007).
The cytotoxicity of Curosurf® observed by us may have been caused by inappropriate 
storage and/or transport condition, resulting in possible oxidation of pulmonary surfactant 
associated lipids. Oxidised lipids, especially oxidised phospholipids have been shown to
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possess pro-inflammatory potential (Bochkov 2007), which could ultimately cause cell 
death. The complexity of pulmonary surfactant of animal origin makes it difficult to identify 
possible harmful component in it. The possible batch to batch variability o f animal derived 
pulmonary surfactant preparations underlies the importance of development of new, 
clinically more active artificial surfactants. Comparison studies between available natural 
and synthetic surfactants have shown greater potency of animal products in the prevention 
and treatment of IRDS (Soli &  Blanco 2001). These studies reported that animal derived 
pulmonary surfactant therapy as opposed to synthetic surfactant therapy was associated with 
shorter ventilation, fewer pneumothoraces and higher survival rate in premature infants, 
probably due to the presence of hydrophobic proteins SP-B and SP-C. More efficient 
synthetic pulmonary surfactant therapy would offer better quality control and greater 
chemical purity than treatments based on animal products.
Reduction o f influenza virus induced chemokine production is not a consequence o f  altered 
infectivity o f influenza virus
Pulmonary surfactant associated proteins SP-A and SP-D, which are depleted from animal 
surfactant preparations, were previously demonstrated to control various viral infections, 
including influenza virus (Benne et al. 1995), CM V (Weyer et al. 2000), H IV-1 (Meschi et 
al. 2005), RSV (Levine et al. 1999; Levine et al. 2004) and adenovirus (Harrod et al. 1999) 
infections. These proteins were shown to increase viral phagocytic clearance (Benne et al. 
1997) and to modulate innate responses during viral infections (Hartshorn et al. 1994) in 
vitro and in vivo. In contrast, little is known about the function o f pulmonary surfactant 
lipids in viral infections in vitro. Balakireva and co-workers (Balakireva et al. 2003) 
reported that entry of adenovirus in alveolar epithelial cells to be increased in the presence 
of DPPC, the major component o f natural and synthetic pulmonary surfactants. In their
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experimental model cells were incubated with adenovirus in the presence of DPPC. The 
phospholipid binding activity of adenovirus, associated with increased entry in alveolar 
epithelial cells, may result from the absence o f a lipid envelope in adenovirus particles 
(Balakireva et al. 2003), suggesting that entry of influenza virus would not be affected in the 
presence of pulmonary surfactant preparations. Further experiments were carried out to 
verify this assumption.
In our model bronchial epithelial cells were incubated with pulmonary surfactant 
preparations prior to influenza virus infection and then the effect of Curosurf90 and 
Survanta® on influenza virus entry was assessed. Results from plaque assay and 
CellTiter96® A Q ue0us one solution proliferation assay show that infection of bronchial 
epithelial cells by influenza virus was not altered by Curosurf® and Survanta® pre-treatment 
in vitro, which suggests that reduction of influenza virus induced cytokine production was 
not a consequence of altered infectivity of influenza virus and that pulmonary surfactant 
possibly affected cellular responses o f BEAS-2B cells induced by influenza virus. Our in 
vitro findings suggest that exogenous pulmonary surfactant administration w ill probably not 
facilitate entry of influenza virus into respiratory epithelial cells in distal parts o f lungs in 
vivo. However uptake of other, especially non-enveloped viruses (like adenoviruses), 
respiratory pathogens could be increased by pulmonary surfactant. Adenoviruses cause 
rarely severe respiratory infections.
Pulmonary surfactant can inhibit NF-kB and IF N -(3promoter activation 
The present study showed the importance of TLR3 and RIG -I in pro-inflammatory and anti­
viral responses to dsRNA, and the involvement of RIG-I receptor in anti-viral response to 
influenza virus A/WSN/33 in bronchial epithelial cells. These results suggest that after
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binding of influenza virus to cell surface sialic acid (Rogers et al. 1983), endosomal 
internalisation (Sieczkarski &  Whittaker 2003) and subsequent release of vRNPs into 
cytoplasm, the ssRNA of influenza virus is sensed by cytoplasmic RIG-I receptor. The RIG- 
I receptor activates mitochondrial membrane associated CARDIF adaptor molecule (Lin et 
al. 2006), mediating IFN-/3 related anti-viral response. After replication and transcription in 
the nucleus (Braam et al. 1983), and translation and assembly in the cytoplasm (A li et al. 
2000), the mature virus detach from the cell, using the host cytoplasmic membrane as an 
envelope. Possibly due to excessive membrane damage lung epithelial cells undergo 
necrotic cell death (Seo et al. 2001), releasing intracellular materials, including the dsRNA 
intermediates produced during virus replication, into the surrounding environment. 
Internalised dsRNA could be recognised in endosomal compartments by TLR3, which 
recruits adaptor molecule TRIF (Oshiumi et al. 2003), and by cytoplamic RIG -I receptor, 
leading to subsequent activation of NF-kB mediated pro-inflammatory and IFN-/3 dependent 
anti-viral response.
Using different stimulants, including synthetic dsRNA, influenza virus and measles virus as 
a control, the mechanism by which pulmonary surfactant affect cellular responses leading to 
the production of inflammatory mediators was assessed by us in BEAS-2B and HEK293 
cells, using Dual-Lusiferase® Reporter Assay System. Like influenza virus, measles virus is 
ssRNA respiratory virus, which was shown in our in vitro model to be a potent inducer of 
chemokine production in human bronchial epithelial cells. As shown in FIEK293 cells, 
porcine Curosurf® inhibited both TLR3 and RIG-I dependent dsRNA and measles virus 
induced NF-kB promoter activation. These findings indicate that in the presence of 
pulmonary surfactant presumably endosomal membrane associated TLR3 signalling 
pathways and mitochondrial membrane associated RIG-I signalling pathways may be
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impaired. This is supported by findings of Tonks and co-workers who have reported that 
incorporation of DPPC into MM6 cells significantly decreased membrane fluidity (Tonks et 
al. 2001). In addition, several membrane associated enzymes have been shown to be affected 
by DPPC and pulmonary surfactant treatment. Curosurf*0 was shown to inhibit intracellular 
accumulation of cyclic adenosine monophosphate (cAMP) in monocytes stimulated with 
membrane dependent (cholera toxin and forskolin) but not membrane independent agents 
(Pinot et al. 2000). DPPC suppressed LPS stimulated production of platelet activating factor 
(PAF) in M M 6 cells by inhibiting two membrane associated enzymes (coenzyme A (CoA) 
independent transacylase and CoA: lyso PAF acetyltransferase) involved in PAF synthesis 
(Tonks et al. 2003). Using the same in vitro model, DPPC was shown to modulate release of 
ROIs by inhibiting the activity o f protein kinase C (PKC), membrane related enzyme 
involved in ROIs production (Tonks et al. 2005). Also human pulmonary surfactant, isolated 
from broncho-alveolar lavage fluid, was reported to affect bactericidal functions of 
monocytes by altering the activity of PKC (Geertsma et al. 1994). Pulmonary surfactant 
possibly may impair the activity of membrane associated enzymes or receptors by disruption 
of specific membrane rafts. Raft domains, particularly rich in glycosphingolipid and 
cholesterol, have been shown to be present in cell membrane (Harder et al. 1998). They have 
been implicated in important cellular processes such as signalling transduction, by acting as 
platforms able to concentrate various signalling molecules and receptors (Kurzchalia &  
Parton 1999). Decreasing membrane fluidity was shown to retard the formation of such 
clusters and inhibit cellular activation (Peck 1994).
In order to completely elucidate whether mechanisms by which pulmonary surfactant 
influences TLR3 and RIG-I signalling pathways are caused by endosomal and mitochondrial 
membrane disruption, additional experiments would be required. This could be achieved by 
investigating the effect of pulmonary surfactant on NF-kB and IFN -13 promoter activation, in
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our in vitro model, in the presence of vector expressing either truncated TRIF protein 
(adaptor molecule o f TLR3) containing the TIR  region only, able to bind to TIR  domain of 
TLR3 and to prevent its down-stream signalling or truncated TRAF3/6 proteins containing 
TRAF domain only, able to bind to TRAF interaction motif (T IM ) of CARDIF (adaptor 
molecule of R IG -I) and to prevent its down-stream signalling.
The present study also showed that pulmonary surfactant inhibits N F-kB promoter 
activation in measles virus infected BEAS-2B cells and IFN-/3 promoter activation in 
dsRNA transfected and influenza virus infected BEAS-2B cells. The inhibition of N F -kB 
activation by bovine Survanta® has been previously shown in LPS stimulated alveolar 
macrophages and monocytic cell line (Antal et al. 1996) which was evident in the 
suppression of TNF-a, IL-1 and IL-6 production in these cells (Thomassen et al. 1992). The 
role of pulmonary surfactant in the modulation of anti-viral response is unknown. Non­
specific inhibition of both N F-kB and IFN-/3 promoter activation indicates that pulmonary 
surfactant may attenuate both pro-inflammatory and anti-viral responses in vitro and in vivo. 
Interestingly, the activation of IFN-/3 promoter in measles virus infected BEAS-2B cells was 
not affected by pulmonary surfactant treatment, indicating that other than TLR3/RIG-I 
mediated signalling pathways may be involved in anti-viral response to measles viruses in 
bronchial epithelial cells. This is adding a possible new pathway compared to what was 
observed by others. According to these results, expression of RIG-I/M DA5 but not TLR3 
was important for IFN-/3 promoter activation in measles virus (Berghall et al. 2006) and 
influenza virus (Siren et al. 2006) infected endothelial and epithelial cells.
The observed inhibitory effect of Curosurf® on NF-kB promoter activation in dsRNA 
transfected and measles virus infected BEAS-2B and HEK293 cells was comparable to that
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of dexamethasone (synthetic member of corticosteroid hormones), suggesting similar anti­
inflammatory potential in vitro and in vivo. Corticosteroids are potent inhibitors for various 
inflammatory agents in vitro (Mukaida et al. 1994) and exogenous corticosteroids therapy, 
like pulmonary surfactant treatment, was shown to improve oxygenation (Steinberg et al. 
2006), lung injury (Meduri et al. 2007) and to reduce the requirement for ventilatory support 
(Steinberg 2006) in patients with ARDS. It was unclear whether administration of 
corticosteroids increased ARDS associated survival rate, however, long term exogenous 
corticosteroids therapy has been shown to be associated with severe side effects, including 
immunosuppression, and metabolic and hormonal imbalance (Deshmukh 2007). Pulmonary 
surfactant treatment could potentially offer safer anti-inflammatory action only at the local 
level of the lung.
Relevance o f the study
To assess the effect of pulmonary surfactant on influenza virus infected human airway 
epithelial cells, the cells were treated with Curosurf® or Survanta® prior to influenza virus 
infection. In this setup what was actually determined was the role of pulmonary surfactant in 
healthy lung prior to influenza induced inflammatory damage. It would be interesting to see, 
whether in cells infected with influenza virus prior to pulmonary surfactant treatment, 
cellular responses induced by influenza virus would be affected in the same manner.
As mentioned above, data obtained from the in vitro experiments are greatly influenced by 
the cell type used. Comparison studies between different types of lung cell lines (including 
monocytic cell lines), as well as between cell lines and cells isolated from primary tissue 
would help to make assumptions about the in vivo situation. Similarly, studies with 
laboratory adapted strains of influenza virus should be extended to wild type strains of 
influenza virus. To overcome limitations which result from the lack of complex interactions
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between different cell types and cellular mediators, our in vitro studies should be validated 
in a more complex in vitro lung model an animal model in the future.
Weaknesses o f  the work
1) In order to examine whether synthetic dsRNA (poly(I-C)) induced activation of 
pulmonary epithelial cells BEAS-2B shares any characteristics with that stimulated by 
influenza virus or measles virus and whether production of inflammatory mediators in 
response to a viral infections can occur in the presence or absence of multiplication of the 
pathogen, a complete comparison of effects from these inducers in the human bronchial 
epithelial cell line BEAS-2B should be performed. This could be achieved by doing a time 
course and concentration curve for cytokine and chemokine production in the presence of 
these stimulants.
2) In order to ascertain that dexamethasone inhibits virus induced IL-8 production in BEAS- 
2B cells by preventing NF-kB activation (activation of this transcription factor manifest by 
nuclear translocation), the level of NF-kB should be determined in nuclear and cytoplasmic 
extracts before and after infection, without and in the presence of dexamethasone. This 
could be achieved by Western blot analysis.
3) In order to characterise signalling pathways involved in cytokine and chemokine 
production in virus infected HEK293 and BEAS-2B cells and the effect of pulmonary 
surfactant on signalling pathways involved in cytokine and chemokine production in virus 
infected HEK293 and BEAS-2B cells,
- expression and localisation of TLR3 and RIG -I receptors should be analysed in 
unstimulated and stimulated cells before and after transfection (RT-PCR could be used to
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test the presence of TLR3 and R IG -I mRNA in these cells whereas protein expression level 
of TLR3 and RIG-I receptors could be examined by flow cytometry),
- the optimal time for assessing reporter activation in cells of interest should be ascertained 
(this could be achieved by doing a time course and concentration curve for the luciferase 
assay data set).
Summary
Present in vitro studies demonstrate that commercially available SP-A and SP-D depleted 
pulmonary surfactant preparations can reduce IL-8 and RANTES production in influenza 
virus infected human bronchial epithelial cell line BEAS-2B. Porcine Curosurf® had more 
pronounced inhibitory effect on cytokine production than bovine Survanta®. Liquid 
chromatography and mass spectrometry revealed that these two pulmonary surfactant 
preparations differed in phospholipid content therefore this may be at least in part 
responsible for differences seen. Pulmonary surfactant was not cytotoxic in BEAS-2B cells 
and had no effect on influenza virus infectivity, suggesting that in the presence of 
pulmonary surfactant cellular responses of BEAS-2B cells induced by influenza virus were 
altered. This was supported by Dual-Luciferase® Reporter Assay data which show that 
pulmonary surfactant suppressed TLR3 and RIG -I mediated NF-kB promoter activation in 
HEK293 cells, and NF-kB and IFN-|3 promoter activation in BEAS-2B cells. Hence, 
exogenous pulmonary surfactant therapy may be of clinical benefit by reducing NF-kB 
dependent pro-inflammatory responses during influenza virus infection; however, a 
weakening of IFN-/3 dependent anti-viral responses can not be excluded.
The present in vitro studies on the function o f clinically approved pulmonary surfactant 
preparations during influenza virus infection in human airway epithelial cells may help the
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development of new therapies aimed at achieving cytokine balance at the site of 
inflammation, thus reducing the severity o f influenza disease.
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ABSTRACT
(2008 American Society for Virology 27th Annual Scientific Meeting, Ithaca, N Y, USA)
This in vitro study of commercially available SpA/D depleted surfactant preparations shows 
that i. surfactant preparations approved for clinical use are generally not cytotoxic in human 
airway epithelial cells, ii. have no effect on influenza virus infectivity, and iii. downregulate 
pro-inflammatory cytokine secretion comparable to a glucocorticoid (dexamethasone) 
control. Human lung type II alveolar epithelial cells A549 and BEAS-2B human bronchial 
epithelial cells were infected with endotoxin-free influenza A virus H1N1 strains 
A/Swine/1976/31, A/WSN/33, and A/PR/8/34. Pro-inflammatory cytokines IL-8 and 
RANTES, as well as IFN-/3 were quantified by ELISA. Measles virus strain Edmonston, 
poly I:C and Escherichia coli O il 1 :B4 LPS were used as cytokine stimulation controls. In 
the presence of physiological concentrations of commercially available SpA/D depleted 
surfactant preparations (up to 500 /-ig/ml), IL-8 and RANTES responses of human airway 
epithelial cells to infection with influenza virus were reduced up to 30% (p < 0.05) between 
12 and 48 hours following infection in comparison to uninfected controls and comparable to 
treatment with 1 /tg/ml dexamethasone (p < 0.05). The reduction of pro-inflammatory 
cytokine responses were also observed when LPS was added as an additional stimulant (p < 
0.05). However, in contrast to dexamethasone, commercially available SpA/D depleted 
surfactant preparations inhibited both NF-kB and IFN-/3 promoter activity in luciferase 
reporter assays. Surfactants from different manufacturers and even different batches from 
the same manufacturer showed considerable biological variability. This data may explain in 
part the widely different clinical outcomes when selected commercially available SpA/D 
depleted surfactant preparations were used as a non-systemic alternative for anti­
inflammatory treatment of virally induced ARDS.
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